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Synopsis
This thesis describes the regulation of CD25 gene expression by inteiieukin-4-activated 
signal transduction pathways in quiescent human B lymphocytes. In particular, the 
importance of a cAMP-dependent pathway, which down-regulates binding of a putative 
transcriptionally repressive protein factor from a negative regulatory element in the 
promoter region of the CD25 gene, is highlighted. CD25 is the alpha chain of the multi- 
component interleukin-2 receptor complex and is a requirement for formation of high 
affinity interleukin-2 receptors. In addition, CD25 is the only unique component of the 
interleukin-2 receptor and as such it confers rigourous specificity for binding of 
interleukin-2. To date, inteiieukhi-4 is the only cytokine recognized to be capable of up- 
regulating CD25 in human B lymphocytes.
The initial aim of this work was to identify signalling pathways which were responsible 
for up-regulation of CD25 expression, by artificially activating specific second 
messenger systems. These early studies were based on the limited knowledge of 
interleukin-4-induced signal transduction pathways available at the time; treatment of 
resting human B cells with phorbol ester, calcium ionophore and forskolin results in 
modest increases in cell surface levels of CD25. Additionally, these stimuli and those 
required for elevation of surface CD23 levels are similar. It seemed possible therefore, 
that the ability of IL-4 to promote increases in intracellular calcium, protein kinase C 
activation and cAMP generation might have a role in IL-4-induced CD25 expression. 
Additionally, chelation of intracellular calcium and down-regulation of PKC, by chronic 
phorbol ester treatment, attenuates the ability of IL-4 to up-regulate CD25. Similarly, 
this latter treatment abrogates any increase in CD25 levels observed in response to anti­
immunoglobulin and anti-CD40 antibodies, the only other stimuli capable of inducing 
CD25 expression in primaiy human B cells.
Upon binding to its receptor, IL-4 induces a biphasic elevation of intracellular cAMP; a
I I
transient increase which peaks at approximately 2 minutes and is followed by a more 
sustained increase after 10 minutes. This sustained cAMP generation is maintained until 
approximately 30 minutes after stimulation, before dropping back to basal levels. 
Additionally, we have demonstrated that IL-4-induced cAMP production is dose 
dependent and leads to the activation of the cAMP-dependent protein kinase, PKA, in 
primary human B cells.
The ability of forskolin to elevate cell surface levels of CD25 suggested that cAMP 
generation might regulate expression of the CD25 gene. The work presented here 
demonstrates that IL-4 promotes a decrease in uanscription factor binding to a negative 
regulatory element in the promoter region of the CD25 gene and that this attenuation of 
DNA binding activity can be mimicked by stimulation of human B cells with agents 
which increase levels of intracellular cAMP. Additionally, we have demonstrated that 
inhibition of PKA and protein tyrosine kinase activity, but not PKC, results in the 
abrogation of the ability of IL-4 to attenuate binding activity at the negative regulatory 
element. Thus, we have determined that IL-4 promotes the removal of a transcriptional 
repressor protein from a negative regulatory element in the CD25 promoter, via a 
cAMP/PKA -dependent pathway, and that this event is at least partially responsible for 
the ability of IL-4 to up-regulate CD25 expresion.
The mature, EBV transfonned EDR B cell line is deficient in response to IL-4 in a variety 
of ways; i.e., IL-4 does not induce CD25 expression, their ability to promote cAMP 
generation in response to IL-4 is severely diminished in comparison to primary B cells 
and IL-4 is unable to promote attenuation of protein binding activity for the negative 
regulatoiy element. Investigations into tianscriptional activation of the CD25 gene have 
demonstrated that forskolin, but not IL-4, is able to increase the activity of a 
chloramphenicol transferase reporter gene under the control of a CD25 promoter 
fragment in the EDR B cell line and, in addition, forskolin promotes a decrease in DNA 
binding activity to the negative regulatory element. Co-stimulation of transfected EDR
III
cells with IL-4 and forskolin results in enhancement of both reporter gene activity and 
cell surface expression of CD25, compared with forskolin alone. Therefore, by 
artificially generating cAMP in these cells it possible to overcome a block in an cAMP 
regulated-IL-4-induced signal transduction pathway and promote transcripitional 
activation of the CD25 gene. The ability of forskolin and IL-4 to synergise with respect 
to CD25 expression, suggests that removal of transcription factor binding to the negative 
regulatory element is a necessary but insufficient signal for a maximal response. Thus, 
the work presented in this thesis has also tried to identify a candidate for a second IL-4- 
induced signal transduction pathway, which may be responsible for CD25 up-regulation. 
In particular, IL-4-mediated regulation of transcription factor binding to a putative IL-4 
response element has been examined.
The work presented here has defined a partial mechanism for IL-4-mediated regulation of 
CD25 up-regulation in mature human B lymphocytes. Thus, an IL-4-induced cAMP 
generating/PKA activating pathway is responsible for the down-regulation of 
transcription factor(s) which bind to a negative regulatory element in the promoter of the 
CD25 gene and it appears that this pathway is necessary for activation of expression of 
the gene, but is insufficient for induction of a maximal response. Additionally, IL-4 
elevates the binding of an as yet unidentified transcriptional complex to a putative IL-4 
response element in the CD25 promoter, an event which may act in conjunction with the 
cAMP-dependent pathway as a co-activational stimulus for the CD25 gene.
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1.1 B Cell Development
The humoral arm of the immune response in mammalian systems i.e., the production of 
antibody in response to invasion by foreign antigens and pathogens, is mediated by B 
lymphocytes. The process of development of B cells is both complex and lengthy and 
can be largely divided into two distinct phases, an antigen independent phase which 
occurs in the bone marrow and an antigen-dependent phase which occurs largely in the 
periphery, i.e., the tonsils, lymph nodes, blood etc (Figure 1.1). B cells, like all 
haematopoietic cells, develop from pluripotent haematopoietic stem cells, a single 
precursor cell type which arises in the bone maiTOW [Kee and Paige, 1995]. In addition 
to being a precursor for B cells, the pluripotent haematopoietic stem cell also develops 
into T lymphocytes and myeloid cells, including eiythrocytes, neutrophils, granulocytes 
and macrophages. Commitment to the B cell lineage is defined early in lymphoid 
development and can be identified by the expression of CD 19, a pan B cell surface 
marker which is expressed firstly in early pro-B cells and then throughout B cell 
development. The development process itself involves maturation from stem cells 
through a series of intermediate B cell precursor stages to finally become either mature 
antibody secreting plasma cells, or mature memory B cells. This process of 
differentiation is marked by the presence of a variety of cell surface proteins, the 
expression of which are often both transient and dependent upon the specific stage of 
development of the B cell, and perhaps more importantly by the expression of membrane 
immunoglobulin (mig), which forms the B cell antigen receptor (BCR) in association 
with accessory molecules such as Iga, Igp and CD19 [Jongstra and Misener, 1993; 
Pleiman et al,  1994].
1. 1.1  Immunoglobulin Gene Re-arrangement
The accepted dogma of immunoglobulin expression is that during the antigen- 
independent phase of B cell development there is no expression of intact Ig on the plasma
2
membrane of the B cell, but early in this phase somatic reaiTangement of immunoglobulin 
genes occurs (i.e., VDJ rearrangement of heavy chain genes and VJ rearrangement of 
Kappa or Lambda, light chain genes) [Reviewed by Alt et al., 1992]. This process 
begins in early pro-B cells with heavy chain gene rean angement and the expression of a 
cytoplasmic p chain (IgM heavy chain) marks progression to the large pre-B cell stage of
development. Expression of fully fuctional plasma membrane IgM (mIgM), capable of 
complex signal transduction [Cushley and Harnett, 1993], does not occur until much 
later in development and until one of the light chain genes (usually the kappa gene) has 
undergone successful rearrangement, i.e., until the complete Ig structure is available. 
However, the discovery that proteins encoded by the lambda-5 and V(pre-B) genes 
(termed the sun'ogate light chain) formed a membrane complex with the Ig heavy chain p 
protein early in B cell development [Karasuyama et al,  1990], suggested that the 
expression of membrane Ig molecules occuiTed earlier than originally thought [Melchers 
et al, 1993]. Disruption of the lambda-5 gene in murine embryonic stem cells, results in 
the blockade of B cell development at the pre-B cell stage [Kitamura et al., 1992]. 
Expression of the p-X5-VpreB complex at the surface of pre-B cells acts as an indicator 
of successful heavy chain gene re-arrangement and a signal lor progression to re- 
aixangement of the kappa tight chain gene [Ehlich et al., 1993; Tsubata et al., 1992]. The 
appearance of mIgM on the B cell surface occurs late in the bone maiTOw phase of B cell 
development and defines the immature B cell. This is followed closely by transition of 
immature B cells from the bone marrow to the periphery, whereupon development 
becomes antigen-dependent. The initiation of Ig gene rearrangement is a function of 
commitment to the B cell lineage and a process which can be compared with 
rearrangement of the genes which encode the T cell receptor (TCR) in T lymphocytes 
[Borst et. al., 1993]. The signals which are responsible for inducing commitment of 
stem cells to a particular cell lineage are ill understood; however, recent discoveries have I
highlighted the importance of DNA-binding proteins encoded by Ikaros, E2A and pax-5
,:3genes, with respect to the development of lymphoid cells. Disruption of the Ikaros gene 
results in failure of murine T and B cell development [Clevers et al., 1993]. Similarly, I
Ou, c/3
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inactivation of E2A and pax-5 genes results in the arrest of B cell development at the 
CD43+ pro-B cell phase and total abrogation of Ig gene rearrangement [Urbanek et al, 
1994; Zhuang et a l,  1994]. The implications of this are, that E2A and pax-5 gene 
products are able to facilitate recombination of Ig genes. However, the pax-5 gene 
product, B cell-specific activation protein (BSAP), also regulates expression of CD 19 
and CD 19 transcripts are absent in pax-5 gene knockout mice [Urbanek et al, 1994]. 
Thus, there is a possibility that CD19 expression is also a requirement for commitment to 
the B cell lineage and for maturation of B cells. This latter suggestion is supported by the 
finding that CD 19 deficient mice, while having normal levels of bone marrow B cell 
phases, had reduced levels of peripheral B cells, which did not proliferate in response to 
mitogenic stimuli, and reduced serum immunoglobulin [Engel et al,  1995]. In recent 
years the importance of CD 19, particularly in the presence of low concentiations of anti- 
IgM, as a co-activator of B cells has been highlighted and the synergy between 
membrane IgM and CD 19 signal transduction demonstrates that CD 19 has a role to play 
in B cell activation and development [Reviewed by Fearon and Carter, 1995]. All phases 
of development of B lymphocytes in the bone marrow aie regulated by cytokines and 
growth factors produced by stromal cells, e.g. IL-7 and IL-11, and to a lesser extent by 
some T cell derived cytokines [Burrows and Cooper, 1993]. It is probable that the 
effects of such growth factors act in combination with Ig gene rearrangement and 
expression to promote B cell maturation.
The B cell compartment of the immune system can be divided into B cell subsets, 
depending upon anatomical location, surface marker expression and biological function. 
These B cell subsets are characterized by the expression of certain cell surface markers; 
thus, conventional B-2 cells are IgM^o, IgD^", CD19^^\ M acl“, IL-5R“ and FceRIU 
[Waldschmidt et a l,  1991], whereas B-la are CD5+, IgM*^ i, IgD^ ®, CD1 9 o^ Macl+, IL- 
5R+ [Kantor, 1991] and FceRIT and B-lb cells display a cell surface marker pattern 
similar to B-la, but are CD5". B-1 cells constitute between 5 and 30% of the total B cell
population and are found predominantly in spleen of newborns and within the peritoneal 
cavity, while being rare in lymph nodes and peripheral blood. Whereas conventional B-2 
cells are continuously generated in adult bone maiTow, B-1 cells appear to be produced 
early in ontogeny and constitute a separate B cell lineage; as evidenced by the inability of 
adult bone marrow to replenish B la stocks in irradiated mice [Kantor et. ai,  1992].
CD5 can be induced in B-2 cells by treatment with anti-IgM and IL-6 and it has been 
hypothesised that Ig cross-linking in the absence of T cell help triggers pre-B cells to 
become CD5+ B- la cells [Haughton et ai,  1993]. This conelates with the appearance of 
B-la cells early in development and also with the diversity in Ig gene re-arrangement 
observed between B-la, B-lb and B-2 cells. B-la cells have a restricted V gene 
repetoire and often express self-reactive antibodies, a phenomenon which would favour 
clonal expansion early in ontogeny, where exposure to self protein is more likely [Fennel 
et al, 1989; Tornberg and Holmberg, 1995]. As development progresses the B cell 
repertoire is expanded substantially, due to greater diversity in light and heavy chain re­
arrangements and the B-2 subset begins to predominate.
1 . 1 . 2  Activation and Differentiation of B Lymphocytes
Following mIgM expression and entry of B cells into the periphery, regulation ol 
development becomes a function of exposure to antigen. In addition, B cell development 
in the antigen-dependent phase is also regulated by T cell intervention and can be split 
into T cell-independent and T cell-dependent processes. T cell-dependent regulation is 
controlled both by soluble protein growth factors known as cytokines and cell-cell 
contact through cell surface adhesion molecules expressed on T cells and B cells [Jelinek 
and Lipsky, 1988; Lederman et al, 1993; Patel et al, 1992; Tohma and Lipsky, 1991].
Thus, T cell dependent antigen responses were defined as those processes which 
required the action of T cell-manufactured cytokines and adhesion molecules to promote 
B cell development. It is now evident that many of what were originally thought of as T 
cell-independent developmental processes are regulated in some part by T cell factors, 
emphasizing that this reliance upon T cell help is even more integral to B cell
a
development than was first thought [reviewed by Banchereau et al, 1994; Jelinek and 
Lipsky, 1987].
Exposure to antigen induces immature B cells to either undergo apoptosis, i.e., 
programmed cell death, or cellular anergy [Ales-Martinez et al., 1991]. This clonal 
deletion of immature B cells during early exposure to antigen, permits the removal of 
potentially self-reactive B cells; i.e., B cells which, if allowed to mature, would mount an 
immune response to self proteins, resulting in the development of autoimmune disorders. 
Maturation of mIgM positive mimature B cells, to mIgM/mlgD double positive mature B 
cells, results in a positive response when the latter come into contact with antigen; i.e., 
mature resting B cells are activated in response to antigen. Activation of mature resting 
B cells, via mIgM or ralgD, results in proliferation (i.e, the expansion of specifically 
activated B cell clones) and secretion of antibody from the cell [Brink et al, 1992]. Cell 
division has been deemed a necessary step in the differentiation of B cells into mature 
antibody secreting cells; treatment of human peripheral blood B cells with inhibitors of 
DNA synthesis, mitomycin C and hydroxyurea, prevents the generation of Ig secreting 
cells in response to pokeweed mitogen [Jelinek and Lipsky, 1983]. This requirement is 
not universal however, as some studies have shown the development of small resting B 
cells into IgM secreting cells in the absence of DNA synthesis [Andersson et. al, 1980]. 
Thus, it appears that in some cases at least, cell division has a role in B cell activation 
which goes beyond the expansion of Ig secreting cells. In addition, it has been 
suggested that on-going Ig synthesis and secretion requires continual proliferation of 
differentiated B cells [Jelinek et al, 1987]. The implications of this are that factors such 
as cytokines like IL-2, which are essential to promote proliferation of activated B cells 
following their initial differentiation [Lipsky et at., 1988], are integral in both the extent 
and maintenance of a specific immune response. In addition to this primary immune 
response, B cells undergo further processes of differentiation; this includes isotype 
switching, with resultant IgA, IgE and IgG secretion [Lutzker et al, 1988; Rothman et 
al, 1988], and somatic mutation of the hypeiwariable region of the antigen binding sites,
1.2  The Importance of IL-2 in B Cell Development
an event which leads to production of higher affinity antibodies [Both et a i,  1990;
Tonegawa, 1983]. The final stages of the B cell developmental process are tenninally 
differentiated-antibody secreting plasma cells and memory B cells. The latter express 
very high affinity antigen receptors and are responsible for the initiation of rapid 
secondary immune responses upon re-infection, whereby re-challenge with the same 
antigen results in production of high affinity antibodies often of the IgG and IgE classes.
It is thought that many rounds of B cell prohferation enhance the rate of Ig secretion by 
tenninally differentiated plasma cells and may also be important in both promoting heavy 
chain isotype switching and providing opportunities for somatic mutation, which leads to 
the production of high affinity antibodies. The initial concept of B cell activation was that 
mature resting B cells were activated in response to antigen stimulation and that following 
this, T cell factors helped promote proliferation and differentiation. However, the 
discovery that IL-4 (as a co-stimulant along with anti-Ig antibodies) acts on resting B 
cells to activate them and promote DNA synthesis, cell division and Ig secretion 
[Kotowicz and Callard, 1993], suggests that IL-4 'primes' small resting B cells to
:respond to antigen and demonstrates that T cell intervention is not only a regulator ol 
aheady proliferating cells, but is integral in the initial processes of B cell activation.
1. 2.1 The Role of IL-2 in B Cell Activation, Proliferation and 
Differentiation
B lymphocyte development, as well as being regulated by exposure of the cell population 
to antigen and activation through the B antigen cell receptor complex, is heavily regulated 
by cell-cell surface contact by means of adhesion molecules and by the action of soluble 
protein factors known as cytokines. A subfamily of cytokines, known as lymphokines, 
are produced by and are particularly responsible for the regulation of development of
Haematopoietic cells [Callard, 1990; Paul and Seder, 1994]. All cytokines mediate their
:
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effects by binding to specific receptors expressed on the surface of target cells, and 
subsequently generating a cascade of intracelluar signalling pathways which ultimately 
result in the activation or suppression of a specific set of genes [Fox well et ai, 1992; I hie 
et cil, 1995; Taga and Kishimoto, 1993]. The classification of cytokine receptors allows
:them to be grouped into a number of superfamilies based on their structural homology to 
one another. One such superfamily is the haematopoietin receptor superfamily, which is
I
characterized by the presence of four conserved cysteine residues and a WSXWS motif 
in the extracellular, amino temiinal domain of the receptor [Cosman et ai, 1990; Foxwell 
et al,  1992]. Other superfamilies to which cytokine receptors belong include: the 
Immunoglobulin superfamily, e.g. IL-1 and PDGF receptors ; a tumour necrosis/nerve 
growth factor receptor superfamily with cysteine rich repeats, eg. TNF a and p receptors; 
a type II TGFp receptor superfamily with a serine/threonine kinase domain; an IL-8 
receptor superfamily belonging to the G-protein coupled, seven transmembrane domain, 
receptor supergene family, e.g. IL-8 and platelet factor PF-4 receptors [Taga and
.
Kishimoto, 1993].
One cytokine which plays a key role in lymphoid cell development is interleukin 2 (IL-2), 
a 15.4 kDa protein, produced and secreted by activated T lymphocytes and originally 
identified as T cell-growth factor. IL-2 is produced as a result of either mitogenic (by 
agents such as phytohaemagglutinin), or antigenic (via the T cell receptor complex) 
stimulation of T cells. Secreted IL-2 acts in both autocrine and paracrine growth 
stimulating modes upon the surrounding T cell population and is important in controlling 
their proliferation and differentiation. Interestingly, the stimulation of IL-2 production 
occurs in conjunction with up-regulation of a high affinity form of the IL-2 receptor 
complex, thereby allowing T cells to make a maximal response to the cytokine. The 
discoveiy that B cells could be induced to express receptors for IL-2, led to the idea that
:
IL-2 might act as more than just a T cell growth factor. Thus, in addition to activation of 
T cells, IL-2 is also found to induce activation of natural killer cells, proliferation of
oligodendroglial cells and growth and differentiation of B lymphocytes. As is the case
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with T lymphocytes, the high affinity form of the IL-2 receptor is only expressed on 
activated B cells of the mature circulating population. A quiescent GO B cell population 
is driven into G1 by a variety of stimuli and an integral part of this activation process is 
the expression of high affinity IL-2 receptors, an event which primes B lymphocytes for 
further activation; i.e., proliferation and expansion of B cell clones and differentiation 
into mature memory B cells.
Antigenic stimulation of T and B cells is profoundly different: the T cell antigen receptor 
binds either a class I or II MHC antigen/peptide complex, which are expressed on the 
surface of antigen presenting cells (APC); the B cell antigen receptor binds freely 
occurring antigenic molecules which circulate in the blood and require no prior 
processing. Similarly, there is a high degree of vaiiability in other stimuli which activate 
T and B cells; including, the accessory molecule complexes which associate with the T 
and B cell antigen receptors and are thought to be responsible for mediating signal 
transduction in réponse to antigen, and reponses to adhesion molecule interactions and to 
various cytokines. The induction of expression of high affinity IL-2 receptors on these 
different cell types is also subject to entirely different regulatory mechanisms and will be 
discussed in this chapter.
1, 2 . 2  The Structure of the IL-2 Receptor
The high affinity form of the receptor for IL-2 (IL-2R) consists of three distinct subunits, 
a 55kDa a chain (also referred to as the Tac antigen or as CD25), a 75kDa p subunit 
[Waldmann et al., 1984] and a 64kDa y subunit, and has a Kd of 10-HM [Robb et al,
1984]. Two of the subunits found in the IL-2 receptor complex, the IL-2Rp and y 
components, are members of the haematopoietin receptor superfamily, whereas the third 
component, IL-2Ra, appears to be unique in that it showed no identifiable sequence 
homology to any other known cytokine receptor component, until the recent discovery of 
the IL-5 receptor a chain which has a degree of homology to IL-2Ra. In addition to the
1» .
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high affinity form, IL-2 also binds two receptors of low and intennediate affinity; these 
receptors are comprised of a IL-2Ra chain (Kd= lO'^M) and a complex of lL-2Rp and y
chains (Kd“ lO-^M), respectively [Robb et aL, 1984]. One of the key advantages of
jthis multi-component structure with respect to maximising the cellular effects of IL-2, 
appears to be the combination of certain kinetic features of the individual components.
;fThus, the high affinity form of the IL-2R demonstrates a very fast association with its 
ligand, a feature of the IL-2Ra subimit, combined with a slow dissociation rate, a 
property of the intermediate form of the receptor which was fnst associated with the IL- 
2Rp chain. This fast 'on'/slow 'off rate of ligand association facilitates a rapid response
to IL-2 which can also be sustained to allow a maximal response to the cytokine.
It has become apparent that the extent of constitutive and inducible expression of the a, p , i
and y components of the IL-2 receptor complex is variable depending upon cell type.
Thus, in resting human B cells both the p and y subunits are constitutively expressed 
while levels of a (CD25) are both veiy low and inducible [Waldmann et ai,  1984]. In 
contrast, resting T cells express low levels of y but not a or p on the cell surface [Nakarai 
et al,  1994]. The a and p chains are expressed in response to mito genic stimulation of 
resting T cells; however, in later stages of development, the levels of p chain are reduced 
and it is this component which limits the availability of high affinity IL-2 receptors 
[Nakarai et ai, 1994]. The situation is entirely different in natural killer cells, where it is 
predominantly the y component of the receptor which is inducible and is, therefore, the 
limiting factor with respect to expression of high affinity receptors [Nakarai et ai, 1994].
IL-2 receptor expression is also tightly regulated in non-lymphoid cells. Thus, in human
'monocytes IL-2Rp is constitutively expressed, but IL-2 stimulation does lead to post- 
transcriptional stabilization of IL-2RP mRNA. These cells also constitutively express IL- 
2Ry mRNA, which is up-regulated by IFNy and IL-2, again via a mechanism of post- 
transcriptional stabilization [Bosco et ai,  1994]. IL-2Rain connast, is not constitutively 
expressed on resting monocytes, but is induced by stimulation with IFNy [Bosco et al.,
1994]. Thus it seems that the expression of high affinity IL-2 receptors and, therefore,
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responsiveness to IL-2 is dependent upon the level of inducibility of different 
components of the receptor complex, an event which appears to be differentially 
regulated depending upon cell lineage and also upon the developmental phase of the 
particular cell type.
1. 2 . 3  Signalling Components of the IL-2 Receptor
Early evidence suggested that IL-2 signalling pathways are predominantly mediated by 
the p subunit, however, important intracellular signals activated by the y component have 
also been identified. In contrast, it was suggested that the a chain had no signal 
transduction capability and was purely responsible for regulation of the affinity of IL-2 
receptor binding. An initial feature of IL-2 induced signal transduction, like a variety of 
other cytokines, is tyrosine phosphorylation of IL-2Rp and direct association of tyrosine 
kinase activity with the receptor complex. Like other cytokine receptors however, none 
of the individual components of the IL-2 receptor have protein tyrosine kinase domains 
within their structure [Reviewed by Taga and Kishimoto, 1993]. Therefore, the premise 
was that the IL-2 receptor was closely associated with independent cytosolic tyrosine 
kinases and recent studies have revealed that IL-2 activates a complex array of 
intracellular signalling molecules. Transfection studies using wild type and mutant forms 
of IL-2RP demonstrated that the transmembrane domain and a central region in the 
cytosolic domain are dispensable, with respect to signal transduction. However, both 
functionally unique and redundant elements exist in the proximal and distal regions of the 
cytoplasmic domain [Goldsmith et al,  1994]. The basis for these studies hinged on the 
ability of IL-2 to induce a proliferative response in the BA/F3 B cell line [Goldsmith et 
aL, 1994] and it was, therefore, a possibility that regions responsible for induction of 
signalling pathways unrelated to the proliferative response were overlooked. The 
cytoplasmic domain of IL-2Rp contains three regions, designated S, A and H, which 
appear to have distinct signalling capabilities. IL-2Rp interacts both physically and 
functionally with members of the src proto-oncogene family; thus, p5 6 ^^ k jg activated in 
peripheral blood lymphocytes in response to IL-2 [Hatakeyama et ai, 1991] and in an
.:S
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analogous manner, and p53/56^ y^  ^are activated in BA/F3 derived cells [Toiigoe et
aL, 1992]. lL-2 Rp-p5 6 c^k association appears to require the A region of the receptor 
subunit [Hatakeyama etaL, 1991]. The S region of IL-2Rj3 [Hatakayama etaL, 1989] is 
responsible for activation of Jakl [Witthuhn et aL, 1994], Syk/ZAP-70 [Miyazaki et aL, 
1994], p2H^-GTP binding protein [Satoh et aL, 1992], Raf-1 and also the induction of 
c-myc early gene expression [Shibuya et aL, 1992]. IL-2 induction of other early 
response genes, c-fos and c-jun, appears to correlate with activation of [Minami 
et aL, 1993]. In addition and more recently, it has been shown that IL-2 induces 
expression of members of the bcl-2 gene family, including bcl-2, b cl-X L  and bax, and 
that this induction also requires the S region of IL-2Rp [Miyazaki et aL, 1995]. The H 
region of IL-2R(5 is an absolute requirement for activation of STAT5, although it is a 
possibility that this is only in the capacity of physical association, as Jakl appears 
necessary to functionally activate STAT5 [Gaffen et aL, 1995]. IL-2Rp also associates 
with the 85kDa regulatory subunit of phosphatidyl inositol-3-kinase (PI-3 kinase or p85) 
[Truitt et aL, 1994]. In IL-2-stimulated T cell lysates a fusion protein, containing the N- 
and C-terminal SH2 domains of p85, co-precipitates with an 80kDa tyrosine 
phosphoiylated protein shown to be the IL-2Rp chain [Truitt et aL, 1994]. Therefore,
interactions.
PI-3 kinase physically associates with IL-2Rp through SH2-phosphotyrosine
Following the identification of yc as the third component of the IL-2 receptor complex 
[Takeshita etaL, 1992a; Takeshita etaL, 1992b], it was discovered that the gene for IL- 
2Ry (localized to chromosome Xql3) and the locus for X-linked Severe Combined 
Immunodeficiency (X-SCID) appeared at the same chromosomal position [Noguchi et 
aL, 1993]. A number of unrelated X-SCID patients have mutations in their IL-2Ry gene, 
resulting in different premature stop codons which lead to C-terminal truncation mutants 
[Noguchi et aL, 1993]. A variety of internal deletion, truncation and point mutations in 
the IL-2Ry of a number of patients were shown to result in an inability to form high
affinity IL-2 receptors; thus, a range of different mutant IL-2Ry chains from many X-
I
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SCÏD patients all manifested the same symptom, i.e., an inability to associate with IL- 
2Rp [DiSanto et aL, 1994]. X-SCID is characterized by an absent or drastically reduced 
T cell population, normal numbers of functionally deficient B cells and severely 
diminished cell-mediated and humoral immunity. The severity of the disease is in 
contrast with autosomal SCID, characterized by greatly reduced IL-2 production, where 
patients develop almost normal numbers of peripheral T cells and the condition can be 
corrected by administration of exogenous IL-2. The extreme severity of X-SCID, 
compared with other forms of SCID, and the apparent relationship of the disease with 
mutations in IL-2Ry, led to the notion that IL-2Ry was involved in the receptor mediated 
signalling of other cytokines, as an inability to produce IL-2 does not in itself result in 
total abrogation of T cell development. IL-7 is integral in the regulation of early T cell 
and thymic development and IL-4 is recognized as one of the major B cell growth 
factors. The discovery that EL-2Ry is required for expression of high affinity IL-4 and 
IL-7 receptors [Kawahara et aL, 1994; Kondo et aL, 1994; Russell et aL, 1993], goes 
some way to explaining the extreme nature of X-SCID; i.e., a number of cytokines 
which regulate development rely on IL-2Ry [y-common or yc] for efficient signal 
transduction. Indeed, monoclonal antibodies to IL-2Ry block both T and B lymphocyte 
development during, and at stages prior to, seeding of the thymus by precursor cells and 
the appearance of pro-B cells, respectively [He etaL, 1995a]. Signalling pathways 
activated by IL-2Ry are far less complex than for IL-2R|3 but are nonetheless important; 
activation of Jak3 is solely attributed to yc and it is tyrosine phosphoiylated in response 
to IL-2, IL-4 and IL-7 [Kondo et aL, 1994; Russell et aL, 1993]. Co-expression of IL- 
2Ra, p and y subunits in fibroblasts and stimulation with IL-2 results in induction of the 
nuclear proto-oncogenes c-fos, c-jun and c-myc. Regions of the IL-2Rp chain which are 
responsible for activation of these genes have been well characterized. However, co­
transfection of a mutant IL-2Ry gene, lacking all but seven of the cytoplasmic domain 
amino acid residues, and a fos-CAT construct into F7 cells (a BA/F3 derivative, stably 
transfected with IL-2Rp) results in a drastic decrease below basal of CAT reporter activity 
in response to IL-2; compared with cells transfected with the full length wild type IL-2Ry
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Figure 1.2: IL-2 Induced Signal Transduction
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receptor, where an increase in reporter gene activity was observed [Kawahara et al. $
1994]. This dominant-negative effect also occurs in IL-2-induced c-myc expression and 
cellular proliferation. Therefore, IL~2Ryis necessary for the efficient transduction of 
certain signals that have previously been associated with the IL-2Rp component. In -
addition, proliferation in response to IL-4 and IL-7 in BA/F3 cells transiently transfected 
with the IL-4Ra and IL-7Ra chains, was augmented by co-transfection with wild type 
IL-2Ry, but inhibited by the IL-2Ry truncation mutant [Kawahara et. al,  1994], 
Transfection of CTLL-2 T cells with chimeric IL-2 receptor molecules, i.e., the 
extracellular domain of c-kit (a receptor which homodimerizes in response to stem cell 
factor - SCF) and the intracellular domains of IL-2Rp and IL-2Ry (named kit/2p and 
kit/2y, respectively) demonstrated that a proliferative response to SCF only occurred 
when both kit/2p and kit/2y were co-expressed [Nelson et al., 1994]. In addition, co­
expression of chimeric IL-2Rp and IL-2Ry receptor molecules with different extracellular 
receptor domains (G-CSFRa and c-kit) resulted in a loss of proliferative responses to 
either of these ligands [Nelson et al,  1994]. Thus, it appears that the cytoplasmic 
domains of both IL-2Rp and IL-2Ry are necessary for IL-2 to promote an efficient 
proliferative signal. Furthermore, association of the extracellular haematopoietic domains 
of IL-2RP and y is required to induce heterodimerization of the cytoplasmic domains and i.
subsequent signal transduction.
(I
1 . 2 . 4  The Importance of CD25 Expression
CD25 is differentially expressed throughout the various stages of lymphocyte 
development. Thus, in later stages of differentiation which occur in the periphery, 
expression of CD25 is observed only on activated, mature T and B cells [Waldmann et 
al,  1984]. However, CD25 is also found on the cell surface of both T and B cells in the 
early stages of development, in the thymus and bone marrow respectively. CD25 is 
expressed on CD47CD8“ thymocytes [Uchiyama et al, 1981] and more recently its 
expression has been demonstiated in the pre-B cell and immature stages of murine B cell
differentiation [Chen et al,  1994]. Chen et. al  (1994) demonstrated that the onset of
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CD25 expression occurs during progression from the pro- to pre-B cell stage and is 
associated with p heavy chain expression. CD25 is also expressed in immature murine B 
cells but is lost during the process of maturation to IgM+/IgD+ B cells [Chen et aL,
1994]. Other studies have demonstrated that expression of CD25 occurs in a transition '
between pre-B cell subsets and is expressed upon maturation from pre-B I to pre-B II 
cells in the murine system, an event which is also marked by down-regulation of TdT 
and c-kit [Rolink et aL, 1994]. In addition, in mature resting murine and human B cells 
levels of CD25 expression are either very low or non-existent, but can be induced to 
express this IL-2 receptor component in response to various stimuli. In human B cells,
CD25 is the only inducible component of the IL-2 receptor, whereas both the p and y 
subunits are constitutively expressed [Takeshita et aL, 1992a; Waldmann et al,  1984].
'Therefore, regulation of cell surface levels of CD25 in B lymphocytes is essential in
-order for them to express the high affinity form of the IL-2 receptor, a necessity for 
maximal activation by IL-2. In addition, CD25 is the only unique component of the IL-2 
receptor complex; the y subunit designated y-common (yc) is also a component of the 
IL-4, IL-7, IL-9 and IL-15 receptors [Grabstein et al, 1994; Kondo et al, 1994; Russell 
et al,  1993] and a receptor consisting of the p and yc subunits i.e., the intermediate form 
of the IL-2 receptor, also binds IL-15 [Giri et al, 1994; Grabstein et al,  1994]. IL-15, 
despite sharing certain functional cellular effects with IL-2, is structurally distinct and the 
differential response of some cells to IL-2 and IL-15 is likely regulated by the unique a 
chain of the IL-15 receptor [Giri et al,  1995]. The a subunit of the IL-2 receptor is not 
part of the IL-15 receptor complex, therefore, the implications are that it is the IL-2Ra
'chain (CD25) which confers specificity for IL-2 binding. It is likely, therefore, that 
CD25 expression is a requirement for the mediation of cellulai* events uniquely associated 
with stimulation by IL-2. Both the IL-2R p and yc subunits appear to have important and 
distinct signal transduction capabilities; in contrast, CD25 has no intrinsic signalling 
motifs in its structure and does not appear to associate with any intracellular signalling 
molecules. It was considered therefore, that IL-2 activated intracellular signalling 
pathways were mediated via tlie p and yc components of its receptor and that CD25, as an
i
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absolute requirement for formation of high affinity receptor complexes, was limited to 
modulating IL-2 binding affinity of the IL-2 receptor [Robb et ai,  1984; Waldmann et 
aL, 1984]. However, recent studies have suggested that CD25 may be responsible for 
generating a negative regulatory signal in murine peripheral blood monocytic cells 
[Kasinrerk et aL, 1994; Kumar etaL, 1987]. The evidence for this is based on the ability 
of an anti-IL-2Ra antibody to enhance the proliferative response of lymphocytes to 
antigen. It must be noted, however, that this antibody-induced enhancement is only 
observed at sub-optimal concentrations and that at high concentrations the anti-IL-2Ra 
antibody inhibits a proliferative response. These observations outline the possibility of a 
role for CD25 which goes beyond simply regulating affinity and specificity of ligand 
binding, i.e., that it plays an integral part in IL-2-induced signalling pathways.
1.3 The Role of IL-4 in B Cell Development
1.3.1 Production and Biological Roles of IL-4
Interleukin 4 (IL-4) is a 15-19kDa cytokine principally derived from helper T cells, but 
also produced by mast cells, certain myeloid cell lines, some B cell lymphomas, B cells 
from SLE patients and certain bone marrow stromal cell lines [Howard etaL, 1982; 
O'GaiTa et aL, 1990; Okayama et al,  1995; Toellner et al, 1995]. IL-4 has a number of 
key roles in the development and differentiation of many lymphoid cell lineages, acting as 
a co-stimulator for activated B cells, T cells and mast cells. In addition, IL-4 also 
induces growth and differentiation of haematopoietic progenitor cells in the presence of 
additional cytokines. However, the major role of IL-4 and therefore, the principal 
interest with respect to the activity of this cytokine, lies in its involvement in B 
lymphocyte development and differentiation. Thus, IL-4 exerts a number of effects on B 
cells which include: enlargement of the B cell, a feature which is generally associated 
with activation; increased expression of surface IgM and IgD, CD23, CD25, CD40, 
LFA-1, and MHC Class II; isotype switching to produce IgE and certain IgG isotypes:
ÿ'
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reduction of cell surface CDS expression [Reviewed by Callard, 1991]. Such effects 
result in increased differentiation of B lymphocytes and many lead to the heightened 
responsiveness of the B cell to subsequent stimuli.
IL-4 enhances the responsiveness of B lymphocytes to anti-Ig reagents by elevating 
levels of surface IgM and IgD and, in addition, by inducing isotype switching [Kotowicz 
and Callard, 1993]. At high concentrations of IL-4, LPS stimulated B cells undergo 
isotype switching and synthesis of both IgE and IgGqis promoted [Rothamn et al.,
1988]. In tonsillar B cells, IL-4 can promote elevation of levels of membrane CD23 in
Igreater than 70% of the B cell population [Defiance et aL, 1989] and triggers release of soluble CD23, which is shed from the B cell surface following proteolytic cleavage of 
membrane CD23 [Bonnefoy et aL, 1988]. CD23 is recognised as the low affinity 
receptor (FcRell) for IgE and soluble CD23 is known to act as an autocrine growth factor 
for normal B cell blasts and EBV transformed B lymphoblasts [Swendeman and Thorley- 
Lawson, 1987]. An additional receptor for CD23 is CD21, the B cell specific receptor 
for EBV and C3d (Complement Receptor 2), and a novel CD23 receptor expressed on 
the cell membrane of a pre-B cell line has recently been discovered [White et aL, 1996]. 
Antibodies to CD23 inhibit IgE production, suggesting a link between CD23 and IL-4 
regulation of IgE secretion [Bonnefoy et aL, 1990]. IL-4 promotes expression of Class 
II major histocompatablity antigen (MHC) in B cells [Noelle et a.i., 1984], an event 
which enhances the capacity of B cells to act as antigen presenting cells, i.e., in their 
ability to present peptide antigen to CD4+ T cells. CDS is a pan T cell marker which is 
expressed on a subset of normal B cells and on most B-CLL cells. IL-4 down-regulates 
surface expression of CDS on tonsil B cells and B-CLL cells, but not T cells [Defiance et 
aL, 1989; Freedman et aL, 1989]. This down-regulation of CDS appears to be 
exclusively regulated by IL-4 and can be blocked by anti-IL-4 neutralizing antiserum.
r l i
Resting B cells i.e., those in GO, express only a few hundred high affinity IL-4 
receptors. Stimulation with IL-4 results in activation of B cells but is unable to promote
19
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SDNA synthesis or cell division, ht vitro stimulation with high concentrations of anti-Ig antibodies initiates a li'ansition from the GO to G 1 phase of the cell cycle, an event which 
can be detected by an increase in the size of B cells and elevated levels of cytoplasmic 
mRNA, and the cells become committed to DNA synthesis. In contrast, low levels of 
anti-Ig antibodies or stimulation with protein antigen, cannot promote this proliferative 
response. Co-stimulation of B lymphocytes with anti-Ig antibodies and IL-4 promotes 
DNA synthesis and cell division [Reviewed by Callard, 1991]. In physiological 
cii'cumstances levels of circulating protein antigen are likely to be relatively low, and so 
the responding B cell population requires additional stimuli to promote a proliferative 
response. Previously, it had been shown that culturing normal human B cells in the 
presence of irradiated T cells, monocytes and Pokeweed Mitogen (PWM) resulted in 
elevated levels of CD25 at the cell surface [Waldmann et aL, 1984]. Such responses
■ ■indicated that regulation of CD25 expression on human B lymphocytes was a feature of 
T cell-dependent B cell activation but gave no indication of any specific stimuli which 
regulated this response. It has since been demonstrated that IL-4 is the sole cytokine 
capable of inducing CD25 expression in primary resting human B cells [Burlinson et aL,
1995; Butcher and Cushley, 1991; Butcher et aL, 1990; Zola et aL, 1991], an
'obseiwation which to some extent explains the ability of IL-4 to act as a co-stimulant lor 
B cell activation. Thus, it may be considered that as well as responding to antigen or 
anti-Ig, B cells are ‘primed’ by IL-4 to respond to additional activation stimuli, probably 
by eliciting some of the cellular responses which have been described: for example, 
increasing CD23 and release of soluble CD23, thereby promoting its autocrine growth 
effects on B cells, and elevating cell surface levels of CD25 and promoting formation of 
high affinity IL-2 receptors, allowing a maximal response to IL-2.
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In addition to initiating activation of B cells, IL-4 can, in certain circumstances, promote 
an anti-proliferative response particularly with respect to IL-2. IL-2-induced stimulation 
of proliferation, but not differentiation, of B-CLL and follicular lymphoma cells is 
inhibited by IL-4 [Defiance etaL, 1989; Shields etaL, 1989]. In addition, the activity of
IL-2 in specific antibody responses to the influenza virus is attenuated by IL-4 [Callard et 
aL, 1991] and immunoglobulin secretion in response to IL-2, SAC and T cell replacing 
factor is also inhibited [Jelinek and Lipsky, 1988; Splawski et aL, 1989]. It has been 
suggested, that the ability of IL-4 to inhibit ÎL-2-specific proliferative responses is 
mediated by inhibiting the expression of high affinity IL-2 receptors. As IL-4 displays 
both agonistic and antagonistic effects on proliferation of normal B cells it was suggested 
that IL-4 and IL-2 stimulate distinct B lymphocyte populations and IL-4 blocks 
proliferation of an IL-2 responsive population. However, such an hypothesis does seem 
unprecedented if one considers that IL-4 is the only cytokine capable of up-regulating 
CD25 in human B cells. This latter observation would suggest an increase in potential 
responsiveness of these B cells to IL-2, as CD25 is an absolute requirement for 
formation of high affinity IL-2 receptors. IL-4 only promotes CD25 expression of 30- 
40% of the resting B cell population [Burlinson et aL, 1995; McKay and Cushley,
1995], perhaps indicating that only a specific sub-population of B cells are primed to 
respond to IL-2, whereas it may be that IL-2 responses of the remaining B cell 
population are actively inhibited by IL-4.
1. 3 . 2  IL-4-Induced Signal Transduction
The receptor for IL-4, like many cytokine receptors, is a multi-subunit structure 
consisting of a 140kDa a chain (IL-4Ra) [Harada et aL, 1990; Idzerda et aL, 1990; 
Mosley et aL, 1989] and the common yc chain [Russell et aL, 1993]. The IL-4Ra chain 
has been identified as a member of the Haematopoietin Receptor Superlamily and 
contains a number of signalling motifs within its cytoplasmic domain. The yc chain is a 
component of a number of other cytokine receptors, as mentioned previously, and as 
such, intracellular signals which are a feature of this subunit appear to be common to the 
signal transduction pathways of many of these cytokines. A comprehensive 
understanding of IL-4 signal transduction in human B cells remains to be elucidated and 
present knowledge shows it to be a complex process involving several second messenger 
systems.
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Early studies into signal transduction in resting, human tonsillar B cells revealed that, 
following IL-4 binding to its receptor, there is a transient increase in IP3 production and 
consequent calcium mobilization with intracellular levels returning to basal within a
■■ I;-
minute of ligand binding. This initial phosphoinositide hydrolysis is followed, after a lag 
period of approximately 10 minutes, by a sustained elevation in intracellular cAMP
■[Finney et al,  1990]. As well as IP3 production, PIP2  hydrolysis results in the 
production of diacyl glycerol (DAG), a second messenger which subsequently activates 
PKC and induces its translocation to the plasma membrane [Reviewed by Cook and 
Wakelam, 1992]. It has been reported that, in human monocyte cells, IL-4 induces 
translocation of PKC to both membrane and nuclear fractions of the cell and has a dose-
Idependent effect on increasing PKC activity [Aimda and Ho, 1992]. In addition, it has 
been possible, using agents such as phorbol ester, calcium lonophores and the dipterene 
forskolin, to mimic the ability of IL-4 to increase soluble CD23 production by primary 
human B cells [Finney etaL, 1990]. These data are in direct contrast with IL-4 induced 
signal transduction in primary, murine B cells. Thus, IL-4 fails to induce PIP2 
hydrolysis and resultant IP3 or DAG production in murine B cells, nor does it promote 
calcium mobilization [Justement et aL, 1986; Mizuguchi et aL, 1986; O' Garra et aL, 
1987]. It has also been reported that high concentrations ol EGTA in the culture medium 
were unable to abrogate IL-4 induced expression of MHC Class II in murine B cells, a 
result which is in direct contrast to the inhibition of anti-IgM induced MHC Class II 
expression in murine B cells in the presence of relatively low levels of EGTA [Mizuguchi 
et aL, 1986]. Stimulation of both human and murine B cells with anti-Ig antibodies 
results in PIP2  hydrolysis, IP3 and DAG production and Ca^+ mobilization. Co­
stimulation of murine and human B cells with anti-Ig and IL-4 results in DNA synthesis 
and cell division [Howard et aL, 1982]. Reports that IL-4 failed to induce PIP2 
hydrolysis suggested that, in the murine system at least, this particular signalling 
pathway was not responsible for this synergistic, proliferative response. However,
further studies revealed that co-stimulation of murine B cells with IL-4 and the phorbol
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esters PMA and PBu2  induce DNA synthesis, an effect not observed upon co-stimulation 
with IL-4 and calcium ionophore [Klaus and Harnatt, 1990]. Therefore, it seems that 
PKC may have a role to play in the cross-talk between the signalling pathways activated 
during the co-stimulation of murine B cells by anti-Ig and IL-4. Initial studies 
concerning the ability of IL-4 to activate protein tyrosine kinase activity revealed, that in 
murine B cells, IL-4 induced tyrosine phosphorylation of a 42-44kDa intracellular protein 
[Justement et aL, 1986; McGarvie and Cushley, 1989a]. Similar experiments in the 
human Daudi B cell line showed no phosphorylation of a protein of this particular 
molecular weight [Justement et aL, 1986]. IL-4 was also shown to induce tyrosine 
phosphoiylation of a 75-80kDa molecular weight protein murine splenic B cells, an effect 
which was unique to stimulation with IL-4 in these cells [McGarvie and Cushley, 
1989b]. The implication of all these studies is, that there exist distinct, species-specific, 
signalling mechanisms which are employed by IL-4 in both primary B cells and B cell 
lines in murine and human systems.
More recently, the nature of IL-4 signal transduction, particularly with respect to protein 
tyrosine kinase activity, has been partially elucidated. Studies have revealed a number of 
pivotal IL-4-induced signal transduction pathways, common to both human and murine 
systems. IL-4 stimulates tyrosine phosphorylation of a 170kDa protein (initially 
designated 4PS) in two IL-13-dependent myeloid progenitor cell lines, FDC.P2 and 
32D, which proliferate in response to IL-4 [Keegan etaL, 1994; Wang et aL, 1992]. In 
addition, phosphoiylated bands of 130-140kDa, 120kDa and 97kDa were also observed 
in these cells [Wang et aL, 1992]. The 140kDa protein is the IL-4Ra chain and it now 
seems probable that the 97kDa protein is Stat6 . Thus, IL-4 induces tyrosine 
phosphorylation of its receptor, probably via association with intracellular tyrosine 
kinases. It was at first considered that 4PS (now designated IRS-2), as a target for 
cytokine-mediated signalling, was unique to IL-4-linked signal transduction, however, it 
has recently been shown that IL-9 also activates IRS-2 and that it is present in a range of 
cells lines as well as in normal primary cells. Analysis of the amino acid sequence of
a
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IRS-2 revealed a large degree of sequence homology with IRS-1 (insulin receptor 
substrate-1 ), a protein which is phosphoiylated in a number of cell types in response to 
stimulation with either insulin or IGF-1 (insulin-like growth factor-1) [Wang et aL,
1993]. Indeed, treatment of certain IL-4 responsive cell lines with insulin and IGF-1 
results in phosphorylation of IRS-2. Treatment of the myeloid progenitor cell line 
FDC.P2 with IL-4 leads to a dramatic association of IRS-2 and the 85kDa subunit of PI- 
3 Kinase (p85), although this interaction does not involve the phosphorylation of p85 
itself [Wang et aL, 1992]. Interestingly, the doses of IL-4 required to initiate this ..
interaction and the mitogenic response in these cells, are very similar. In addition, it has 
been demonstrated that IL-4 can activate 1RS-1, which has been over-expressed in 32D 
cells [Keegan et aL, 1994], and that activation of IRS-1 in these cells is necessaiy for PI- 
3 Kinase and pYO^ yh activation by insulin, IGF-1 and IL-4 [Myers et aL, 1994]. 
However, it must be noted that activation of p70^yk in response to IL-4 is weak when 
compared with IL-4 induced activation of PI-3 kinase and, therefore, may not be as 
important in terms of IL-4 signal transduction pathways. Like insulin, IL-4 induces 
association of GRB2/Sos with activated IRS-1, but unlike insulin, fails to activate Ras 
and extracellular signal regulated kinases (ERKs), or induce GRB2 association with She 
[Pruett era/., 1995].
;
The discovery of the Janus family of tyrosine kinases revolutionised understanding of 
cytokine receptor signal transduction (see section 1.4) and it is now known that IL-4 
stimulates activation and tyrosine phosphorylation of two members of this family, Jakl 
[Yin et aL, 1994] and Jak3 [Witthuhn et aL, 1994], in lymphoid cells. Jakl is 
phosphoiylated in response to IL-4 and associates with both the IL-4Ra chain and IRS-2 
[Pernis et aL, 1995a], whereas Jak3 associates with the yc subunit of the IL-4 receptor 
complex. Many cytokine receptors regulate gene expression by activation of a family of 
proteins known as Stats (Signal Transducers and Activators of Transcription) and these 
proteins are often tyrosine phosphoiylated by members of the Janus family of kinases. 
IL-4 activation of a Stat transcription factor was first reported in murine T cells, where
I
Figure 1.3: IL-4 Induced Signal Transduction
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ÏL-4-activaiecl DNA -binding activity was observed to have a sti'ong affinity for an IFNy- 
activation site (GAS) [Schindler et al,  1994]. This activity was isolated and 
characterized in the Thp-1 T cell line, where extracts from IL-4 activated cells were found 
to have DNA-binding activity for an IL-4 response element in the promoter of the human 
FcyRI gene [Hou eta l ,  1994]. This activity was subsequently purified and found to be 
a protein of -lOOkDa and described as IL-4Stat protein, now designated Stat6  [Hou et 
al,  1994]. Stat6  binding sites have since been identified in the promoter regions of a 
number of IL-4 inducible genes. IL-4 induces tyrosine phosphorylation of Stat6  via 
Jakl, an event which is followed by formation of Stat6  homodimeric complexes termed 
STF-IL-4 [Quelle et al,  1995]. STF-IL-4 in turn translocates to the nucleus of the cell 
and binds to IL-4 responsive elements in the promoters of IL-4 inducible genes. Despite 
the reported association of Jakl with IRS-2 upon IL-4 stimulation, the activation of Stat6  
does not appear to rely on IRS-2 signalling pathways [Kotiandes et al,  1995]. Thus, 
IL-4 seems to stimulate two major, independent signal transduction pathways via 
activation of Jakl protein tyrosine kinase.
1. 3 . 3  Critical Signalling Domains of the IL-4 Receptor
A major endeavour in recent years has been to characterize the IL-4Ra chain and define 
regions of the cytoplasmic domain which ^ e  critical for IL-4 induced signal transduction. 
One of the initial problems was the relatively low expression of IL-4 receptors on the 
majority of cell types, between 500-5000 receptors per cell. A subclone of the CTLL-2 T 
cell line, CTLL-19.4, was isolated by fluorescence activated cell sorting and was found 
to over-express IL-4 receptors on the cell surface (-10^ receptors/cell) [Mosley et al,
1989]. This discovery facilitated the partial purification and isolation of a full length 
cDNA clone of the receptor. The full length form of the receptor is a 140kDa protein 
with extracellular, transmembrane and intracellular domains and the fuU length receptor 
cDNA encodes a protein of ~ 810 amino acids [Mosley et al,  1989]. IL-4 responsive
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cells, as well as expressing a 140kDa IL-4 receptor protein, were also shown to express 
a 60-70kDa protein which associated with biotinylated IL-4 [Harada et ai,  1990]. More 
recent studies have identified this second binding protein as the yc subunit of the 
receptor. The extracellular domain of the 140kDa receptor chain is 220 amino acids in 
length and features two cysteine residues and a WSXWS motif, both of which are 
characteristics of the haematopoietin receptor superfamily [Harada et al., 1990]. Initial 
studies of the cytoplasmic domain of the IL-4 receptor demonstrated no particular 
homology with other cytokine receptors. However, more recently, short consensus 
sequences termed PRMl and 2 (proline rich motif 1 and 2), first identified as the gpl30 
box 1 in the gpl30 component of the IL- 6  receptor [Murakami et al., 1991], have been 
located in the cytoplasmic domains of the majority of haematopoietin cytokine receptors 
[O'Neal and Yu-Lee, 1993].
A number of studies using transfected forms of the murine pro-B cell line BA/F3 have 
helped identify critical signalling regions of the human IL-4Ra chain. Transfection of 
wild type and a variety of deletion and tmncalion mutants of the human IL-4 receptor into 
this cell line, revealed that a 41 amino acid sequence located between amino acids 433 
and 473 (numbering from the carboxy terminus) was critical for IL-4-induced growth 
signal transduction [Harada et al., 1992]. This region is highly conserved between 
human and mouse but is non-homologous with other cytokine receptors. Other studies 
have revealed the importance of this membrane proximal region and also a membrane 
distal region, both of which have glutamate and serine rich sequences within them, in IL- 
4-induced proliferation of BA/F3 cells [Seldin and Leder, 1994]. In addition, it is 
possible to inhibit IL-4 induced proliferation of this cell line by the introduction into the 
cell of a synthetic peptide (SPl); a 41 amino acid peptide which corresponds to the 41 
amino acid, critical growth signal transduction region of the IL-4 receptor [Izuhara et ai,
1995]. In contrast, SPl was unable to inhibit IL-4-induced proliferation in the HT2 and 
CTLL-2 T cell lines or the erythroleukaemic cell line TFl, indicating that different 
regions of the IL-4Ra cytoplasmic domain may be responsible for growth signal
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transduction in different lymphoid and myeloid cell types [Izuhara et al,  1995]. The 
amino acid sequence of the IL-4Ra chain revealed that it has no intrinsic tyrosine kinase 
activity in its cytoplasmic domain, however, despite this it was shown to have two 
potential tyrosine phosphorylation sites and one PKC phosphorylation site [Harada et ai,
1990]. Scatchard analysis of IL-4 binding to various IL-4Ra chain truncation mutants 
demonstrated that the cytoplasmic domain is non-essential for forming high affinity 
binding sites in the extracellular domain. Therefore, association of the IL-4Ra chain and 
yc is likely to be mediated by the transmembrane and/or extracellular domains of IL-4Ra 
[Harada et al,  1990]. In addition to growth signal transduction, regions responsible for 
other IL-4 induced signalling pathways and cellular events have also been identified. The 
32D myeloid progenitor cell line expresses few IL-4 receptors and does not mount a 
mitogenic response to IL-4; however, over expression of IRS-1 cDNA in these cells 
(32D-IRS-1) results in a mitogenic response to IL-4. Truncation mutants of the human 
IL-4Ra chain, which lack amino acids 437-557 of their cytoplasmic domain, are unable 
to induce tyrosine phosphorylation of IRS-1 in these cells [Keegan et al,  1994]. There 
is, within this region, a particular motif which is also found in the insulin receptor and 
the receptor for insulin like growth factor 1 (IGF-1). Site directed mutagenesis of a 
tyrosine at position 497 (Y497) in this motif of the IL-4Ra chain resulted in almost total 
abrogation of IL-4-induced phosphorylation of 1RS-1 in 32D-IRS-1 cells [Keegan et al.,
1994]. This 437-557 amino acid region of the IL-4Ra chain is also a requirement for 
STF-IL-4 activation and, interestingly, Jak3 activation [Pernis etal ,  1995a]. A previous 
report has indicated that neither IL-4-induced IRS-2 nor Stat6 activation involves the 
association of these two molecules with one another [Kotiandes et al,  1995]. 
Therefore, a possible interpretation is that either IRS-2 and Stat6 associate the 437-557aa 
region independently or the commonly associated Jakl kinase associates with this region 
and in turn activates both IRS-2 and Stat6. Jak3 is found to be associated with the yc 
chain of a number of cytokine receptors including the IL-4 receptor complex. Therefore, 
it is possible that the association of IL-4Ra chain and yc in response to IL-4 requires this 
437-557aa region and that deletion mutants are unable to mediate this association, with a
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resultant failure to phosphorylate and activate Jak3. Recombinant human IL-4 is able to 
induce both proliferation and inhibition of apoptotic cell death in human IL-4Ra- 
transfected BA/F3 cells. Human IL-4Ra constructs with deletions of either the gpl30 
boxl or the acidic amino acid 333-365 region fail to stimulate IL-4 induced growth or 
inhibition of apoptosis [Deutsch et al., 1995]. A point mutation in the gpl30 boxl 
(P242S) results in loss of growth stimulation via the IL-4 receptor but does not affect the 
ability of IL-4 to inhibit apoptosis or to induce expression of c-myc RNA [Deutsch et ai,
1995]. Other IL-4-induced biological responses, e.g. isotype switching from IgM to 
IgGl and IgE, can also be linked to specific regions of the IL-4Ra chain. An Abelson 
virus-transformed, murine pre-B cell line A20, transfected with the human IL-4Ra, 
induced production of germline Ce (IgE heavy chain) transcripts. In contrast, complete 
cytoplasmic domain truncation mutants and mutants lacking the previously described 41 
amino acid, critical growth signal transduction region [Izuhara et al., 1995] failed to 
induce germline Ce transcripts [Schultz et ai,  1995]. Therefore, it appears that the 
critical regions for IL-4 induced growth and differentiation signal transduction are one 
and the same.
1 .4  Janus Kinase/S tat Signalling Pathways in Lymphocytes
In recent years the discovery of the Janus (or Jak) family of protein tyrosine kinases and 
their relationship to cytokine signal transduction, has provided great insights into one of 
the underlying mechanisms of control and regulation of development of lymphoid and 
myeloid cell lineages. In addition, the relationship between Jak kinases and their ability 
to activate Stat proteins has uncovered important links in cytokine regulated gene 
expression. It has been known for some time that many cytokines, upon binding to theii' 
receptors, have the capacity to induce tyrosine phosphorylation - both phosphorylation of 
intracellular proteins and also phosphorylation of the receptor components themselves. 
However, as none of these receptors have intrinsic tyrosine kinase activity within their 
cytoplasmic and transmembrane domains, it was assumed that association of
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independent, intracellular protein tyrosine kinases with these receptors was the probable 
mechanism of activation. This hypothesis has been borne out by the discovery of the 
association with and activation of members of the src -proto-oncogene family by some 
cytokine receptors, e.g. IL-2 induces activation of p5 6 lck [Hatakeyama et ai,  1991], and 
IL-4 and IL-9 both induce activation of IRS-2 [Wang et al., 1993; Yin et al., 1995].
Since the identification of Jak kinases it has been demonstrated that the vast majority of %
cytokines activate at least one, and usually two, members of this family. Jak kinases 
have a physical structure which distinguishes them from other groups of tyrosine 
kinases. Thus, they are characterized by the presence of two carboxyl terminal-kinase 
related domains and the absence of any SH2 or SH3 {src homology) domains, a feature 
common to the src family of tyrosine kinases and to certain plasma membrane receptors i
I ' .with intrinsic kinase activity in their cytoplasmic domains, e.g. the receptors for EGF and 
PDGF.
One of the major targets for activated Jak kinases are Stat proteins; a family of proteins «
with a carboxyl terminal SH2 domain which lies in close proximity to the target tyrosine 
residue for Jak kinase activity. Jak kinases activate Stat proteins by phosphorylation of I;
specific tyrosine residues, whereupon monomeric Stat molecules form transcriptionally
■ 1'
active homo- and heterodimers, via interactions between their SH2 domains and the 
newly phosphoiylated tyrosines. The dimeric Stat complexes then translocate to the 
nucleus of the cell and bind specific DNA sequences within the promoter regions of 
specific cytokine activated genes and thereby regulate transcription.
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1. 4.1 The Janus family of Tyrosine Kinases
The Janus family consists of four members, Jakl, Jak2, Tyk2 and Jak3, which were 
originally identified by PCR and low stringency hybridization methods [Wilks, 1989]. §
Full length Jakl and Jak2 cDNA clones were isolated using PCR amplification with 
probes characterizing their kinase catalytic domains [Wilks et al., 1991]. Similar 
approaches were used to identify Tyk2 and, more recently, Jak3 [Gance et al., 1993]. f
Figures 1.4: Mechanism of Jak-Stat Activation
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Using kinase-specific antisera the association of various cytokine receptors with one or 
more members of the Jak kinase family have been defined (Table I).
Table 1.1 Cytokine Activation of Jak Tyrosine Kinases
Cytokine Jak Kinase
IL-2, IL-4, IL-7, IL-9, IL-15 Jakl, Jak3
EPO Jak2
IL-3, GM-CSF, IL-5 Jakl, Jak2
IL-6 , CNTF, LIE Jakl, Jak2, Tyk2
IFNa/p Jakl, Tyk2
IFNy Jakl, Jak2
■il
i
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The importance of cytokine-induced association of multi-component receptors and 
concomitant association and aggregation of Jak molecules has been extensively studied.
.The accepted mechanism appears to be that in an inactive state, Jaks associate with the 
cytoplasmic domains of specific cytokine receptor components and ligand binding- 
induced receptor oligomerization brings different Jaks into close enough proximity to 
allow cross-phosphorylation at their autophosphorylation sites. The number of Jak 
molecules which are associated with each receptor is unknown, however, it has been 
hypothesized that the initial phosphorylation of one or two molecules allows the 
recruitment and subsequent activation of others thus, amplifying the signalling cascade.
An excellent example of receptor association and co-operativity in Jak kinase activation is 
the IL-2 receptor. A number of independent studies have shown that IL-2 activates Jakl 
and Jak3 in a variety of cell types, upon binding to its receptor [Beadling et aL, 1994; 
Johnston et ai,  1994; Miyazaki et ai,  1994; Tanaka étal ,  1994; Witthuhn et ai,  1994],
Use of chimeric receptors which have CD4 extracellular domains and both wild type and
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mutant forms of the IL-2RP and IL-2Ry intracellular domains, have demonstrated that 
Jakl co-immunoprecipitates specifically with IL-2Rp, and Jak3 with IL-2Ry [Miyazaki et 
aL, 1994]. In addition, Jakl appears to associate with the serine rich membrane 
proximal 'S' region of the cytoplasmic domain of IL-2Rp and mutant receptors lacking 
this region are unable to activate not only Jakl but also Jak3 [Miyazaki et aL, 1994]. 
This latter observation strongly suggests the requirement for receptor association in order 
for successful activation of a specific pattern of Jak kinases to occur. The ability of other 
cytokines which have yc as a receptor component (i.e., IL-4, IL-7, IL-9 and IL-15) to 
activate Jak3 [Johnston etaL, 1995; Witthuhn etaL, 1994; Yin et aL, 1995; Zeng etal., 
1994], demonstrates the extent of functional similarity between certain cytokine 
receptors. Indeed, the ability of almost all cytokines to activate at least one of the four 
Jak kinases, despite the fact that patterns of activation vary between cytokines, does beg 
the question of how a particular cytokine regulates the expression of a specific set of 
genes. One of the possible mechanisms underlying this specificity is the activation of 
specific patterns of Stat proteins.
1. 4 , 2  Activation of Stat Proteins
The Stat family of proteins was initially identified in studies which dealt with interferon 
regulation of gene expression. IFNa/p activation of T cells was found to induce the 
formation of a DNA binding complex containing proteins of 91kDa, 84kDa, 113kDa and 
48 kDa, a complex which is designated Interferon Stimulated Growth Factor-3y(ISGF- 
3y) [Fu, 1992a; Fu et aL, 1992b; Schindler et aL, 1992a]. The 91 and 84 kDa proteins 
have since been characterized as two splice variants of the same gene and have been 
designated Statla and Statip, respectively [Schindler et aL, 1992b]. pi 13 is Stat2 and 
p48 is a component which is specific to IFNo/p-induced DNA binding complexes. This 
oligomeric complex binds specific DNA elements in IFNa/p inducible genes. In 
contrast, IFNy induces the formation of a Stall homodimer (STF-IFNy) which interacts 
with IFNy-activated sequences (GAS elements) in IFNy-responsive genes [Shuai et aL, 
1992; Shuai et aL, 1993]. There are now six identified and cloned members of the Stat
I
s
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family and their activation by various cytokines is well characterized, though still not 
complete. Although the majority of Stat proteins are activated by more than one 
cytokine, the patterns of activation by particular cytokines seems to vary to a degree 
which, at least partially, accounts for the regulation of transcription of a specific set of 
genes. Thus, IL-2 and IL-4, both of which activate Jakl and Jak3, differentially activate 
Stat proteins; IL-4 activates Stat6  and induces homodimerization to form the 
transcriptionally active STF-IL-4 [Hou etal., 1994; Quelle etal., 1995; Schindler etal.,
1994], whereas IL-2 activates Statl, Stat3, Stat5 and two related Stat-like proteins, p94 
and p95 [Frank et al,  1995; Fuji et al., 1995; Gaffen et al., 1995; Johnston et al., 1995]. 
IL- 6  activates Statl and Stat3 and induces the formation of both Statl and Stat3 
homodimers, as well as Statl/3 heterodimers. IL-12, which also activates Jakl, is able 
to activate Stat4 [Bacon et aL, 1995] and IL-9 which, like IL-2, IL-4, IL-7 and IL-15 
activates Jakl and Jak3, induces activation of Stat3 [Yin et aL, 1995]. In addition, 
although Stat-binding DNA sequences have a high degree of homology with one another, 
the ability of Stat homo- and heterodimeric complexes to bind these elements is highly 
variable. Therefore, although almost all cytokines are capable of activating one of a 
limited number Jak kinases, their activation of Stat proteins appears to be more selective 
and it is possible that it is this latter observation, together with restriction in the DNA- 
binding capacity of specific Stat complexes to individual response elements, which 
defines the specificity of a particular cytokine response. Another factor which probably 
contributes to this specificity is the differential expression of Stats, depending on both the 
cell lineage (e.g. myeloid or lymphoid) and also the specific stage of development; e.g., 
Stat4 expression is restricted to early stages in myeloid development.
1. 4 . 3  The Role of Jak/Stat Signalling Pathways in Haematopoietic Cell 
Development
The importance of the role of cytokines in developmental regulation of a number of cell 
lineages although being clearly in evidence, particularly m myeloid and lymphoid cells, is 
not entirely understood. Thus, the discovery that almost all cytokines activate signal
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transduction pathways involving Jak kinases and Stat proteins suggested possible 
important implications for such pathways in cell development and mitogenesis. This 
remains an area where very little is understood, but is expanding rapidly, particularly 
with the production of a variety of gene knockout animals. Studies of IL-2-induced 
signal transduction in cells transfected with mutant IL-2Rp, revealed that the serine rich 
'S' region of the cytoplasmic domain, which is necessary for activation of Jakl and 
Jak3, is also a requirement for mitogenesis [Witthuhn et al,  1994]. In addition, over­
expression of a Jak3-C terminal/PTK domain truncation mutant in F7 cells resulted in 
selective inhibition of IL-2 induced activation of Jakl and Jak3 and inhibition of cell 
proliferation in response to IL-2 [Kawahara et al,  1995]. Thus, it seems that Jak 
kinases do have a role in cell mitogenesis, e.g. Jak 1 and Jak3 are important in IL-2 
induced proliferation of T cells. Over-expression of the Jak3 dominant negative mutant 
also inhibits IL-2 induction of expression of the proto-oncogenes c~fos and c-myc, but 
not of bcl-2 [Kawahara et al, 1995]. In contrast, deletion of the C terminal region of IL- 
2Rp, which is essential for IL-2 induced activation of Stat5, inhibits neither Jakl and 
Jak3 activation, nor cell proliferation in response to IL-2 [Fuji et al,  1995]. Similarly, 
IL-4 induced activation of Stat6  has been demonstrated to require the membrane distal 
region of the IL-4Ra chain [Quelle et al,  1995], a region which is distinct from the 
acidic membrane proximal region reported to be critical for IL-4 induced cell growth and 
differentiation [Harada et al,  1990; Harada et al,  1992; Schultz et al., 1995]. 
Therefore, whereas Jak kinases appear to have some role in cytokine induced 
proliferative responses, Stat proteins are not required for mitogenesis, despite their 
obviously important functions with respect to regulation of transcription. This is a 
hypothesis which so far seems to be supported by Jak/Stat gene knockout studies.
One usage of a Jak/Stat pathway is particularly interesting and demonstrates how 
selectivity of signal nansduction pathways can profoundly influence cellular' development 
and differentiation. IL-4 and IFNy differentially regulate proliferation and differentiation 
of helper T cell (Th) clones; IFNy inhibits the generation of Th2 but not Thl clones
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[Gajewski and Fitch, 1988]. IFNy activates tyrosine phosphorylation of Jak 1 and Jalc2, 
which in turn results in the phosphorylation of Statl and formation of Statl homodimers 
(STF-IFNy) [Muller et al,  1995; Shuai etal ,  1992; Watling etal ,  1993]. Stimulation 
of Th2 and Thl clones with IFNy results in activation of Jakl and Jak2, phosphorylation 
of Statl and resultant STF-IFNy formation and induction of IRF-1 mRNA transcripts in 
Th2 but not Thl clones [Pernis et al, 1995b]. Thl clones produce IFNy, however, 
addition of anti-IFNy blocking antibodies to cell culture prior to assay of IFNy activation 
of STF-IFNy did not affect the response, ruling out the possibility that prolonged 
exposure to IFNy results in down-regulation of the receptor. In addition, all the 
intracellular components of the pathway were both present and functional in both Th2 
and Thl clones [Pernis et al,  1995b]. In fact, Thl clones temper their responses to 
IFNy by preventing the expression of the IFNy-Rp component of the receptor, thereby 
preventing activation of STF-IFNy and transcription of a specific set of genes. Thus, 
selective use of a particular Jak/Stat pathway contributes to selective differentiation of T 
cells.
Recent findings have suggested there may be a degree of adaptability of cytokine 
receptors with respect to the signalling mechanisms they use. Fxpression of Jak3 is 
restricted to cell lineages which are lymphoid in origin, whereas the other Jak kinases are 
ubiquitously expressed. There is now evidence to suggest that IL-4 induces the tyrosine 
phosphorylation and activation of both Jakl, Jak2 and Tyk2 in epithelial cancer cells 
[Murata et al,  1995]. Neither Jak3 nor the IL-2 receptor yc chain is expressed in these 
cells, however, a 70kDa protein which was distinct from yc was found to associate with 
the 140kDa IL-4Ra chain [Murata et al,  1995]. Such observations indicate that 
cytokines may adapt their signal transduction pathways in different cell lineages 
depending on the available receptor components and associated signalling machinery.
;;5
3 6
a1.5  Structural and Functional Similarities Between IL-4 and 
IL -I3
IL-13 was first identified as a human cDNA homologue of a murine cDNA sequence 
(P600) in a human T cell cDNA library. The expressed proteins of both human and 
murine sequences were found to have a variety of immunoregulatory properties and were 
thus designated IL-13 [McKenzie et al, 1993]. IL-13, synthesised and secreted by T 
cells, is an unglycosylated protein of -10 kDa which is very closely related to IL-4. The 
genes for IL-4 and IL-13 are both located on chromosome 5 and the expressed proteins 
have approximately 30% sequence homology with one another and have a predominantly 
a-helical stmcture, as demonstrated by circular dichroism spectroscopy. In addition to 
sharing structural similarities, IL-4 and IL-13 exert many of the same functional effects 
upon target cells. Human IL-4 and IL-13 both elicit morphological and cell surface 
changes in human monocytes and promote the proliferation of B lymphocytes which 
have been pre-activated with anti-IgM antibodies or anti-CD40 (the latter presented to the 
B cells by a transfected murine Ltk" cell line) [McKenzie et al,  1993]. IL-13 also 
stimulates human B cells to induce isotype switching and IgE production, up-regulation 
of MHC Class II and up-regulation of CD23 [Aversa et al, 1993; Punnonen et al,
1993]. As well as regulating monocyte and B cell activity, IL-13 and IL-4 also act on 
human mast cells in a functionally similar manner. Thus, both of these cytokines induce 
c-fos expression, decrease proliferation, increase expression of ICAM-1 and decrease 
expression of the Stem Cell Factor (SCF) receptor kit, on the HMC-1 cell line [Nilsson 
and Nilsson, 1995]. Interestingly in the case of the latter three responses, IL-4 is 
substantially more potent (EC5 0  - 5ng/ml) than IL-13 (EC5 0  - lOOng/ml), indicating the 
possibility of a degree of differential signalling between the two cytokines [Nilsson and 
Nilsson, 1995]. The major role of IL-4, not shared by IL-13, is activation of human T 
cells and in addition, IL-4, but not IL-13, is able to inhibit mononuclear cell/SCF induced 
differentiation of tryptase-positive mast cells [Nilsson and Nilsson, 1995].
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The first evidence that IL-4 and IL-13 shared a receptor component was provided by the 
discoveiy that IL-13 competitively inhibits binding of IL-4 to IL-4 receptors on an IL-13 
and IL-4 responsive myeloid cell line, TF-1 [Zurawski et a i,  1993]. In addition, 
investigation of tyrosine phosphorylation patterns of IL-4 and IL-13 demonstrated that 
both induce phosphoiylation of the 140kDa subunit of the IL-4 receptor, IL~4Ra [Smerz- 
Bertling and Duschl, 1995]. The yc subunit of the IL-2 receptor was proposed as a 
candidate for an IL-4 and IL-13 common receptor subunit [Kishomoto et ai, 1994] (yc 
has been defined as the common receptor subunit of the lymphoid cytokine receptor 
subfamily and is a component of the IL-2, IL-4, IL-7, IL-9 and IL-15 receptors). 
However, there is little evidence in favour of 7c being a component of the IL-13 receptor 
complex. Binding of hIL-4 to its receptor on a cell line which does not respond to IL-13, 
and also to a cloned IL-4 receptor expressed in heterologous cells, was not inhibited by 
IL-13 [Zurawski et ai, 1993]. In addition, there was a 100-fold difference in binding of 
hIL-4 to these two different cell types suggesting firstly, a form of the IL-4 receptor 
which was unable to bind IL-13 and secondly, that these functional IL-4 receptors 
contain a subunit which dramatically affects IL-4 binding affinity. IL-2 and IL-7, unlike 
IL-4 and IL-13, are unable to phosphoiylate the 140kDa subunit of the IL-4 receptor 
[Smerz-Bertling and Duschl, 1995]; therefore, it is unlikely to be yc, a component of 
both IL-2 and IL-7 receptors, which mediates IL-4 induced phosphorylation of the IL- 
4Ra chain. Examination of IL-4- and IL-13-induced signal transduction demonstrates 
that while both induce phosphorylation of IRS-2 and Jakl in myeloid TF-1 ceils and 
monocyte U937 cells, only IL-4 induces phosphorylation of Jak3; a tyrosine kinase 
known to be associated with yc in IL-2, IL-4 and IL-7 receptor signalling [Keegan et ai, 
1995; Schnyder et al., 1996a; Wang et ai, 1995; Welham et al., 1995]. X-SCID is 
useful as a model for naturally occurring mutant yc proteins. B lymphocytes from X- 
SCID patients do not proliferate in response to IL-2 and IL-15 but do proliferate and 
secrete IgE in response to IL-4 and IL-13 [Matthews et al., 1995], suggesting that these 
IL-4-induced responses do not rely on yc and that the receptor for IL-13 probably lacks 
yc altogether. These differences in IL-4 and IL-2/IL-15 responses in X-SCID patients
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may be partially explained by the finding that monoclonal antibodies to two distinct yc i
epitopes indicate that the regions which bind IL-7Ra and IL-2RP overlap, while the 
region of yc which binds IL-4Ra is distinct [He et al., 1995b], Thus, IL-13 signal 
transduction would seem to involve tyrosine phosphorylation of the IL-4Ra chain and
IRS-2, but not Jak3. More recent studies have backed up such observations and also
revealed that IL-13, like IL-4, is able to induce the association of phosphorylated IRS-2 
with the 85kDa subunit of PI3-kinase [Wang et al., 1995; Welham et al, 1995]. In 
addition, there is also conflicting data concerning the ability of IL-13 to induce 
association of IRS-2 with Grb-2 [Wang et al., 1995; Welham et al., 1995] and more 
conclusive evidence against IL-13 being able to activate erk-1 and erk-2 and mediate IRS- 
2-She association [Welham etal., 1995].
There is now plentiful evidence in favour of IL-4Ra, as opposed to yc, being the 
receptor component shared by IL-4 and IL-13 receptors and it seems probable that :
signalling pathways activated via IL-4Ra, upon IL-4 stimulation, are also integral in IL- 
13 induced signal transduction. However, more recent studies point towards the 
presence of a third, novel receptor component that may be part of both IL-4 and IL-13 
receptor complexes. IL-4 affinity cross-linking studies in colorectal carcinoma cells 
indicate the presence of a novel 65kDa component [Schnyder et al., 1996a], as well as 
the expected IL-4Ra chain and the yc subunits, in the IL-4 receptor complex and in 
epithelial cancer cells the IL-4 receptor appears to consist of the IL-4Ra chain and a novel 
70kDa receptor component [Murata et al, 1995]. The novel 65kda subunit is also able to 
bind 125i_il-13 and in epithelial cancer cells [Schnyder et al, 1996a] and IL-13 inhibits 
the binding of to both 140- and 70kDa receptor components [Murata et al,
1995]. Further radiolabelIed-IL-4 cross-linking studies, followed by 
immunoprécipitation with an anti-IL-4Ra monoclonal antibody (S697), showed IL-4 
specific binding to IL-4Ra and to a lesser extent to a 65kDa band in endothelial cells 
[Schnyder et ol., 1996b]. In contrast, IL-13 bound this 65kDa subunit strongly, but no 
cross-linked receptor was precipitated by S697 and although IL-13 competed for binding
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of the 65kDa subunit with IL-4, it could not completely displace IL-4 from the IL-4Ra 
chain [Schnyder et. a l,  1996b]. Interestingly, in these endothelial cells anti-yc 
monoclonal antibodies failed to precipitate cross-hnked IL-4 receptors, indicating tliat in 
these cells yc is not a functional component of the IL-4 receptor. More recently, cloning 
and characteiization of a murine protein (NR4) has revealed it to be the alpha subunit for 
the IL-13 receptor, which induces a proliferative response to IL-13 when it is expressed 
in CTLL-2 cells and leads to cross-reactivity in the binding of IL-4 and IL-13 in these 
cells [Hilton et al,  1996]. Together, these studies suggest the presence of a receptor 
component which, as well as being part of the IL-13 receptor, may also form weaker 
associations with the IL-4 receptor complex. Interestingly, these data suggest that the 
components which constitute the IL-4 receptor may vary depending upon cell lineage; 
e.g., in lymphoid and myeloid cells the IL-4 receptor almost certainly contains the yc 
subunit of the IL-2 receptor, whereas in endothelial cells it appears it does not. Such 
observations may explain the apparent ability of IL-4 to activate different members of the 
Jak kinase family [Murata et al., 1995] as mentioned in the previous section, a 
phenomenon which also appears to be dependent upon cell lineage. However, there is 
also evidence that IL-4 induces low levels of tyrosine phosphorylation of Tyk2, as well 
as activation of Jakl and Jak3, in lymphoid cells [Welham et al, 1995] and that IL-13 
induces tyrosine phosphorylation of Tyk2 and Jakl in these cells. It may be, therefore, 
that the pattern of Jak kinases activated by IL-4 is dependent on the components which 
constitute the receptor to which it is bound and that the expression of different IL-4 
receptors is not necessarily restricted to distinct cell lineages; i.e., there is a possibility 
that two different, functionally active receptor complexes may be expressed on a single 
cell type.
1.6  CD40 Regulation of B Cell Development
As mentioned earlier, B cell activation and development is regulated by T cell-B cell 
surface interactions, events which are mediated by cell surface adhesion molecules acting
4 0
in concert with stimulation through the B cell antigen receptor. One such interaction 
between adhesion molecules is the binding of the B cell antigen CD40 to its ligand, 
which is expressed on the surface of activated T cells. This interaction appears to 
participate in all T cell-dependent immune responses throughout the latter stages of B cell 
development.
1. 6.1 CD40: Structure and Function
CD40, a 277 amino acid, type I glycoprotein with two N-glycosylation sites [Paulie et 
ai, 1989], is a member of a family of cell surface glycoproteins which includes the low 
affinity nerve growth factor receptor, two tumour necrosis factor a (TNFa) receptors, 
fas, CD27 and CD30 and has a Mgh degree of homology to these proteins [Stamekovic et 
al,  1989]. CD40 expression is observed fairly early in B cell development, following 
CD 19 and CD 10 expression and preceding the expression of CD21, CD22, CD24 and 
membrane IgM. As well as being expressed on B lymphocytes, CD40 is also found in 
monocytes, follicular dendritic cells, thymic epithelial cells and certain carcinoma cells 
[Clark et a l,  1989; Paulie et a l,  1989]. CD40 expression varies between different 
stages of B cell developement, e.g. lower levels are observed on peripheral blood B cells 
than on tonsillar B cells [Ledbetter et al,  1987]. Stimuli which regulate expression of 
CD40 include anti-p antibodies and IL-4, but not IL-2, although IL-2 can induce CD40 
expression when administered as a co-stimulus with IL-4 [Ledbetter et al, 1987; Valle et 
al, 1989]. Activation via CD40 on the B cell surface has been studied using both the 
ligand for CD40 and anti-CD40 monoclonal antibodies.
Stimulation of resting, tonsillar B cells or B cell lines with anti-CD40 does not induce B 
cell proliferation, but promotes enlargement of resting tonsillar B cells, a feature which is 
indicative of partial activation. When used as a co-stimulant with either anti-p antibodies 
or IL-4, anti-CD40 promotes proliferation of B lymphocytes [Ledbetter et al,  1987; 
Paulie et al,  1989]. This co-stimulant activity of anti-CD40 is unique to these two 
situations, as anti-CD40 does not stimulate proliferation when applied together with
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either IL-1 or IL-2. Early studies on anti-CD40-stimulated signal transduction 
demonstrated that it did not induce an increase in c-myc expression or intracellular Ca^+ 
levels, indicating that synergy with B cell receptor signalling does not rely on either of 
these pathways [Clark et al,  1989]. B-CLL cells have a phenotype of mature, partially 
activated B cells and culture of these cells with IL-4 and anti-CD40 results in prohferation 
[Crawford and Catovsky, 1993], suggesting that while either of these two stimuli alone 
are insufficient to promote DNA synthesis and cell division, they are involved in B cell 
activation. Similarly, treatment of B cells with E. coli lipopeptide enhances proliferative 
responses to IL-4 and CD40 [Edinger et al, 1994]. However, it should be noted that in 
both of these cases, the presence of feeder cells expressing FcyRII molecules were 
necessary to implement this proliferative response, indicating that cross-linking of anti- 
CD40 may be a requirement for proliferation. In addition to promoting a proliferative 
response, anti-CD40 co-stimulates B cells to induce isotype switching [Splawski e ta l,
1993]; co-stimulation with IL-4 induces IgE secretion, whereas co-stimulation with IL- 
10 induces IgG and IgA secretion. Anti-CD40-induced isotype switching is enhanced 
further by treatment with the polyclonal activator, Staphylococcus aureus Cowan I 
(SAC). Indeed SA/anti-CD40/IL-4 induced isotype switching demonstrates a distinct 
distribution of Ig heavy chain expression i.e., IgE , as compared with SA/IL-2-induced 
switching, which promotes IgGa and IgA production [Splawski et al, 1993]. Co­
stimulation of B cells with anti-CD40 and IL-2 does not induce Ig production, indicating 
that anti-CD40 will only synergize with specific activation signals. Due to the ability of 
anti-CD40 to induce proliferation and isotype switching when used as a co-stimulant, 
CD40 and interaction with its ligand is now considered to be the major mediator of cell 
contact-dependent activation signals delivered to B cells during T cell-B cell interaction.
1. 6 . 2  CD40 Ligand: Structure and Function
The ligand for murine CD40 (CD40L) was cloned and found to be a 260 amino acid, 
type II transmembrane glycoprotein, related in structure to TNFa [Armitage etal, 1992]; 
the 33kDa human CD40L has very similar structural char acteristics. CD40L is expressed
%
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only on activated T cells and appears shortly after activation of both Thl and Tli2 clones 
and is therefore not exclusive to a particular helper T cell subpopulation. CVl/EBNA 
cells transformed with murine CD40L, induce proliferation of both murine and human B 
lymphocytes in the absence of any other co-stimulation [Armitage et ai, 1992]. This 
latter finding is consistent with the observation that cell association supports anti-CD40 
stimulation of proliferation and suggests that the degree of cross-linking of CD40 is a 
major factor in implementing B cell activation. As well as proliferation, CV1/EBNA cells 
in combination witli IL-4, also induce B lymphocytes to secrete IgE [Armitage et ai,
1992]. The difference in co-factors required for anti-CD40 induced proliferation and 
isotype switching emphasizes the potential difference in intiacellular signals required for 
both of these cellular effects. Pre-activated T cells induce B cells to grow and secrete Ig 
in response to IL-2 [Blanchard et ai, 1994]. This is in direct contrast with the effects of 
anti-CD40/IL-2 co-stimulation and indicates that the CD40-CD40L interaction may play a 
role in IL-2 mediated B cell responses. Antibodies to CD40L and soluble CD40 are both 
able to block T cell-dependent B cell activation [Nishioka and Lipsky, 1994]. However, 
CD40L deficient T cell clones were found to be still capable of inducing initial B cell 
activation and Ig secretion [Nishioka and Lipsky, 1994], suggesting that T cell-B cell 
interactions other than CD40-CD40L are involved in regulation of B cell development. 
There appears to be an optimal balance of CD40-CD40L binding for induction of B cell 
activation: 40-100% binding of CD40 results in aggregation and apoptosis of B cells, 
whereas intermediate CD40 binding promotes B cell proliferation and Ig secretion 
[Bergman et al., 1996]. Untreated B cells do not respond to CDdO^ow j  cells unless 
accompanied by co-stimulation with anti-Ig [Poudrier and Owens, 1994], indicating that 
in a physiological situation, activation via the B cell antigen receptor is necessary to 
synergize with CD40-CD40L binding. The importance of CD40-CD40L interactions, 
with respect to isotype switching, is demonstrated in X-linked hyper IgM syndrome 
(HIgM-XL), a condition characterised by the excessive production of IgM but almost 
total absence of IgG, IgA and IgE secretion. Recently the HIgM-XL locus and the gene 
for CD40L have been localized to the long arm of the X chromosome at Xq26.3-27.2,
indicating that mutations in the gene for CD40L are responsible for development of this 
syndrome [Graf et al, 1992].
1. 6 . 3  Signal Transduction via CD40
CD40 is a transmembrane molecule with a short cytoplasmic tail of 65 amino acid 
residues. Patterns of protein phosphorylation demonstrate that anti-CD40 induces the 
dephosphorylation of proteins in a 50-110 kDa range and transient phosphorylation of a 
28 kDa protein, in human B cell lines [Paris et ai,  1994]. In resting tonsillar B cells 
phosphorylation of this 28 kDa protein is more sustained [Paris et at., 1994]. This 
pattern of phosphorylation is distinct from either anti-IgM or IL-4 stimulated 
phosphorylation and can be inhibited by both protein tyrosine phosphatase and protein 
tyrosine kinase inhibitors. Thus, at least one CD40 signalling pathway involves an array 
of tyrosine kinase and phosphatase activation. However, the cytoplasmic domain of 
CD40 contains no intrinsic tyrosine kinase or phosphatase activity [Paulie et al, 1989] 
and it is likely, therefore that association with independent, cytoplasmic effector 
molecules is involved in CD40-mediated signal transduction. Mutagenesis studies 
suggest that threonine^^^ in the cytoplasmic domain of CD40 is essential for activation of 
intracellular signalling pathways [Hu et a i,  1994]. In addition to protein 
phosphorylation, a Ca^+ dependent signalling pathway has been implicated in CD40 
activation of B cells, a result which is in conflict with previous studies [Clark et al.,
1989]. Anti-CD40 and IL-4 co-stimulation of murine B cell proliferation is abrogated by 
FK506 (an inhibitor of Ca^+ dependent signalling pathways in T cells), as is anti-IgM 
stimulated proliferation [Klaus et a i,  1994]. However, the former stimulus becomes 
drug resistant following 24 hours whereas anti-IgM stimulation takes longer to acquire 
this resistance. Ligation of either CD40 or mIgM in the presence of IL-4 results in 
activation of the transcription factor NF-AT, via a FK506 sensitive pathway, indicating 
that CD40, anti-IgM and IL-4 activation of B cells may all occur through a Ca^+ 
sensitive- NF-AT activating pathway, but that this pathway may only be functional in the 
early stages of B cell activation [Klaus et ai, 1994]. In addition to induction of NF-AT,
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anti-CD40 also induces activation of NF-dB in resting tonsillar B cells [Berberich etal...
1994]. Activation is rapid and occurs via a tyrosine kinase dependent pathway. DNA 
mobility shift assay allowed the isolation of a NF-kB binding complex which contains 
p50, p65 (Rel-A) and c-rel gene product proteins. Transient transfection assays in the 
Daudi B cell line demonstrated that cross-linking of CD40 promotes NF-KB-dependent 
gene expression [Berberich et al, 1994]. In addition to this, a CD40 binding protein 
was cloned using the yeast-two hybrid system. This protein contains an N-terminal 
RING finger motif found in a number of DNA binding proteins (including the VDJ 
recombination activating gene product - RAGl) and a central coiled-coil segment which 
may promote homo- and hetero-oligomerization, suggesting that one mechanism of 
CD40 signalling may involve the direct activation of a DNA binding factor [Hu et ai,
1994].
1.7  Adenylyl Cyclase and the Generation of Cyclic AMP
3
Cyclic Adenosine- 3’, 5’-monophosphate (cyclic AMP or cAMP) is a ubiquitous 
regulatory molecule in both prokaryotic and eukaryotic cells. In the latter it functions 
principally as a second messenger in signal transduction pathways, which ultimately 
result in regulation of gene expression. In mammalian systems cAMP generation is 
initiated by a vast range of stimuli in the majority of cell types and it is likely that it is 
downstream signalling events, particularly regulation of gene expression, which define 
the specificity of the stimulus which initiates this early signalling cascade. Intracellular 
levels of cAMP are controlled by a process of dual regulation; thus, cAMP is generated 
from cytosolic ATP by the enzyme adenylyl cyclase and degraded to 5AMP by 
phosphodiesterase enzymes. Phosphodiesterases are required to define both the length 
and potency of a cAMP response and do so by degrading the second messenger at the 
correct time. In addition, the activity of phosphodiesterase enzymes is now known to 
play a very important regulatory role in a variety of signalling cascades by suppressing
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levels of cAMP [Reviewed by Nicholson et ai, 1991]. However, it is the initial and 
often extensive generation of cAMP by adenylyl cyclase, which defines the importance of 
the second messenger as a signalling molecule.
Initial studies revealed that activation of adenylyl cyclase was hormone-sensitive and
polypeptides and some prostaglandins [Chiba et a i,  1989; Johnson et al., 1978;
■I
could be activated by a range of molecules including p-adrenergic amines, proteins.
Mosishita et al., 1990]. Following this, it was also noted that adenylyl cyclase was
subject to inhibitory control by opiates, a-adrenergic amines, adenosine and acetyl 
choline [Reviewed by Combest et al, 1988; Ross, 1980]. These honnones act upon a 
particular cell type by binding to membrane receptors which are linked by membrane-
-associated G protein molecules, to adenylyl cyclase [Reviewed by Neer, 1994; Segre,
1993]. The classical nature of G-protein linked receptors is a protein structure bearing 
seven hydrophobic transmembrane domains with an extracellular amino terminal domain, 
an intracellular carboxyl terminal domain and a large, third intracellular loop. The 
structure and function of G proteins is now well characterized and initial identification of 
a Gs (stimulatory) G protein revealed a structure of three distinct subunits, a, p and y 
[Simon et al, 1991]. In the inactive state, GDP is bound to the a subunit of Gs and is 
exchanged for GTP upon activation by a G protein-linked receptor, with resulting 
dissociation of the a subunit from py. GTP-bound Gsa then activates adenylyl cyclase. 
Hormone receptors which inhibit adenylate cyclase are also linked by an inhibitory G 
protein (Gi) and in this instance it is the Gia subunit which inhibits adenylate cyclase.
Since the initial discovery of G proteins, a large and complex family has been identified 
and characterized, which demonstrates vast evolutionary diversity. Gs and Gi are now 
designated subfamilies of G proteins and in addition to these, two other sub-families, Gq 
and G 12, have been identified [Reviewed by Simon et al, 1991; Spiegel, 1992]. Each
.of these families has a number of distinct G proteins within them and, to complicate 
matters further, different isoforms of the a, p and y subunits are being identified within 
these groupings [Strathmann and Simon, 1990; Strathmann and Simon, 1991;
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Strathmann et al., 1989; Tsukaraoto et al., 1991]. Thus, regulation of activation of 
adenylyl cyclase is dependent upon the particular hormone receptor which is bound by its 
ligand and also the specific G protein which is involved. Molecular cloning and 
characterization of adenylyl cyclase has been undertaken relatively recently and has 
revealed that there are a number of distinct isoforms of the enzyme. In addition, it has 
been demonstrated that regulation of adenylate cyclase activity is not confined to the alpha 
subunits of G proteins, as different isoforms are also regulated by the py G protein 
subunits, Ca^+ZCalmodulin and certain protein kinases.
1.7.1 Adenylyl Cyclase Isoforms
There are now eight recognized, distinct isoforms of adenylyl cyclase; full length cDNA 
sequences for types I-VIII have been cloned, sequenced and characterized. [Cali et ai, 
1994; Defer et ai, 1994; Helleuvo et al., 1995; Katsushika et. al., 1992; Kiupinski et ai, 
1989; Watson et al., 1994; Yoshimura and Cooper, 1992]. The first mammalian 
adenylyl cyclase isoform to be cloned was type I, a Ca^+ZCalmodulin sensitive form 
cloned from bovine brain [Krupinski et al., 1989]. The structure, which has been 
predicted from all the available sequences, is a membrane protein with twelve 
transmembrane domains (two sets of six hydrophobic regions separated by a large central 
cytoplasmic loop) and intracellular N~ and C-termini, the latter occuixing at the end of a 
long cytoplasmic tail [Krupinski et al., 1989]. The central cytoplasmic loop and N- and 
C-termini are highly conserved between the different isoforms of adenylyl cyclase and it 
is thought that these regions of high homology form part of the catalytic site. Indeed, 
using a baculovirus expression system in Sf9 cells, it has been demonstrated that there is 
no adenylyl cyclase activity upon expression of either of the two six transmembrane- 
spanning region domains alone. However, co-expression of both domains results in 
considerable enzyme actvity, suggesting that a physical interaction between the two is 
required for catalytic activity of adenylyl cyclase [Tang et al., 1991a]. The tissue 
distribution of adenylyl cyclase is variable depending on the isoform: some are highly 
specific, such as type I, which seems to be confined to neuronal tissues; others like types
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II, IV, V and VI are widely distributed throughout neuronal and non-neuronal tissues.
While all isoforms are expressed to some degree in the brain, there is regional 
distribution of types I-II, V and VIII.
1. 7 . 2  Regulation of Adenylyl Cyclase Activity
(i) G-protein Regulation
All mammalian isoforms of adenylyl cyclase cloned so far are stimulated by Gsa and 
forskolin, whereas Gia inhibits only types II, III and VI. Type I is inhibited by the fly 
subunits of G-proteins [Katada et aL, 1987; Tang et al., 1991a]. In contrast, types II |  
and IV are stimulated by py in the presence of activated Gsa [Tang and Gilman, 1991b], 
whereas types III, V and VI are unaffected by py. There is evidence that adenylyl 
cyclase isoforms are capable of integrating a number of G protein-related signals at one 
time. In HEK cells transiently transfected with the Type II isoform, adenylyl cyclase 
activation by a Gs agonist is augmented by Gi- and Gq-activating agonists, via the Gi Py 
subunits and PKC, respectively [Lustig e ta l,  1993]. Down-regulation of PKC activity 
results in prevention of stimulation of Type II adenylyl cyclase by both PMA and Gq- 
linked receptor agonists [Lustig etal., 1993].
(ii) Ca '^^ Regulation
Types I, n i and VIII are activated by Ca^+ZCalmodulin; for type I this activation occurs 
independently of Gsa, whereas Ca^+ZCalmodulin activation of type III is inhibited by 
G sa and activation of type VIII is synergistically increased in response to 
Ca^+ZCalmodulin and Gsa [Cali et al, 1994; Choi et ai,  1992; Cooper et al., 1988; 
Krupinski et al., 1989; Tang et al., 1991a]. Types V and VI are inhibited by low 
(micromolar) concentrations of Ca^+ [Debernardi etal., 1993; Yoshimura and Cooper,
1992]. Type V and VI have a high degree of sequence homology, even in the 
transmembrane regions, where generally the greatest degree of divergence between 
isoforms exisits. As such, types V and VI have been classified as a distinct adenylyl 
cyclase sub-group [Katsushika etal., 1992]. Isoforms II, IV and VII are independent of 
any Ca^+ mediated regulation [Watson etal., 1994].
(Hi) Protein Kinase regulation
It has been demonstrated that type II adenylate cyclase is the major target for PKC, as it 
can be activated by both PMA and PBu2  but not the inactive PMA isomer, 4aPMA 
[Yoshimura and Cooper, 1993]. Additionally, these effects are inhibited by the PKC 
inhibitor staurospoiine [Yoshimura and Cooper, 1993]. This same study also observed 
that PKC was not involved in the activation of types I or III adenylyl cyclase. However, 
other reports have demonstrated weaker regulatory effects of PKC activators on types I 
and III. Thus, pre-treatment with PMA augments Ca^+/Calmodulin activation 
[Jacobwitz et al, 1993] and forskolin activation [Choi et al, 1992] of types I and III, 
respectively, in transiently transfected kidney 293 cells. PKC activation of type II does 
not require Gsa and produces nearly a 10-fold increase in intracellular cAMP levels in 
certain intact cells. Interestingly, PKC treatment abolishes Gia-induced inhibition of the 
type II enzyme but does not affect Gia inhibition of types III and VI. Recently, both rat 
and human forms of type VII have been shown to be activated in response to phorbol 
ester treatment [Helleuvo et a l,  1995; Watson et al, 1994], indicating possible 
regulation by PKC. Pre-treatment with pertussis toxin (an inhibitor of Gi) does not 
affect this sensitivity to phorbol ester, suggesting that this activity is independent of 
modification by Gi [Watson et al,  1994]. cAMP-dependent decreases in adenylyl 
cyclase activity have been observed in hepatocytes and S49 kin' lymphoma cells. 
Treatment with 8 -bromo-cAMP results in a decrease in fluoride activation of adenylyl 
cyclase in chicken hepatocytes and addition of the cataltic subunit of PKA to S49 kin' 
lymphoma membranes, inhibits both fluoride and forskolin-stimulated adenylyl cyclase 
activity [Premont et al, 1992]. Type VI adenylyl cyclase is common to both of these cell 
types and it has been suggested that PKA initiates a negative feedback loop to regulate 
activity of this isoform
The implications of this diversity in regulation of adenylyl cyclase isoforms is, that any 
individual type may be able to integrate a variety of signals in order to give a very 
measured and specific response. In addition, recent studies have revealed that there are
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three splice variants of type VIII (VIII-A, VIII-B and VIII-C). VIII-A is the initially 
characterized type VIII, whereas, VIII-B and VIII-C differ by deletions of 90 and 198 
base pair exons encoding a 30 amino acid extracellular domain with two N-glycosylation 
sites and a 6 6  amino acid cytoplasmic domain, respectively, VIII-A and VIII-C are 
modified by N-glycosylation and are sensitive to N-glycosidase, whereas VIII-B which 
lacks the relevant extracellular domain is not [Cali et ai, 1996]. Thus, it appears that 
differential regulation of sphce variants of single isoforms of adenylyl cyclase may exist, 
hinting at additional regulatory controls.
1. 7 . 3  cAMP Regulated Gene Expression
In eukaryotic cells the major target for cAMP action is a serine/threonine-specific cAMP- 
dependent protein kinase, protein kinase A (PKA). The inactive holoenzyme of PKA is 
composed of two regulatory (R) subunits and two catalytic subunits (C), R2 C2 . The 
enzyme is activated upon cAMP binding to the dimeric R2  regulatoiy subunit, an event 
which induces the release and activation of the two catalytic subunits; thus, cAMP acts as 
an aliosteric effector of PKA. The mechanism of cAMP activation of gene expression in 
prokaryotic cells has been well understood for a number of years, but it is only in the last 
ten years that the mechanism behind cAMP-dependent regulation of gene transcription in 
eukaryotes has come to light [Reviewed by Nigg, 1990]. There are two proposed 
mechanisms of regulation of cAMP-inducible genes by PKA in eukaryotic cells. Firstly, 
that the active catalytic subunit acts upon transcription factors which bind elements in the 
promoter sequence of cAMP-inducible genes, either by translocating to the nucleus and 
phosphorylating a transcription factor directly or by acting on an intermediate nuclear 
factor, or alternatively, by remaining in the cytosolic fraction and phosphorylating an 
intermediate activator which in turn translocates to the nucleus to initiate gene expression 
[Meinkoth et al, 1990; Montminy and Bilezikjan, 1987; Sato-Bigbee et ai,  1994; Short 
et al, 1986]. The second, more controversial, hypothesis is that the regulatoiy subunits 
of PKA, once bound by cAMP and released from the catalytic subunits, translocate to the
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I'nucleus and regulate transcriptional activation directly by binding to specific sequences upstream of cAMP-inducible genes [Constantinou et aL, 1985; Nagamine and Reich, 
1985].
1.7.3.a Activation of CREB
Initial research demonstrated that PKA affected gene expression when it was observed 
that PKA-deficient cell lines were unable to stimulate transcription in response to cAMP. 
In addition, the role of the C subunit in particular was identified when it was 
demonsti'ated that micro-injection of the C subunit directly into cells specifically activated 
transcription of cAMP inducible genes [Montminy and Bilezikjan, 1987]. In the case of 
one particular cAMP responsive gene, somatostatin, deletion mutants of gene promoter- 
CAT constructs, transfected into PCI2 cells, defined a 30 nucleotide sequence which
was essential for cAMP responsive transcription [Montminy etal., 1986]. This 30 base 
pair region contains a short palindromic sequence motif, 5’- TGA CGT CA -3’, which is 
very highly conserved in the promoter regions of a large number of cAMP inducible 
genes, including the c-fos proto-oncogene, somatostatin, tyrosine hydroxylase and many 
others [Montminy et al., 1986]. This region was designated the cAMP responsive 
element (CRE) and shows classical enhancer sequence characteristics e.g., stimulating 
transcription from a distance and displaying functional activity irrespective of orientation. 
In addition, this sequence induces cAMP responsiveness when introduced into non- 
cAMP inducible genes. Footprinting analysis of PC 12 extracts demonstrated the 
presence of a single footprint, covering 23 base pairs, which mapped to the site of the 
somatostatin CRE sequence [Montminy and Bilezikjan, 1987]. Using this particular 
sequence, a CRE binding protein (CREB) was purified by affinity chromatography and a 
43kDa protein, which turned out to be both specific for CRE binding and which was 
phosphorylated by purified PKA catalytic subunits, was isolated [Montminy and 
Bilezikjan, 1987]. Other CRE binding proteins which are homologous to CREB 
[Habener, 1990; Short et al., 1986] have been identified, building up a recognized 
family of CREB proteins, e.g., a 45kDa protein in oligodendroglial cells [Sato-Bigbee et
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al, 1994]. Gel retardation assays demonstrated two major CRE-binding, mobility shilt 
bands - a monomeric and a dimeric form of which only the dimeric form appears to be 
transcriptionally active [Yamamoto e ta l ,  1988]. Cloning and sequencing of the full 
length cDNA has predicted a three domain structure: a transactivation domain with a 
series of PKA, PKC and casein kinase II phosphorylation sites, of which serine 133 
seems to be critical for transcriptional activation [Gonzalez and Montminy, 1989]; a DNA 
binding domain, containing a series of basic amino acid residues; a leucine ‘zipper’ 
dimerization domain, critical for formation of the transcriptionally active dimeric form of 
CREB [Montminy et al,  1990]. All this evidence points to CREB being a major 
substrate for PKA and the principal mediator of cAMP induced gene expression.
1.7.3.b Regulation of Gene Expression by the Regulatory Subunit of 
PKA
The idea that the R2  subunit, when bound by cAMP, acts directly as a regulator of 
transcription by binding to consensus DNA sequences in cAMP responsive genes, is 
controversial and the evidence supporting this hypothesis is tentative. The type-2 
regulatory subunit of PKA appears to possess intrinsic topoisomerase activity and it has 
been suggested that by altering the chromatin structure of genes the R subunit may 
subsequently regulate gene expression [Constantinou et al,  1985]. An additional 
hypothesis is that the R subunit acts in a manner that is analogous to the bacterial CAP 
protein [Nagamine and Reich, 1985]. In prokaryotic cells cAMP binds to the catabolite 
repressor protein (crp) or the cAMP binding protein (CAP) and the complex binds to 
specific promoter sequences which influence gene transcription. A 29 base pair sequence 
in the 5’ flanking region of a urokinase form of the plasminogen activator gene has been 
proposed as an R subunit binding site; 5' GAA AGG GTG AG A AAG AGC TGA TTG 
AGG GG 3' [Nagamine and Reich, 1985]. This sequence is highly homologous to 
sequences in other cAMP-inducible genes, bears no resemblance to the CRE element and
..
is homologous with the E. coli gal operon sequence and other bacterial cAMP-CAP 
controlled gene promoter sequences. In addition, certain regions of the R subunit of
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bovine cardiac PKA share characteristics with DNA binding regions of the bacterial CAP 
proteins. However, despite this, no direct evidence in favour of R2 acting as a 
transcriptional activator has been published.
1.7.3.C other cAMP Responsive Elements
cAMP-responsive transcription factors and promoter elements, other than CREB and
■
CRE, have also been identified. AP2, a 50kDa protein which interacts with regulatory 
elements of a number of genes is cAMP responsive [Comb et al, 1986]. However, this 
responsiveness seems to be dependent upon the proximity of CREs, as gene expression 
is only noted when multiple copies of AP2 are present upstream of the transcriptional 
initiation site, whereas a single AP2 site will not respond to cAMP unless CRE is also 
present in the promoter region [Comb et al, 1986]. Another element, placental tissue 
specific element (TSE), is usually found adjacent to two tandem CRE sites and is cAMP 
responsive only in the presence of CREB binding [Delegeane et al, 1987]. However, 
recently the human tryptophan hydroxylase gene promoter has been shown to be cAMP- 
responsive and the critical cAMP-inducible element of this promoter is a motif which is 
entirely distinct from CRE [Boularand et al,  1995]. Thus, it seems cAMP-induced 
regulation of gene expression can potentially be mediated via multiple signalling 
pathways and transcription factors. Recently, a second co-activator of transcription 
(CBP/p300) which associates with CREB has been identified. CBP or p300 interacts 
with CREB and phosphorylation of Serine 133 on CREB appears to be a requirement for 
this association. CBP can also bind to the basal transcription factor TFIIB, thereby 
acting as a bridging molecule between CREB and the machinery which initiates :
transcription. CREB also undergoes PKA-independent phosphoiylation by PKC upon 
activation of the T cell receptor [Brindle et al, 1995], an event which does not lead to 
association with CBP. However, co-stimulation with a sub-optimal dose of a cAMP 
agonist results in CREB-CBP association in the absence of CREB phosphorylation, 
suggesting that PKA-induced phosphorylation of a second factor, possibly CBP itself, is 
required for co-activation of transcription. Injection of anti-CBP antibodies into cells
i:
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inhibits c AMP-stimulated gene activation, [Chakravarti et al, 1996; Kamei et ai, 1996] 
and nuclear receptors for steroids, thyroids and retinoids also interact with CBP upon 
binding of the requisite hoimone [Kamei et al,  1996]. The HTLV-1 viral protein Tax 
can form a transcriptionally active complex with CREB and CBP and increases the 
binding of CREB to viral CRE sequences independently of CREB phosphorylation. In 
contrast. Tax induced binding to host cell CREs requires CREB phosphorylation [Kwok 
etal,, 1996].
1. 7 . 4  cAMP Generation in Lymphocytes
The role of cAMP generation in lymphocytes remains equivocal and the available 
information demonstrates a dichotomy with respect to stimulatory and mhibitory effects; 
indeed there appears to be a great deal of variability dependent upon cell type, species and 
developmental stage. Cytokines which elevate intracellular cAMP in lymphoid cells 
include, IL-1 in murine thymocytes 70/Z3 pre-B cells, YT human natural killer-like cells 
and CESS human B lymphocytes [Shirakawa et al., 1988], and IL-4 in human B i
lymphocytes [Finney etal., 1990]. In addition, other cAMP generating stimuli which 
act upon lymphoid cells are PGE2  and, interestingly, ligation of MHC class II in resting 
murine B cells [Andre et ai, 1994]. In T lymphocytes, elevation of cAMP levels exerts a 
variety of effects including inhibition of IL-2 production [Tsuruta et al., 1995] and 
inhibition of expression of the p and a subunits of the IL-2 receptor complex [Krause and 
Deutsch, 1991], while having no effect upon IL-4 production. Elevation of cAMP also 
synergizes with Ca^+ to regulate expression of CD7, a marker of T cell activation. VDJ 
recombination activity in lymphoid cells, an event which is associated with development 
and differentiation, is induced by agents which elevate cAMP [Menetski and Gellert,
1990]. In addition, cAMP activation of PKA acts to stabilize ionomycin-induced 
transcription of the IFN-y gene in cytotoxic T cells, i.e., it stabilizes ionomycin-induced
mRNA transcripts of the gene and promotes IFN-y expression and secretion [Kaldy and 
Schmitt-Verhulst, 1995]. As well as positively regulating post-transcriptional events, 
cAMP has a role in transcriptional regulation in lymphoid cells. cAMP elevating drugs
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and cAMP analogues are able to mimic IL -l’s ability to induce biological responses such 
as K-lighl chain expression in 70/Z3 pre-B cells and IL-2Ra chain expression in YT 
natural killer cells [Shirakawa et a l,  1989a; Shirakawa et al,  1986]. IL-1 and cAMP 
generation are both able to induce transcriptional activation of x-immunoglobulin-CAT 
constructs in 70/Z3 cells, and also activate cytosolic NF-kB and induce its translocation 
to the nucleus [Shirakawa and Mizel, 1989b]. All of these effects are inhibited by H8 , an 
inhibitor of PKA and PKC, but not by PKC-specific inhibitors, suggesting that IL-1 acts 
upon NF-kB via a cAMP generating/PKA activating pathway. In addition IL-1, 8- 
bromo-cAMP and forskolin all induce activation of NF-kB in YT cells and the promoter 
of the IL-2Ra chain gene, which is expressed in response to IL-1 and cAMP in these If
cells, contains a binding site for NF-kB. IL-1 and 8 -bromo-cAMP promote NF-kB I
binding to its specific promoter element in these cells and again, these effects are Iinhibited by H8  [Shirakawa and Mizel, 1989b]. Thus, it was concluded that IL-1 'I#
activates expression of IL-2Ra and K-immunoglobulin genes, at least partially, by cAMP
■|
induced activation of NF-kB.
The role of cAMP in B lymphocyte proliferation seems particularly variable. In murine B 
lymphocytes, PGE2  and other cAMP elevating agents inhibit IgM production, 
proliferation and enlargement of B cells, MHC Class II hyper-expression and CD23 
expression [Roper et ai, 1994]. In addition, ligation of MHC class II in resting murine 
B cells induces cAMP generation [Andre et ai, 1994], a response which appears to have 4 
an anti-proliferative effect and induces apoptosis. In contrast, there is no observed 
generation of cAMP upon hgation of MHC class II in activated murine B cells. In human 
tonsillar B cells, the effects of cholera toxin and other cAMP elevating agents, such as 
forskolin and dibutyryl-cAMP, are dependent on the presence of other stimuli. Thus,
Icholera toxin, forskolin etc., enhance proliferation of activated B cells stimulated with 
anti-IgM in a dose-dependent fashion and they also enhance IL-4-induced DNA synthesis 
in anti-IgM-activated B cells [Garrone and Banchereau, 1993]. In contrast, cholera
toxin, forskolin etc. inhibit IL-2 induced DNA synthesis in anti-IgM-activated B cells, an
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effect which has been partially attributed to cholera toxin induced reduction in CD25 
expression [Garrone and Banchereau, 1993]. However, this latter effect is 
unconvincing as levels of CD25 in these cells remains greatly elevated above basal and 
any observed decrease appears to be minimal. Thus, in murine B cells the effects of 
cAMP appear to be profoundly negative, whereas in human B cells elevated cAMP, in 
the majority of cases, seems to positively regulate proliferation. This is extremely 
interesting when one considers the ability of IL-4, which is a co-stimulant of B cell 
activation, to generate cAMP production in human B cells but not in murine B cells 
[Garrone and Banchereau, 1993].
1.8  The CD25 Promoter
As has been outlined in previous sections, the regulation of development of lymphoid 
cells is mediated by exposure to antigen, cytokines and adhesion molecules and is 
marked by the transient appearance of cell surface proteins which act as receptors for 
such stimuli. The activity of IL-2, with respect to T and B lymphocyte development, is i
dependent upon the presence of the high affinity (apy) form of the IL-2 receptor complex 
at the cell surface. In both resting human T and B cells, the expression of CD25 (IL~2Ra 
chain) is mmimal or non-existent and regulation of expression is key to the production of 
high affinity IL-2 receptors and subsequent maximal activation responses to IL-2.
Stimuli which regulate the expression of CD25 in T and B cells are markedly different 
and the signalling pathways employed in up-regulation of CD25 are poorly understood.
In human B cells, the expression of CD25 in response to IL-4 does not appear until 24 
hours after initiation of culture, suggesting that de novo synthesis of CD25 is required.
enhancer elements in the 5' promoter region of the CD25 gene and the intracellular 
signalling pathways involved in regulating binding of transcription factors. The CD25 
promoter has been well studied and is known to contain a number of common nucleotide
IThus, in order to understand regulation of CD25 expression, it is necessary to examine 
the regulation of transcriptional activation, the pattern of DNA-protein binding to various
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sequences which, by association with their appropriate transcription factors, are involved 
in regulation of a wide series of genes. These motifs include sites for NF-kB family
■
proteins, Spl and serum response element (SRE) binding proteins. In addition, a 
number of other nucleotide sequences which define more lineage specific transcription 
factor binding elements have been identified within the CD25 promoter. These include 
motifs which bind two negatively acting factors, the retinoic acid response element 
(RARE) and a negative regulatory element (NRE), and a positive regulatory element, the 
IL-4 response element (IL-4RE). More recently, a Stat6  homodimer (STF-IL-4) binding 
site has been identified in the CD25 promoter. These various transcription factor binding 
elements and their spatial positions within the CD25 promoter are outlined in Figure 1.5.
1. 8.1 Positive Regulatory Elements of the CD25 Promoter
l.S .l.a  NF-KB/SRE/Spl Binding Sites
While little is known of transcriptional regulation of CD25 in human B cells, there is 
considerably better understanding of the activation of transcription of CD25 in T cells.
Resting T cells do not express CD25, but can be induced to do so through the activation 
of T cells by antigenic and mitogenic stimuli. In contrast, HTLV-1 infected T cells 
constitutively express high levels of CD25. HTLV-1 (human T cell lyniphotropic vims- 
1 ) is a retrovirus considered to be responsible for the development of an aggressive form 
of adult T cell leukaemia (ATL). The expression of CD25 protein and mRNA transcripts 
in the HTLV-1 infected T cell lines MT2 and HUT 102 provided a model for initial 
studies on transcriptional activation of the CD25 gene [Cross et al, 1987]. Transfection 
of MT2 cells with CD25 promoter-deletion mutant-CAT constructs, indicated that 
progressive deletion from the 5' end of the promoter resulted in increases in reporter gene 
activity and a negative regulatory element lying 5' of -369bp from the transcription 
initiation site was proposed [Cross et a l,  1987]. Reporter gene activity fell from 
elevated levels when -253 and -244 deletion mutant-conshucts were transfected into MT2 
cells, and no detectable activity was observed after deletion beyond -177. Unlike HTLV- 
1 infected cells, normal Jurkat and YT-1 T cell lines show very low levels of basal
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promoter-reporter gene activity, but can be readily induced by mitogenic stimulation with 
PM A or PHA [Cross et al, 1987; Lowenthal et al, 1988]. PMA induced a 4- to 12-fold 
increase in CAT activity in Jurkat and YT-1 cells transfected with -471 and -317 deletion 
mutants, whereas only a 2 -fold increase was observed with -271 mutants, suggesting a 
46bp PMA-inducible region located between nucleotides -317 and -271 [Lowenthal et 
al, 1988]. Certain 5' deletion mutants which possess high activity in HTLV-1 infected 
cells (i.e., A-267 and a-253 mutants) are not transcriptionally active in Jurkat cells 
[Cross et al, 1987], therefore, a region from -327 to -253 was defined as a potential site 
for HTLV-1 or HTLV-1 induced-host cell gene products. Tat-1 is the HTLV-1 gene 
product which transcriptionally activates PITLV-l-long terminal repeats (LTR) and co­
transfection of Tat-1 cDNA with a CD25 promoter-CAT construct into Jurkat cells, 
reproduced some of the regulatory patterns observed in HTLV-1 infected T cell lines; 
thus, in the presence of Tat-1, PMA was no longer required to induce CD25 promoter 
activity. In region -293 to -241 of the CD25 promoter two imperfect direct repeats (IDR) 
occur. In DNA mobility shift assays, using extracts from PMA-activated T cells, 
oligonucleotides encompassing both of these IDRs or the downstream IDR alone, but not 
the 5' upstream IDR, are able to form DNA-protein binding complexes. Similarly the 
first two of these oligonucleotides, but not the third, are able to compete with each other 
for DNA-protein binding activity [Lowenthal et al, 1988]. Thus, a positive regulatory
element in the CD25 promoter occurs between base pairs -217 and -253 of the CD25 
promoter and it appears that while the 3' end of this region is a potential site for HTLV-1- 
Tat-1 binding, sequences 5' from this were a requirement for PMA inducibilty in non­
infected cells. A region of the CD25 promoter (-267 to -258) which binds members of 
the c-rel proto-oncogene family has been identified [Leung and Nabel, 1988]. In 
addition, overlapping sequences defining a CArG box (-253 to -244) and a GC box (-
includes; c-rel NF-kB (p50), Rel A (p65), NF-kB2 (p49 and p50B) and Rel B (p6 8 ) 
[Reviewed by Baldwin Jr., 1996]. Homo-and heterodimeric complexes of c-re/ family
245 to -240), which bind SRF and Spl respectively, were identified in a region 3' of this 
site [Poraerantz et al, 1989; Toledando et al, 1990]. The c-rel proto-oncogene family
I
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members regulate genes containing kB binding sequences in their 5’ flanking promoter 
regions. In T cells, a constitutive occupancy of the kB site in the CD25 promoter was 
demonstrated: in unstimulated cells NF-xB-pSO homodimers bind to the promoter and 
inhibit transcription, possibly by prevention of SRF binding to the CArG box. Upon
stimulation the p50 homodimer is exchanged for a NF-kB p50-p65 heterodimer, an event 
thought to facilitate SRF binding to SRE [Algarte et al., 1995]. In Cos cells expressing 
low levels of c-rel family proteins, transfection with c-rel or p50 has been shown to co­
operate with SRF to induce transcriptional activation and enhanced transcription is 
observed in the presence of c-rel, p50 and SRF [Pierce et al., 1995]. Thus, in human T 
cells the major means of activating transcription of the CD25 gene appears to be binding /
of positive regulatory transcription factors to the kB  and SRE sites. In contrast, in
human B cells, binding of transcription factors to kB, SRE and Spl sites remains 
relatively unaltered in response to stimulation with IL-4, the major CD25 inducing 
stimulus for human B cells. It seems therefore, that mechanisms of transcriptional 
activation of the CD25 gene may be differentially regulated depending upon cell lineage.
1.8.l.b  IL-4 Response Elements in the CD25 Promoter
The IL-4 response element (IL-4RE) in the CD25 promoter was identified by its 
sequence homology to an IL-4 response element in the promoter region of the IL-4- 
inducible CD23b (F ce receptor II) gene [Kohler and Rieber, 1993]. Point mutations 
within a 9 base pair sequence (TTC TAA GAA) in this element showed it to be essential 
for IL-4-induced activation of transcription and the transcription factor which binds this 
element (NFIL-4) is not activated by Ca^+ ionophore, phorbol ester or cAMP [Kohler
and Rieber, 1993]. Other similar IL-4 response elements have also been identified in an
-
enhancer element of the k  gene [Ichiki et al, 1993; Kohler and Rieber, 1993] and the 
promoter regions of a number of Class n  MHC genes [Boothby et al, 1988; Kietsovali 
and Papamatheakis, 1995]. A region (NF-BRE) upstream of the murine Class II MHC 
Aa gene, when cloned into an SV40 promoter of a p A IOC AT plasmid and transfected 
into Class II MHC positive B lymphoma M12.A2 cells, shows a 70-fold increase in
I
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reporter gene activity in response to IL-4 [Boothby et al., 1988]. Similarly, nuclear 
extracts from IL-4 stimulated M12.A2 cells fomied DNA-protein binding complexes with 
an oligonucleotide bearing the DNA sequence of this region, as did extracts from both 
normal and athymic spleen cells [Boothby et ai, 1988]. A DNA sequence described in 
the promoter of the Class II MHC Ea gene in murine M12 cells, has been described as an 
IL-4 response sequence (ILRS). IL-4 activates a nuclear factor (NFIL-4), which binds a 
novel element within ILRS. In addition, similar IL-4 inducible complexes are formed
between nuclear extracts from IL-4 treated M12 cells and both the IFNy response 
element (GRR) of the FcyRI gene and the acute phase response element (APRE) of the 
a2 macroglobulin gene promoter region. This complex, designated NFIL-4, also 
recognizes certain GAS-like sequences. Indeed, both GRR and APRE sites have 
sequence homology to GAS elements [Kretsovali and Papamatheakis, 1995]. A 
palindromic GGAA motif present in the response elements of the Ea, IFNp, FcyR and
'a2M promoters has been highlighted as the possible underlying common motif which 
facilitates NFIL-4 binding to all these response elements. Thus NFIL-4, defined as a 
protein with a molecular weight of 75kDa, is able to successfully bind a range of 
cytokine response elements. However, this DNA-protein complex formation is not 
universal, as the IL-4RE of Class II MHC Aa gene [Boothby et ai, 1988], an IFNy- 
stimulated element (a prototype GAS site) in the GBP gene and an IFNa response 
element (iSRE of the ISG54 gene) could not compete for NFIL-4 binding. Monoclonal 
antibodies to Statl (p91), which binds both GRR and APRE sites, do not disrupt the 
formation of an NF-IL-4-Ea gene-ILRS sequence complex, suggesting that IL-4 
activates a unique transcription factor protein which is distinct from any of the Stat family 
proteins [Kretsovali and Papamatheakis, 1995]. Indeed, the molecular weight of NFIL-4 
(75kDa) does not correlate with any of the known Stat proteins, e.g. Stat6  (-lOOkDa)
[Hou et al., 1994; Quelle et al., 1995] which is the recognized member of the Stat family, 
activated by IL-4. Another distinction is, that NFIL-4 activation by IL-4 is not disrupted 
by pre-treatment of B cells with the protein tyrosine kinase inhibitor genistein, whereas 
high concentrations of staurosporine (500nM) abolish IL-4 induced NFIL-4 activation.
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The recognized mechanism of Stat activation by cytokines is via phosphorylation by a 
member of the Janus family of protein tyrosine kinases. However, although inhibition of 
PTK activity does not affect the ability of IL-4 to activate NFIL-4, this activity is 
disrupted by the addition of anti-phosphotyrosine antisera [Kretsovali and 
Papamatheakis, 1995]. This suggests that there is perhaps a requirement for 
phosphotyrosine in NFIL-4-DNA complex formation and the inability of genistein to 
affect this activity may either be a result of NFIL-4 being tyrosine phosphorylated prior 
to activation, or that IL-4 activates a protein tyrosine kinase whose activity is unaffected 
by genistein.
IL-4 was found to induce a novel transcription factor which bound GAS sequences with 
a distinct mobility shift from IFNy-induced p91 homodimers [Schindler et al, 1994]. 
This IL-4 induced activity could be successfully competed for by both an IRF-1-GAS 
sequence and by RRl/2 oligonucleotide, an enhancer sequence from the germline k  
gene, which is homologous to other Stat binding sites. Nuclear extracts from the pre-B 
cell hue 18.81A20, the mature B cell line M 12.4.1, fresh murine spienocytes and human 
peripheral blood leukocytes all contained this IL-4-inducible DNA binding activity, 
designated STF-IL-4 [Schindler eta l,  1994]. IL-4 was found not to phosphorylate p91- 
Statl, nor did anti-Statl antisera affect RR1/2-STF-IL-4 complex fondation [Schindler et 
al, 1994]. Thus, it appeared that IL-4 induced activation of a novel member of the Slat 
family, later isolated, characterized and cloned as Stat6 ; a protein with a molecular' weight 
of lOOkDa [Hou et al, 1994; Quelle et al, 1995]. The available data suggest that IL-4 
induces activation of two distinct transcription factors; the 75kDa NFIL-4 and Stat6  
(-lOOkDa), the latter forming a transcriptionally active homodimer STF-IL-4. 
Interestingly, the putative IL-4 response element in the CD25 promoter, identified by 
sequence homology, is similar to both the NFIL-4 binding site of the Class II MHC Ea 
gene promoter [Kretsovali and Papamatheakis, 1995], to Stat6  homodimer binding sites 
and also to GAS sequences. Despite this homolgy to Stat6  binding sequences, the 
putative CD25 promoter IL-4 response element does not contain the consensus Stat
61
binding motif (TT-N(4 _6 )-AA). However, the implication of the sequence homology of 
this element in the CD25 promoter, with respect to transcription factor binding and IL-4 
regulation of transcriptional activation in human B cells, remains to be determined. As
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well as a putative IL-4 response element, a Stat6 binding site has been identified in the
■CD25 promoter more recently, in a position downstream of the putative IL-4 response 
element, close to the transcription initiation site. The presence of two potential IL-4- 
regulated positive transcription factor sites is curious and the role of these will possibly
'provide a better understanding of IL-4 induced CD25 expression.
1.8.2 Negative Regulatory Elements of the CD25 Promoter
1.8.2.a The Negative Regulatory Element (NRE)
Studies of 5' CD25 promoter deletion mutant-CAT constructs transfected into HTLV-1 
infected MT2 cells revealed, that deletion of 5' sequences of the CD25 promoter resulted 
in a 10-15-fold increase in reporter gene activity [Cross et ciL, 1987], suggesting the 
presence of a Negative Regulatory Element (NRE) in the region 5' of a site -368 base 
pairs from the transcriptional initiation site. Similar studies in Jurkat and YT-1 T cell 
lines revealed, that in the latter a -317 deletion mutant was four times more 
transcriptionally active than a -471 deletion mutant, suggesting the presence of an NRE 
upstream of the PMA-inducible region of the promoter [Lowenthal et ai, 1988]. 
Interestingly, transfection studies in Jurkat cells demonstrated no noticeable difference 
between the ability of -471 and -317 mutants to initiate transcription in response to PMA 
and forskolin. Thus, it seems that the importance of this potential NRE and its binding 
by a tr anscription factor has different properties, dependent upon the developmental stage 
of the T cell; i.e., in cells which have an immature T cell phenotype (YT-1) the presence 
of NRE negatively regulates transcription, whereas in cells with a mature T cell 
phenotype (Jurkat cells) NRE does not appear to have a significant role with respect to 
CD25 expression. More specific deletion studies of the CD25 promoter [Smith and 
Greene, 1989] defined a 31 base pair region between nucleotides -400 and -368, as a 
candidate for the NRE sequence. Within this region there is an 11 base pair core region
6 2
which shares significant sequence homology with a region of the HIV-long terminal 
repeat (LTR) [Smith and Greene, 1989]. DNA mobility shift assay revealed the 
formation of three DNA-protein complexes which were successfully competed by HIV- 
NRE region, whereas mutant competitor oligonucleotides with five base pair 
substitutions within the 11 base pair core were unable to compete. Interestingly, in both 
YT-1 and MT2 cells the presence of NRE inhibits both basal and PMA inducible 
transcription, indicating that in these cells NRE binding proteins are constitutively 
expressed [Smith and Greene, 1989]. DNA crosslinking studies using a 27 base pair 
photoreactive probe containing part of the NRE sequence (-399 to -373) demonstrated the 
formation of a crosslinked species migrating at ~50kDa. This activity has been 
designated SP50, 'silencer protein'-50 [Smith and Greene, 1989]; no further published 
data, concerning the nature or identity of SP50, exists. The question of a similar silencer 
protein being present in human B cells, and if so the regulation of its DNA-binding 
activity for elements in CD25 promoter (in particular any possible regulatory effects of 
IL-4), is of considerable interest.
1.8.2.b The Retinoic Acid Response Element
Retinoic acid (RA), a natural derivative of retinol (Vitamin A), has profound effects upon 
cell growth and differentiation. These effects are mediated by two families of nuclear RA 
receptors: the RA receptor gene family, comprising RARa, RARp and RARy; the RXR 
family, RXRa and RXRp, which only bind the 9-cis stereo-isomer of RA. RA affects 
transcription of CD25 by down-regulating transcription factor binding to a retinoic acid 
response element (RARE) in the promoter region of the gene. Transfection of human B 
cell lines IE8 . 6  and SKW6.4 with a 1.6kb CD25 promoter-CAT construct demonstrated 
increased reporter gene activity in response to RA. A -471 5' deletion mutant had low 
initial reporter activity, which increased in response to RA. In contrast, a -317 deletion 
mutant abolished transcriptional activation in response to RA [Bhatti and Sidell, 1994]. 
Internal deletion mutants lacking the NRE region, showed increased basal promoter 
activity and lost responsiveness to RA [Bhatti and Sidell, 1994]. The implications of this
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were that a RARE site exists in the CD25 promoter, which binds a negatively regulating itranscription factor which is released in response to RA. Also, it seems that this RARE
site is either very closely associated with, or is possibly even indistinguishable from 
NRE.
'
1.9  Research Aims
There exists the potential for IL-4 to regulate CD25 gene expression in human B cells 
through a number of transcription factor binding sites. In T cells, mitogenic stimulation 
by agents such as PMA appears to involve the exchange of transcriptionally repressive 
DNA-binding proteins which occupy the xB site for a complex which activates 
transcription, along with concomitant binding of SRF and Spl. In human B cells IL-4 is i|
the only cytokine capable of inducing CD25 expression. Thus, the main aims of this 
thesis have been to establish how IL-4 regulates transcription factor binding to the CD25 f
promoter and the signal transduction pathways required to mediate such regulation. In 7
;.+J
:
paiticular, identifying the importance of regulation of NRE binding with respect to CD25 
expression in human B cells and the potential for IL-4 to regulate transcription factor 
binding to this element, as a key to understanding IL-4 induced CD25 expression in these 
cells, forms a major part of the work presented here. Thus, we have examined the ability 
of IL-4 to elevate intracellular levels of cAMP and the effects of signalling pathways, 
subsequently activated by this second messenger, upon both the regulation of 
transcription factor binding to various elements within the CD25 promoter and upon 
transcriptional activation itself.
The presence of two putative IL-4 response elements in the CD25 promoter i.e., a Stat6 .•fi
I
binding site and the IL-4RE, are potential targets for positive transcriptional activity of 7  
IL-4. The presence of two potential IL-4 response elements in the same promoter and the 
similarity in their sequence homology is curious. Therefore, determining the effects of 
IL-4 upon transcription factor binding to these regions and any potential relationship they I
6 5
may have with each other may prove crucial in establishing the ability of IL-4 to up- 
regulate CD25 in human B cells. Thus, an attempt to establish the potential of the IL-4 
response element site to act as a Stat6  binding site and also, using activators and 
inhibitors of intracellular signalling pathways, to gauge potential mechanisms of IL-4- 
induced regulation of the DNA binding activity of this element, have been made.
Finally, the potential of cytokines which have receptor components in common with the 
IL-4 receptor, to regulate CD25 expression or transcription factor binding to various 
elements within the CD25 promoter has been analysed. It is possible that the degree of 
redundancy that is observed between cytokine receptors and related signalling pathways 
results in the ability of other cytokines to mimic the ability of IL-4 to regulate, if not 
CD25 expression itself, then at least some of the individual regulatory components of 
transcription which are involved in expression of the gene.
6 6
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Chapter 2 I
Materials & Methods ?
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2.1 Materials
I
2 . 1 . 1  Cell Culture materials
RPMI-1640 medium, penicillin, streptomycin and glutamine were all obtained from Life 
Sciences Ltd., Paisley, U.K. Foetal Calf Serum was purchased from Sigma, Poole, 
Dorset, U.K. Tissue culture flasks were obtained from Costar Biochemicals Ltd, 
Northumbria, U.K. and additional sterile plastics were purchased from Sterilin Ltd., 
Feltham, U.K.
2 . 1 . 2  Materials for Isolation of Primary B Cells
Ficoll, as Histo-paque or FicolLHypaque, was obtained from either Sigma, Poole, 
Dorset, U.K. or Calbiochem-Novabiochem Corporation, Nottingham, U.K., 
respectively, and Percoll was obtained from Sigma, Poole, Dorset, U.K. Sheep
erythrocytes in Alsever's solution were provided by the Scottish Antibody Production 
Unit (SAPU), Carluke, U.K. Tonsils were obtained from the ENT surgical unit of 
Yorkhill Hospital for Sick Children, Glasgow, U.K.
2 . 1 . 3  Cytokines and Antibodies
IL-4 was a gift from the Imraunex Corporation, Seattle, USA. IL-13 and IL-7 were 
obtained from R&D Systems, Europe Ltd., Abingdon, U.K. and IL-2 was donated by 
the Glaxo Institute for Molecular Biology (Geneva, Switzerland). Mouse anti-CD40 
monoclonal antibody was obtained from Sero-tec, Abingdon, U.K. and goat anti-IgM 
antibody was from Sigma, Poole, Dorset, U.K. FITC conjugated anti-CD25 and PE 
conjugated anti-CD 19 antibodies were from DAKO, Denmark; bio tin conjugated anti- 
CD23 antibody was from The Binding Site Ltd., Birmingham, U.K. and Streptavadin- 
Quantum Red was from Sigma, Poole, Dorset, U.K. PY20 (mouse anti- 
phosphotyrosine antibody) and S20 (rabbit anti-human Stat6  antibody) monoclonal 
antibodies were obtained from Santa Cruz Biotechnology Inc., USA. FIRP-conjugated
68
anti-mouse IgG and anti-rabbit IgG monoclonal antibodies were from Amersham 
International Pic., Amersham, U.K.
2 . 1 . 4  Fine Chemicals
Forskolin, Cholera Toxin, lonomycin, Phorbol 12-myristate 13-acetate (PMA), Phorbol 
dibutyrate (PBu2 ), Leupeptin, Aprotinin, Phenylraethylsulfonyl Fluoride (PMSF), 
dithiothreitol (DTT), acetyl co-enzyme A and poly-(dI-dC)-(dI-dC) were all obtained 
from Sigma, Poole, Dorset, U.K. H89 (N-[-2-(p-Bromocinnamylamino)ethyl]-5), 
Genistein, B APT A-Acetoxy methyl ester [l,2-bis(o-Aminophenoxy)ethane-N,N,N',N’ 
-tetraacetic acid tetra(acetoxymethyl) ester] and cyclic AMP were from Calbiochem- 
Novabiochem Corporation, Nottingham, U.K. Bisindolylraaleimide was from 
Boehringer Mannheim, U.K.
2 . 1 . 5  Materials for Gel Electrophoresis and Western Blotting
Acrylamide/bis-acrylamide mixture was from Biorad Laboratories, U.K. N,N,N’,N'- i
,tetraraethylenediamine (TEMED), (Tween 20) and the 205kDa-29kDa molecular weight 
markers were from Sigma, Poole, Dorset, U.K. Nitro-cellulose and Enhanced 
Chemiluminescence (ECL) kits were from Amersham International Pic., Amersham,
U.K. FUJI Medical X-ray film was from Genetic Research Instrumentation, Essex,
U.K.
2 . 1 . 6  Radiochemicals
All radiochemicals were from Amersham International Pic., Amersham, U.K.
6 9
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2 . 1 . 7  Oligonucleotides, CAT Reporter Gene Construct and Plasmid 
Vector
CREB, AP2 and Oct 1 sequences were from Promega, Southhampton, UK. IL-4RE, 
NRE and Stat6  double stranded oligonucleotide sequences were synthesized at the CRC 
Beatson Institute, Glasgow, U.K. T4 polynucleotide kinase and T4 polynucleotide
7 0
2kinase buffer were a kit from Promega, Southampton, UK. A 590bp EcoRI-Hindlll ci
■Ipromoter-containing fragment from pIL-2a-CAT was a gilt from Drs. W.C. Greene and «
D. W. Ballard, Howard Hughes Medical Institute, Duke University Medical Centre, 
Durham, NC, USA. The pGEM-7Zf(-r) cloning vector was from Promega,
Southampton, U.K.
2.2 Methods
2.2.1 Preparation and Culture of Cells
2.2.1.a Isolation of High Density Tonsillar B Lymphocytes
Human B lymphocytes were prepared from a single cell suspension derived from tonsils.
obtained from routine surgery, as described previously [Butcher and Cushley, 1990].
Cells were spilled into 20ml of RPMI-1640 medium supplemented with 10  ^units/ml 
penicillin and lOOpg/ml streptomycin (incomplete medium). The total cell suspension 
was layered, in 10ml aliquots, onto 10ml of Ficoll-Hypaque and centrifuged at 350 x g 
for 15 minutes. Mononuclear cells were harvested from the ficoll interface, washed 
twice and pelleted with AET-Sheep red blood cells for 5 minutes at 90 xg. 1 ml of FCS 
was layered onto the pellet and following a 30 minute incubation on ice the suspension 
was centrifuged through a ficoll cushion for 20 minutes at 350 xg. Non-roselted cells 
were collected from the interface and washed twice in incomplete medium. This B cell 
enriched population was centrifuged through a five-step discontinuous percoll gradient at
1000 xg for 30 minutes [Butcher et al, 1991]. High density, quiescent B cells were |
Ë ..removed from the 1.09 g/ml - 1.08 g/ml interface and washed three times in incomplete iif
medium.
%2.2.l.b  Culture of Primary B Lymphocytes and Cell lines
Following isolation primary B lymphocytes were cultured in RPMI-1640 medium 
supplemented with 1 0  ^units/ml, lOOpg/ml streptomycin, 2mM glutamine and 10% FCS y-:
I
(complete medium), at 37°C in a 5% CO2  humid atmosphere, unless otherwise stated.
The EBV hansformed EDR and Daudi human B cell lines and the human monocyte cell 
line U937 were cultured in complete RPMI-1640 medium (as described above).
2.2.2 Flow Cytometry
2.2.2.a Treatment of Resting B Cells
2.2.2.a-1 Treatment of Resting B Cells With Pharmacological Agents
High density tonsillar B cells were suspended in complete medium at 1x10^ cells/ml.
Cells were pulsed with the following stimuli for 30 second or 2 minute periods: lOnM 
PMA; 2nM PBu2 ; IpM lonomycin; lOOpM Forskolin. Reactions were terminated by 
dilution in a 20-fold volume of PBS, followed by three washes. Cells were also 
stimulated with a combination of PBu2  and ionomycin and, in addition, PMA, PBu2 , 
ionomycin and PBu2 /ionomycin treated cells were stimulated, after approximately 15 
minutes, with a 20 minute pulse with lOOpM forskolin. Cells were then washed three
■times in PBS, resuspended in complete medium and incubated for 24 hours at 37^C.
2.2.2.a-2 Chronic Phorbol Ester Treatment
High density tonsillar B cells were cultured at 1x10^ cell/ml in complete medium 
supplemented with lOnM PMA in 75cm^ flasks for 48 hours. Following chronic PMA 
treatment the cells were harvested, washed extensively to remove the excess phorbol 
ester then re-cultured for 24 hours in the presence of a range of concentrations of IL-4, 
anti-IgM antibody or anti-CD40 antibody.
I
2.2.2.a-3 Chelation of Intracellular Calcium
In order to chelate intracellular calcium high density tonsillar B cells (1 x 10  ^cells/ml) 
were loaded with 5pM B APT A-acetoxy methy lester (final concentration InM) as a 
complex with 0.1% (w/v) Pluronic-F127 detergent; both reagents were dissolved in 
dimethyl sulphoxide and the final concentration of DMSO in tissue culture experiments :
I
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was 0.1% (v/v). After 30 minutes the cells were washed to remove excess BAPTA-AM 
from the culture medium and then stimulated with IL-4.
2.2.2.a-4 Treatment With Cytokines and Monoclonal Antibodies
High density human B cells were suspended in complete medium at 1 x 10  ^ cells/ml. 
Cells were cultured for 24, 48, and 72 hours with a range of IL-4 concentrations. In 
addition, cells were also cultured with a range of concentrations of IL-2, IL-7, IL-13, 
anti-IgM antibody and anti-CD40 antibody for 24 hours. The concentrations of individual 
stimuli are given in the figure legends (see results).
2.2.2.b Fluorescent Antibody Labelling of Cells
Following 24 hour culture with the indicated stimuli (see results sections), both control 
and stimulated cells were harvested and washed three times with PBS. Cells were 
resuspended in PBS (lO^cells/lOOfil) and simultaneously stained with FITC-anti-CD25, 
PE-anti-CD19 and biotin-anti-CD23 monoclonal antibodies. Cells were then incubated 
on ice for 1 hour in the presence of antibody, before being washed twice in PBS. Cells 
labelled with biotinylated antibodies were incubated for a further 30 minutes in the 
presence of Strep tavadin-Quantum Red in order to visualise bio tin-conjugated antibodies. 
Cells were subjected to a final wash in PBS and fluorescence intensity in three 
fluorescence channels FL-1 530nm (FITC), FL-2 585nm (PE) and FL-3 > 650nm 
(Quantum-Red) were measured on a Becton-Dickinson FAC Scan flow cytometer, using 
an argon ion laser tuned to 488nm. For each individual experiment a negative control, 
consisting of B cells incubated in the absence of antibody, was prepared and used to 
determine levels of auto-fluorescence. In experiments where cells were labelled only 
with FITC-anti-CD25 and PE-anti-CD 19 monoclonal antibodies, lOpl of Propidium 
Iodide (10pg/ml)was added immediately prior to data acquisition to allow gating of 
populations of dead or damaged cells. PI was not included in samples labelled with 
biotin conjugated antibodies as it is detected in the FL-3 channel and interferes with the 
detection of Quantum-Red labelling. In addition, cells were gated on forward and side
7 2
populations.
CD25+/CD19+ cells 
%CD25+ B cells= -------------------------------------
CD257CD19+cells +  CD25+/CD19+ceils
" 6
scatter during data acquisition to allow the identification of discreet lymphocyte
2.2.2.c Flow Cytometric Analysis
Simultaneous labelhng of B cells with three fluorescently conjugated antibodies allowed 
analysis of expression of three distinct cell surface proteins, i.e., CD19, CD23 and 
CD25. For analysis of expression of a single surface protein, results were determined as 
the Mean Channel Fluorescence or Mean Fluorescence Intensity of a histogram plot. 
Where analysis of expression of multiple cell surface markers was used, B cell 
populations were identified by labelling with PE-anti-CD19 monoclonal antibody, CD 19 
being a pan B cell surface marker from an early stage in B cell development. It is 
possible by 'two colour' dot-plot analysis, to identify total B cell populations expressing 
either CD23 or CD25. CD23 and CD25 positive B cell populations are calculated as a 
percentage of the total B cell population using the following equation: i;
‘Paint-A-Gate’ software provides an programme that allows ‘multi-colour’ analyses of 
flow cytometry data files. This facility allows the breakdown of a total cell population,
'simultaneously stained with three distinct antibodies into discreet cell subpopulations of 
single-, double- and triple-marker protein positive cells. In this instance CD19+/CD23" 
/CD25-, CD19+/CD23+/CD25", CD19+/CD237CD25+ and CD19+/CD23+/CD25+ 
cells.
Î
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2.2.3.a Stimulation of Tonsillar B Cells and B Cell Lines
2.2.3 Measurement of cAMP Generation
High density tonsillar B cells were isolated and cultured (5 x 10  ^cells/ml) for 1 hour at 
3 7 °C, prior to stimulation. lOOpl aliquots of cells were added to wells of a 96 well 
microtitre plate containing the required stimuli (see results - Chapter 4). Reaction were 
terminated at the indicated time points by addition of an equal volume of 4% perchloric 
acid (final concentration of PCA was 2%(v/v)). All reactions were carried out at 37°C 
and following termination of reactions, all samples were stored at 4°C for 1 hour prior to 
analysis. Samples were diluted 1:5 or 1:10 in assay buffer (50mM Tris/HCl, 4mM 
EDTA, (pH 7.4)) prior to analysis in order to ensure that measurement of the samples fell 
within the range of the standard curve. Each experimental detennination was carried out 
in triphcate.
2.2.3.b Measurement of cAMP Generation.
Determination of cAMP production was measured according to the method described by 
Houslay et al,  (1976) based on the cAMP binding protein saturation assay of Brown et 
al,  (1972). The basis of this assay is the competitive binding of cAMP and tritiated 
cAMP to a cAMP-binding protein (the regulatory subunit of cAMP-dependent protein 
kinase), purified from bovine heart. The cAMP-binding protein was a gift from the 
laboratory of Prof. M.D. Houslay and prepared as described by Spence (1990).
50pl aliquots of stimulated and control samples were incubated with lOOpl cAMP- 
binding protein, lOOpl [%]-3% 5’-cAMP (20 000 - 30 OOOcpm/ml) and 50pl of 50mM 
Tris-HCl/4mM EDTA (pH 7.4) assay buffer. Assay mixtures were mixed by vortexing 
and mcubated for a minimum of 2 hours to allow equilibration of radiolabelled cAMP and
:
cAMP content of B cell samples. Unbound cAMP was removed by addition of 250pl of 
a solution of charcoal/BSA (2g/ml charcoal/ Ig/ml BSA); charcoal adsorbs free cyclic 
nucleotide. The charcoal suspension was removed by centrifugation in a microfuge for 5
7 4
minutes at 13 OOOrpm, 4®C. 400pl aliquots of the supernatant were removed and 
analysed by liquid scintillation counting, in 3 ml Ecoscint. A standard displacement 
curve was constructed for each assay to allow determination of cAMP content of the cell 
lysates. Tritiated cAMP was incubated with cAMP-binding protein in the absence of any 
competing, unlabelled cAMP in order to measure total cAMP binding. Non-specific 
binding was measured by incubation of tritiated cAMP in the absence of any cAMP- 
binding protein or competing, unlabelled cAMP. The standard curve was created by 
making a series of doubling dilutions of a 320nM solution of unlabelled cAMP in 
Tiis/EDTA assay buffer. 50jil of each standard was incubated with lOOpl cAMP-binding 
protein, lOOpl [3H]-3’ 5 -cAMP and 50pl of 50mM Tris-HCl/4mM EDTA (pH 7.4). 
Thus, the concentration of the highest standard was 16pmol/assay tube and the lowest 
0.0625pmol/assay. All conditions from this point were identical to those used for the test 
samples.
The samples were counted in an LKB scintillation counter which utilized an RIA curve 
fitting programme to allow automatic calculation of cAMP content of each sample from 
the standard curve. Results were re-calculated as cAMP produced/10  ^cells, taking into 
consideration the initial dilution factors employed in order to fit into the range of the 
standard curve.
2.2.4 Measurement of PKA Activity
2.2.4.a Preparation of Cell Samples for PKA Assay
High density tonsillar B cells (IxlO^/ml) were stimulated as indicated (see results 
sections). Following stimulation, cells were washed in ice-cold PBS and resuspended in 
extraction buffer ( 25mM Tris-HCl-pH 7.4, 0.5mM EOT A, 0.5mM EDTA, lOmM p- 
mercaptoethanol, Ipg/ml aprotinin, 0.5mM DTT, 1% NP40) and homogenised using a 
Dounce homogenizer, pre-cooled to 4^C. Lysates were centrifuged for 5 minutes at 4°C, 
at high speed in a microfuge to pellet cellular debris. Supernatant was removed and kept
75
on ice until use, or stored at -20^C for long term use.
: | 
72.2.4.b PKA Assay
Reactions were initiated by addition of lOpl of lysate to a reaction mix of PKA assay 
buffer (200mM Tris-HCl, pH 7.4, lOOmM MgCl2 , 0.5mg/ml BSA), 25pM cAMP, 
0.5mM PKA biotinylated peptide substrate (Kemptide - LRRASLG) and [y-^^PJ-ATP
(2) Enzyme activity in pmol [y-32p]_ATP/minute/mg protein =
( cprUreaction with enzyme " Cpt^ treaction wiüiout enzyme) ^ (25)
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mix (100-200 cpm/pmol ATP). The reaction mix was pre-incubated at 30°C for 1 minute 
before addition of cell lysate. Control samples for each assay were made by addition of 
10 pi of 0.1 mg/ml BSA to reaction mix. Total reaction mixtures were then incubated for 
15 minutes at 30°C and reactions terminated by addition of 7.5M guanidine-HCI 
termination buffer. A 25pl aliquot was removed from each sample and spotted onto 
Streptavadin-coated discs, and washed eight times with IM NaCl, followed by two 
washes with distilled H2 O. Discs were allowed to dry at room temperature for 30-60 
minutes. In order to calculate the specific activity of [y-32p]_ATP, 5pl aliquots (standard 
samples) from three separate reaction tubes were spotted onto Whatmann 3MM filters 
and dried immediately without washing. The dried discs were transfened to scintillation 
vials with 3ml of scintillation fluid and counted. The specific activity of [y-^^PJ-ATP :
and PKA activity were calculated using the following equations:
f
(75/5) (X)
(1) Specific activity of [y-32p]-ATP in cpm/pmol of ATP = ------------------
5000
I
(25) X (timemin) x (protein in reactionmg) x (specific activity of [y-32p]-ATP)
I
Where 15 -  sum of reaction volume (50pl) + volume of termination buffer (25pl)
5 = volume in pi of the standard sample 
X = average cpm of the 5pl standard samples 
5000 = number of pmol of ATP in the reaction
2.2.5 DNA Mobility Shift Assay
2.2.5.a Preparation of Nuclear and Cytosolic Extracts
High density, tonsil B cells were cultured for 16 hours in complete medium prior to 
treatment. Human B cell lines were isolated from culture and used one day after addition 
of fresh medium. Treatment of botli primary human B cells and human B cell lines is as 
indicated (see results sections). 5x10^ cells were isolated at hourly intervals following 
initiation of treatment and washed in PBS. Cytosolic extracts were prepared on ice by 
incubating in extraction buffer (10mm HEPES-KOH, pH 7.5, 2mM MgCl2 , O.lmM
I
EGTA, O.lmM EDTA) supplemented with 2pg/ml aprotinin, 2pg/ml leupeptin, ImM 
DTT and 0.5mM PMSF. After 15 minutes NP-40 was added to a final concentration of 
0 .5 % (w/v) and the mixture was immediately subjected to high speed centrifugation to 
isolate nuclei. The cytoplasmic supernatant was removed and stabilised by addition of 
10% (w/v) glycerol. The isolated nuclei were incubated for a further 30 minutes at 4“C, 
in high salt buffer extraction (20mM Hepes-pH 7.8, 450mM NaCl) supplemented with 
2pg/ml aprotinin, 2pg/ml leupeptin, ImM DTT and 0.5mM PMSF and 25% (w/v) 
glycerol. Nuclear extracts were prepared by centrifugation at 10 000 x g to remove
membranes and DNA. Nuclear" and cytosolic extracts were stored at -70°C.
2.2.5.b DNA Mobility Shift Sense Oligonucleotide Sequences
DNA mobility shift assays were canied out using double stranded oligonucleotide with 
the sense sequences described below. CREB, OCTl and AP2 oligonucleotides were 
bought from Promega, Southampton, U.K. NRE, IL-4RE and Stat6  sense and
7 7
antisense oligonucleotides were made at the CRC Beatson Institute, Glasgow, U.K. and 
annealed by mixing equiraolar amounts of sense and antisense sequences, heating for 5 
minutes in an 80°C water bath before being slowly cooled at room temperature.
NRE 5’ TT CAT CCC AGG 3'
IL-4RE 5' CAC TGC CAA GAA GTG CTT GCT 3’
STAT 6  5' GTA T IT  CCA GAA AAG GAA C 3'
CREB 5' AGA GAT TGC CTG ACG TCA GAG AGC TAG 3'
I :
7
■4.,
OCT 1 5' TGT CGA ATG CAA ATC ACT AGA 3'
AP2 5’ GAT CGA ACT GAC CGC CCG CGG CCC 3'
2.2.5.C DNA Mobility Shift Assay
The protein content of nuclear and cytosolic extracts was determined using the Lowry 
Protein Assay method. lOpl of B cell extracts were incubated with 1ml of reagent A (1 
part Coppper/tartrate/carbonate solution [189mM NaCOg, 4mM C11SO4 , 7. ImM KNa 
Tartrate], 2 parts 5% SDS and 1 part 0.8M NaOH) for 10 minutes at room temperature, 
followed by the addition of 0.5ml of reagent B (1 part Folin-Ciocalteau phenol reagent 
with 5 parts distilled H2 O). Samples were mixed thoroughly and allowed to stand at 
room temperature for a further 30 minutes before measurement of absorbance, at 750nm 
in an LKB Biochrom Ultrospec II, light spectrophotometer. Protein content of each 
sample was calculated from a BSA standard curve.
5pg of nuclear and cytosolic protein extracts were incubated with distilled H2 O and 
binding buffer (20% glycerol, 5mM MgCl2 , 2.5mM EDTA, 2.5mM DTT, 250mM
.
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NaCl, 50mM Tris-HCl pH7.5, 0.25 pg/ml poly(dI-dC)-poly(dI-dC)) for 5 minutes prior 
to addition of 0.175 pmole [y-32pj-end labelled, double stranded oligonucleotide.
Samples were incubated for 20 minutes prior to loading onto a 7.5% (w/v) non­
denaturing, polyacrylamide gel in 0,5x TBE (89mM Tris-HCl, 89mM Borate, 2mM 
EDTA-pH8.0) buffer. Gels were pre-run for 2 hours at 150V. Probe retardation was :||
visualised by autoradiography with Fuji Medical X-ray film. Autoradiographs were Ideveloped using a Kodak X-omat Processor Model ME-3.
"I
2.2.6 Western Blotting
2.2.6.a Preparation of Whole Cell Lysates
High density tonsillar B cells were incubated for 16 hours in complete medium prior to 
treatment. The human EDR and U937 cell lines were isolated from culture and used one 
day after addition of fresh medium. Both primary human B cells and human cell lines 
(IxlO^/ml) were stimulated as indicated in the appropriate results sections. Following 
stimulation cells were washed in PBS, resuspended in 1ml RIPA buffer (50mM Tris- 
HCl, 1% NP40, ImM Na Deoxycholate, 150mM NaCl, ImM EGTA, ImM NagVOa, 
ImM NaF, ImM PMSF, 2 pg/ml leupeptin, 0.5mM DTT) and incubated on ice for 30 
minutes. Following incubation, lysates were centrifuged at high speed in a microfuge to
Labelling of oligonucleotide was carried out by incubating double stranded, annealed 
oligonucleotide (1.75pmol/pl) with T4 Polynucleotide Kinase, T4 Polynucleotide Kinase 
buffer (0.5M Tris/HCl-pH 7.6, O.IM MgCli, 50mM DTT, ImM spermidine, ImM t  
EDTA) and [y-32p]-ATP (3000Ci/mmol at lOmCi/ml) for 10 minutes at 37®C. The 
reaction was terminated by addition of 0.5M EDTA and TE (lOmM Tris/HCl-pH 8.0,
ImM EDTA) buffer. Where unlabelled oligonucleotide (specific or non-specific) was 
used as a competitor for protein binding, the final concentration in the reaction was either 
I.75pmole or 17.5pmole (i.e., a 10-fold or a 100-fold greater concentration than 32p_ 
radiolabeUed oligonucleotide).
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remove cellular debris. Supernatant was removed and stored at -20°C until use. lOpg of 
protein together with 5pl of loading buffer (10% (w/v) glycerol) were boiled before 
addition to SDS-PAGE gel.
SO
3'2 .2 .6 .b Preparation of Immunoprecipitates
High density tonsillar B cells were incubated for 16 hours in complete medium prior to 
treatment. The human EDR and U937 cell Imes were isolated from culture and used one 
day after addition of fresh medium. Both primary human B cells and human cell lines 
(5xlO^/ml) were stimulated as indicated in the appropriate results sections. Cells were 
centrifuged at ISOOrpm for 5 minutes, resuspended in 1ml of RIPA buffer and incubated 
on ice for 10 minutes. Cell membranes were disrupted by repeated aspiration through a 
21 gauge needle. Cellular debris was pelleted by centrifugation at 1000 x g at 4^C for 15 :
minutes. Supernatant was transferred to fresh tubes and the lysates pre-cleared by 
addition of 20pl of Protein G-agarose and immediate centiifugation at 275 x g, at 4®C for 
5 minutes. 1ml of supernatant was transferred to microfuge tubes and 1 pg of S-20 
(Rabbit-IgG anti-human-STAT- 6  monoclonal antibody) added. Pre-cleared lysates were 
incubated in the presence of antibody for 1 hour at 4°C followed by addition of 2 0  pi 
agarose-protein G and placed on a rotator in a d^C cold room overnight. 
Immunoprecipitates were collected by centrifugation at 3400 x g for 5 minutes at 4^C. 
Supernatant was discarded, immunoprecipitates washed three times in RIPA bulfer and 
finally resuspended in 40pl of loading buffer (10% (w/v) glycerol). Lysates were stored 
in loading buffer at -20®C. Samples were boiled for three minutes and centrifuged at 
3400 X g for 2 minutes to pellet Protein G-agarose. The supernatant was transferred to a 
fresh tube before addition to SDS-PAGE gel.
2.2.6.C SDS-PAGE Electrophoresis and Western Blotting
A 10% (w/v) acrylamide separating, gel was prepared using a Bio-rad mini rig. The gel 
was set with an isopropanol overlay after which a 5% (w/v) acrylamide stacking gel was 
poured. Both separating and stacking gels were made to the specifications outlined
below. Cell lysates and immunoprecipitates were added to the stacking gel and run at 
100mA in electrophoresis buffer (25mMTris, 250mM glycine, 0.1% (w/v) SDS pH 
8.3). When protein samples had reached the top of the separating gel the current was 
increased to 150V. Following separation of protein the stacking gel was removed and 
the separating gel transferred to a Bio-rad mini-wet blotting apparatus. Protein was 
transferred to a nitrocellulose membrane in protein transfer buffer (48mM Tris-HCl, 
39mM glycine, 1.3mM SDS, 20% methanol - pH 9.2) at 77V.
Table 2.1 SDS Electrophoresis Gel Constituents
Reagent
Final Concentration 
Stacking Gel Separating Gel
Aciylamide (40% w/v)/
bis acrylamide (3.3% w/v) 5% (w/v) 1 0 % (w/v)
Tris -HCl-pH8 . 8 - 0.375M
Tris -HCl-pH6 . 8 0.13M -
Ammonium Persulphate 0 .1 % (w/v) 0.05% (w/v)
SDS 0 .1 % (w/v) 0 .1 % (w/v)
TEMED 0.07% (w/v) 0.03% (w/v)
2.2.6.d Immunoblotting
Nitrocellulose membranes were probed with either PY20 (Mouse-lgG anti-phospho- 
tyrosine monoclonal antibody) or S-20 (Rabbit-IgG anti-human-STAT- 6  monoclonal 
antibody) as indicated in tlie appropriate results sections. Membranes probed with PY20 
were blocked overnight with 5% (v/v) Tween/PBS at 4^C. Following blocking, 
membranes were rinsed with PBS and incubated at room temperature with a 1:2000 
dilution (O.lpg/ml) of PY20 in 0.1% Tween/PBS for 90 minutes. Following incubation
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with primary antibody, membranes were washed extensively with 1% (v/v) Tween/PBS |
for 1 hour, after which a secondary HRP-anti Mouse IgG antibody (1:1000 dilution in 
0.1% (v/v) Tween/PBS) was added and incubated for a further 90 minutes. This 
secondary antibody incubation was again followed by an extensive washing with 1 %
(v/v) Tween/PBS for 1.5 hours. Membranes probed with S-20 were blocked overnight 
with 10% (w/v) Marvel/0.05% (v/v) Tween/0.1% (w/v) Thiomersol/PBS at 4°C. 
Following blocking membranes were rinsed with PBS and incubated with a 1:1000 y.
dilution (O.lpg/ml) of S-20 in 0.5% (w/v) Marvel/0.05% (v/v) Tween/0.1% (w/v) 
ThiomersoFPBS for 45 minutes at room temperature. Membranes were then washed |
twice in 0.1% Tween/PBS followed by three 7 minute washes in PBS. A secondary 
HRP-anti-IgG antibody (1:1000 dilution in 0.5% (w/v) Marvel, 0.05% (v/v) 
Tween/0.1% (w/v) ThioraersoFPBS) was added and incubated for 1 hour followed by
■three 5 minute washes in 0.1% (v/v) Tween/PBS and three 5 minute washes in PBS.
li.
2.2.6,e ECL Detection system
All membranes were developed using the ECL {Enhanced Chemiluminescence ) detection 
system. Horseradish Peroxidase, bound to the immobilized secondary antibody, 
catalyses the conversion of periacid to H2 O, 0 2 ^’, luminol and an enhancer complex. 
Luminol emits small quantities of light which are specifically enhanced up to 100-fold, 
allowing detection using light sensitive Fuji Medical X-ray film. Equal volumes of the 
two ECL solutions were mixed in the darkroom and added to the membrane. ECL 
solution was poured off after 30 seconds and the membranes blotted with tissue to
remove excess liquid, wrapped in cling film and exposed to photographic film for
13varying time periods depending on the intensity of the signal.
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2.2.7. CAT Reporter Gene Assay
2.2.7.a. Transfection and Stimulation of B Cells
EDR B Cells were cultured in fresh medium overnight to ensure they were in log phase 
growth immediately prior to transfection. Cells were harvested and washed and 
resuspended in serum free medium at a density of 6.25 x 10  ^cells/ml. 0.8ml aliquots of 
cells (5 X 10  ^ cells/sample) were added to a Biorad Gene Puiser Cuvette (0.4cm gap) 
along with 40pg of plasmid in TE buffer. Cells were electroporated immediately after 
addition of plasmid at 0.35kV/960p,FD capacitance. After electroporation the contents of 
the cuvette were added to 3ml of complete RPMI-1640 medium in a 6  well plate and 
cultured for two hours prior to stimulation. After 2 hours incubation the contents of each 
well were split into two 1.5ml aliquots which were then cultured with or without 
stimulant for a further 48 hours (this means that each stimulated sample has a 
corresponding control consisting of cells from the same batch of electroporated cells - 
this technique reduces the margin of error between samples due to different efficiencies 
of electroporation),
2.2.7.b Preparation of Cell Lysates and Chloramphenicol Acetyl
Transferase (CAT) Assay
Transfected and stimulated cells were harvested from culture plates, washed once in 
sterile PBS and transferred to sterile eppendorf tubes in 1ml of PBS. The cells were 
centrifuged at 275 x g for 5 minutes after which the PBS was poured off, the cells re­
centrifuged and any remnants of PBS were pipetted off. The cells were resuspended in 
lOOpl of 250mM Tris-HCl pH 7.8 and either stored at 70®C until further use or 
immediately subjected to three cycles of freeze-thawing, in order to lyse the cells, by 
immersing in dry ice-ethanol a bath for 5 minutes followed by 5 minutes in a 37°C water 
bath. Following lysis, the extracts were centrifuged at 15 600 x g for 10 minutes and the 
supernatant retained and heat inactivated at 65^C for a further 1 0  minutes (to inactivate 
cellular acetylases). Samples were then centrifuged at 15 600 x g to pellet any precipitate
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of each sample. In addition TLC plates were developed by autoradiography.
and the supernatant was removed and retained. Acetyl Co A (final concentration 5mM) 
and [^4(2]-chloramphenicol (0.025 pCi) were added to 50pl aliquots of each extract and 
samples were incubated overnight at 37‘^ C. Following incubation the assay was 
terminated by addition of 600pl of ethyl acetate and samples were vortexed for 30 
seconds and centrifuged at 15 600 x g for 5 minutes. The upper phase of the ethyl 
acetate was removed and transferred to fresh sterile eppendorfs, followed by 
lyophilisation in a Jouan RC 10.22. centrifugal evaporator. Once samples were fully 
lyophilised they were resuspended in 20 pi of ethyl acetate and spotted onto silica Thin 
Layer Chromatography (TLC) plates. The TLC plates were run in in a solvent tank in 
95% Chloroform/5 % methanol for 1 hour, dried and placed on a FUJI phosphorimager 
screen for a minimum of 1 hour. Phosphorimager screens were analysed on a FUJIX 
Bas 1000 Bio-imaging Analyser and the generated images were analysed using MacBas 
software. lOpl aliquots of each sample were analysed for protein content using the 
Lowry protein assay method following the freeze-thawing extraction stage and values 
obtained by phosphoriraage analysis were normalised to account for the protein content
1::7I7
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Chapter 3
Induction of Surface Expression of CD25 in Human B
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3 .1  Introduction
CD25 expression in human B lymphocytes is an absolute requirement for expression of 
high affinity IL-2 receptors. Mature, quiescent B cells do not express CD25 but can be 
induced to do so by stimulation with IL-4 [Burlinson et al, 1995; Butcher et al, 1990; 
McKay and Cushley, 1995; Zola et al, 1991]. To date, IL-4 is the only cytokine found 
to be capable of up-regulating CD25 in primary human B cells [Burlinson et al, 1995];
stimulation via the B cell surface adhesion molecule CD40, either by activation with
however, the underlying signalling mechanisms responsible for this event have remained 
relatively unknown. IL-4 is thought to be able to bind two different receptors, a 140kDa
IL-4Ra chain with or without a second yc subunit (forming high and low affinity
If
receptors, respectively) [Russell et al, 1993]. Intracellular signals induced by IL-4 in 
human B lymphocytes include a transient increase in IP3 production and consequent 
Ca2 + mobilization, followed after a lag period by an increase in levels of intracellular 
cAMP [Finney et al, 1990]. It is possible to induce one of the effects of IL-4, namely 
soluble CD23 production, by stimulating B cells with a combination of calcium 
ionophore, phorbol ester and dibutyryl cAMP [Finney et al, 1990]. It was of interest 
therefore, to determine whether similar reagents could be utilized to induce CD25
expression in human B cells, with a view to determining possible mechanisms of action 
of IL-4. In addition, IL-4 also induces tyrosine phosphorylation and resultant activation
Iof both Jakl and Jak3 kinases and of Stat6  [Hou et a l,  1994; Quelle et al, 1995; Witthuhn et a l,  1994]. Phosphorylation of the latter results in formation of a 
transcriptionally active homodimeric complex. IL-4 also induces the activation of 1RS-2 
[Keegan et al, 1994], an event thought to be linked with the activation of PI-3 kinase, 
GRB-2/Shc association and pTO^ yk activation [Myers et al, 1994].
IL-4 is a recognized co-stimulator of B cell activation when it is applied with 
simultaneous stimulation of B cells via the B cell receptor complex [Callard et al, 1991; 
Paul, 1991]. Another T cell-dependent, mechanism of B cell activation involves
t
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CD40 ligand or with anti-CD40 monoclonal antibodies [Annitage et al, 1992; Faillie et 
al, 1989]. Therefore, the ability of stimuli associated with B cell activation, other than 
IL-4, to induce CD25 expression was of paramount interest. A feature of many cytokine 
receptors is the presence of commonly shared subunits in their stinctures. Thus, the IL- 
4 receptor complex contains yc, a subunit common to IL-2, IL-7, IL-9 and IL-15 
receptors [Grabstein et al, 1994; Kondo et al, 1993; Russell et al, 1993]. In addition,
IL-13 is reported to have a number of cellular functions in common with IL-4 [McKenzie 
et al, 1993] and it has been suggested that this is a result of a common receptor subunit 
[Kishomoto et al, 1994]. However, the nature of this purported common component 
remains equivocal. It was, therefore, necessaiy to define whether or not cytokines which 
share yc as a feature of their receptors and also IL-13, which does not, were capable of 
inducing CD25 expression in human B cells.
s3s
3 .2  Up-regulation of CD23 and CD25 in Resting B 
Lymphocytes
3.2.1 IL-4 Induces Dose Dependent Up-regulation of CD23 and CD25
IL-4 acts upon resting tonsillar B lymphocytes to elevate cell surface levels of both CD23 
and CD25 in a dose dependent manner (Fig 3.1). Analysis of the concentrations of IL-4 
necessary for half-maximal expression (EC5 0 ) of these two markers in B cells, stained 
simultaneously for both, demonstrates the EC5 0  for each to be different; with half- 
maximal induction of CD23 occun'ing at ~7 units/ml (approximately 35pM) and CD25 at 
30 units/ml (0.15nM). These data could suggest that IL-4 is promoting CD23 and CD25 
expression via distinct receptors, which are either of different affinities for the cytokine, 
or which are linked to distinct signal transduction pathways. The affinity of the IL-4 
receptor for ligand is influenced by the presence or absence of the yc subunit in such a 
way that the affinity for ligand is increased some three-fold in the presence of yc [Russell 
et al, 1993]; the difference in terms of EC5 0  values observed here would be broadly 
consistent with responses being delivered via these two different receptors.
Simultaneous three colour analyses of the proportion of B cells expressing either CD23 
and/or CD25 over a range of IL-4 concentrations was performed (Fig 3.2). The data 
illustrate that the proportion of CD19+/CD23"/CD25" B lymphocytes drops as the 
concentration of IL-4 increases, and that CD19+/CD23+/CD25" double-positive cells 
and CD19+/CD23+/CD25+ triple-positive cells rise under the same conditions. 
Interestingly, IL-4 induced an increase in a population of CD19+/CD23+/CD25" cells at 
low concentrations (1-10 units/ml), whereas larger concentrations of IL-4 were required 
to induce CD25 expression. A minor population of CD19'’"/CD23"/CD25+ double 
positive cells remained relatively constant over the applied concentration range of IL-4; 
this equlibrium could either be indicative of a constant turnover of CD25 on the cell 
surface of this population or a lack of response to IL-4. Thus, IL-4 is only shown to 
elevate CD25 on B cells which also express CD23 thereby increasing the triple-positive 
population. The proportion of B cells positive for CD23 appears to plateau, or drop 
slightly, at high concentrations of IL-4, an effect which could reflect either a maximal 
response, or alternatively loss, of CD23 as soluble CD23 from the B cell surface. 
However, it may be noted that this plateau effect occurs at a concentration of IL-4 which 
corresponds to the observed increase in the triple positive population. Therefore, this 
'plateau' phenomenon may be due to a switch of cell phenotype from being double 
positive to triple positive; i.e, CD23 continues to be up-regulated in response to IL-4, but 
since CD25 is also being up-regulated, further increases in the CD19+/CD23+/CD25" 
pool are no longer observed. These data are again consistent with IL-4 inducing CD23 
and CD25 expression via receptors of different affinity and also indicates the possibility 
that IL-4 up-regulates these two surface markers on a single B cell population.
3 . 2 . 2  IL-2, IL-7 and IL-13 Do Not Upregulate CD25 in Resting B 
Lymphocytes
The capacity of IL-4 to up-regulate CD25 on resting tonsillar B cells is clear and has been 
reported previously [Burlinson et al, 1995; Butcher et ai, 1990; Zola et ai, 199IJ. The
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data described here are consistent with the interpretation that this response may be 
induced via a low affinity form of the IL-4 receptor, i.e., the IL-4R a chain minus the yc 
subunit. It was, therefore, of interest to determine whether other cytokines which 
contain yc as a component of their receptors had the capacity to induce CD25 expression 
on B cells. Stimulation with a wide range of concentrations of IL-2 and IL-7 ( both of
I
which have yc in their receptors) failed to induce CD25 expression in resting B cells 
(Figs 3.3.A & 3.3.B). In addition, it has been reported that IL-13 shares certain cellular
functions with IL-4 [Keegan et al, 1995; Nilsson and Nilsson, 1995; Smerz-Bertling 
and Duschl, 1995] and that the receptors for IL-4 and IL-13 contain a shared component 
required for signal transduction [Zurawski et al, 1993]. The nature of this shared 
component has remained equivocal for some time, but it now seems likely that it is the 
IL-4Ra chain and not yc [He and Malek, 1995b], as once mooted. However IL-13, like 
IL-2 and IL-7, fails to elevate levels of surface CD25 in resting B cells (Fig 3.3.C). The 
failure of any of these cytokines to induce CD25 expression suggests a requirement for 
both the IL-4Ra chain and the yc subunit (a structure unique to the high affinity form of 
the IL-4 receptor) for elevation of this surface protein. Such an interpretation, however, 
appears at odds with data from the previous section which suggests that IL-4 induces 
CD25 via a low affinity form of the IL-4 receptor.
!
3 . 2 . 3  Anti-Immunoglobulin and Anti-CD40 Induce CD25 Up-regulation
in Resting B Lymphocytes
To date, IL-4 is the only cytokine reported to be capable of up-regulating CD25 
expression on human B lymphocytes [Burlinson et ai, 1995; Butcher et al., 1990; Zola 
et ai,  1991], a fact that is supported by the data presented above. However, resting 
human B cells stimulated with anti-Immunoglobulin and anti-CD40 monoclonal 
antibodies elevate cell surface levels of CD25 in a dose-dependent manner (Figs 3.4 A & 
B) and elevation of CD25 is also observed in response to soluble CD40 ligand 
stimulation [Burlinson et al., 1995]. These three stimuli, along with IL-4, appear to be 
the only reagents capable of inducing CD25 expression in resting human B cells and of
f
the three IL-4 appears to be the most potent, with an EC5 0  of 0 .15nM compared with 
1.3-2nM and ~13nM for anti-immunoglobulin and anti-CD40, respectively. It is 
interesting that three such apparently diverse stimuli should have this cellular effect in 
common; however, if one considers that anti-Ig (as a substitute for antigen) [DeFranco et 
ai,  1982; Jelinek and Lipsky, 1987], anti-CD40 [Spiawski et al., 1993; Valle et al.,
1989] and IL-4 [Callard, 1991] are all signals for B cell activation, it seems logical that 
the induction of CD25 falls under the control of these cellular stimuli. CD25 is an
",'3
absolute requirement for high affinity IL-2 receptors, the expression of which are 
necessary for IL-2 induced proliferation and differentiation in human B cells. Thus, 
stimuli which induce CD25 in these cells play an important regulatory role in B cell 
development.
i
3 .3  Signalling Pathways Which Induce CD23 and CD25 in B 
Lymphocytes
3. 3 . 1  IL-4 Mediated Induction of CD23 and CD25 expression can be 
Mimicked by the Same Pharmacological Agents
In view of the possibility that two different forms of tire IL-4 receptor are responsible for 
CD23 and CD25 induction, it was of interest to determine whether early signal 
transduction events responsible for CD23 and CD25 up-regulation differed in any way.
Thus, it has previously been shown that IL-4 induces IP3 production and subsequent 
Ca2+ mobilization followed, after a lag period, by a prolonged cAMP accumulation 
[Finney et al., 1990]. In addition, it is possible to mimic one of the longer term effects 
of IL-4, namely soluble CD23 expression, using a combination of pharmacological 
agents which activate cellular signalling pathways [Finney et al., 1990]. Figure 3.5 
shows the mean channel number (or mean channel fluorescence) for expression of
:surface CD23 and CD25, following treatment of high density B lymphocytes with PM A 
and forskolin, either singly or in combination. For CD23 expression (Fig 3.5.A),
comparatively modest increases in mean channel number, from 45 in the controls to a
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maximum of 60, are observed in response to either PMA or forskolin as single stimuli; 
whereas a combination of these two stimuli resulted in a mean channel number of 82 
(i.e.,-double the response). More striking increases in mean channel number were 
observed for CD25 levels following treatment with forskolin (from 13 in the control 
samples to 24 in the challenged cells) or PMA (a maximum of 23). However, 
stimulation with both PMA and forskolin resulted in an increase in mean channel 
fluorescence to between 31 and 35, approximately two-fold above baseline (Fig 3.5.B).
The effects of combining other pharmacological agents to stimulate multiple cellular 
signalling pathways were also investigated (Fig 3.6). Short pulses with forskolin, a 
direct activator of adenylyl cyclase, resulted in a modest up-regulation of CD23 and a 
more striking increase in surface CD25 (as above). However, stimulation with PB112 
and/or ionomycin, followed by a more sustained challenge with forskolin caused a 
greater up-regulation of both CD23 (30-80% above baseline) and CD25 (90-160%) 
compared to unstimulated controls. These data are consistent with the interpretation that 
activation of adenylyl cyclase is important in up-regulation of CD23 and CD25, but that 
other stimuli, such as PKC activation and Ca2+ mobilization, are also important in the 
response. Stimulation with either PBu2  or ionomycin alone induced surface CD23 and 
CD25 to a modest degree (20-40% above basal); however, when these stimuli were 
administered in combination an increase in CD23 up-regulation was observed compared 
with the response to single stimuli, whereas the combination of these two stimuli 
appeared not to promote any further increases in CD25 expression. In contrast, either of 
these stimuli singly or in combination, together with a sustained exposure to forskolin, 
resulted in a more substantial increase in levels of CD25 than those of CD23. This is an 
interesting phenomenon and suggests, potentially, that generation of cAMP may play a 
more significant role in induction of CD25 than of CD23.
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3 . 3 . 2  Chronic Phorbol Ester Treatment Abrogates Induction of CD23 
and CD25 Expression in Response to IL-4
The involvement of PKC in IL-4 signal transduction pathways in human B cells was i  
addressed by exposing resting tonsillar* B cells to chronic stimulation with lOnM PMA 
for 48 hours, in an attempt to down-regulate intracellular PKC, prior to treatment with 
IL-4 for 24 hours and assay of CD23 and CD25 induction. The data presented in figures
3.7 A & B demonstrate that following chronic PMA treatment, IL-4 is unable to drive 
expression of either CD23 or CD25, in resting tonsillar B cells, regardless of the dose 
employed. These data suggest that one or more isoforms of PKC may be involved in 
some elements of IL-4 signal transduction in resting B lymphocytes. In addition, 
monoclonal antibodies to IgM and CD40 are able to promote increased expression of 
CD25 in resting human B cells (Figure 3.4), an effect which is also abrogated by chronic 
phorbol ester treatment (Fig 3.8). These latter data are consistent with the idea that 
activation of intracellular PKC is necessary to drive expression of the CD25 gene not | |  
only by IL-4, but also by the other stimuli known to promote expression of CD25 at the 
surface of human B cells. 7
Î
3 . 3 . 3  Chelation of Intracellular Calcium Inhibits IL-4-Driven
'7Upregulation of CD25
Calcium levels in the cytoplasm can be elevated in response to ligand stimulation either |
by an influx of the cation from the extracellular matrix or by release of Ca2 + from 
intracellular organellai* stores. Previous studies have indicated that IL-4 acts upon B cells
tto produce a transient increase in IP3 production and consequent Ca2+ mobilization. 
Therefore, in order to establish whether mobilization of intracellular Ca2+ stores was 
involved in IL-4-driven CD25 expression in human B cells, resting tonsillar B cells were 
loaded with 5|iM BAPTA-AM, a Ca2+ chelating agent, and stimulated with IL-4 (Fig f
3.9). The data illustrate that control B cells respond to IL-4 in a normal dose-dependent 
manner: however, the capacity of IL-4 to drive CD25 expression was severely impaired 1
in BAPTA-loaded cells. Moreover, in BAPTA-loaded cells, CD25 expression in
S
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response to stimulation with 15|Lig/ml anti-IgM was decreased by almost 33% compared 
to normal (data not shown). These results suggest that chelation of intracellular Ca2+ can 
attenuate certain long term effects of IL-4 and are consistent with the interpretation that I
Ca2+ release from intracellular stores is a central element in signal transduction leading to
93
CD25 expression. All experiments described in this chapter were subjected to a 
minimium ot three repeats.
3 .4  D iscussion
7::
The data presented in this chapter illustrate the ability of IL-4 to up-regulate CD25 in 
quiescent, human B cells and also show that this induction is dose dependent, with an 
EC5 0  which differs in magnitude from IL-4-induced expression of CD23. Although the 
difference in EC5 0  values of these two surface markers is small, the values are in good 
agreement with the reported affinities of two IL-4 receptor populations on human B cells 
[Russell et al,  1993]. Simultaneous 'three colour' analyses of cell surface expression of 
CD23 and CD25 on human B cells (CD 19 positive cells), support these findings and 
allow the interpretation that IL-4 potentially up-regulates CD23 and CD25 on a single B
cell population via receptors of two different ligand binding affinities. Since the dose
:response data indicated that CD23 and CD25 expression may be mediated through two 
distinct receptor populations, we attempted to establish whether different intracellular 
signals were responsible for inducing expression of the two cell surface markers. 
Maximal expression of both CD23 and CD25 occurred when cells were pulsed with 
either PMA or PBu2  and/or ionomycin for short time periods, followed by a more 
sustained stimulus with forskolin - suggesting that PKC activation, Ca^+ mobilization 
and elevation of intracellular cAMP may be important in IL-4 induced signal 
transduction. However, it was consistently noted that brief pulses with forskolin 
resulted in significant increases in CD25 expression ( typically a two-fold increase above 
basal). This fact, coupled with the observation that forskolin greatly enhanced CD25 
expression when used in combination with other stimuli, suggests that cAMP may be a
#
necessary event in up-regulation of CD25 expression. Mechanistically, it is possible that 
either activated PKC and/or increased intracellular concentrations of Ca^+ directly 
activate adenylyl cyclase type II and VII, or types I, III and VIII respectively [Cooper et 
al., 1988; Krupinski etal., 1989; Yoshimura and Cooper, 1993]. Alternatively, second 
messengers such as Ca2+ and PKC activation may influence the activity of other 
signalling effectors which in turn activate adenylyl cyclase. However, it must also be 
considered that PKC activation and Ca2+ mobilization, as well as functioning to activate 
adenylyl cyclase, may also act as independent signalling pathways which affect IL-4 
target genes.
The observation that higher concentrations of IL-4 were required to elevate CD25 
expression (compared with those required for CD23 expression), coupled with the 
observation that other cytokines such as IL-2 and IL-7 which share yc as part of their 
receptor structure are unable to induce CD25 expression, suggests that a low affinity 
form of the IL-4 receptor (i.e., the fonn which lacks yc) is responsible for up-regulating 
CD25. However, IL-13 a cytokine which shares a number of cellular functions with IL- 
4, is unable to up-regulate CD25. Although the nature of a shared component in IL-4 
and IL-13 receptors is still under debate, it seems likely that it is the IL-4Ra chain and 
not, as was initially suggested, the yc subunit. If this is indeed the case, then it is 
possible that intracellular signals activated via both the yc and IL-4Ra, a feature unique 
to the high affinity IL-4 receptor, are required for induction of CD25 expression. The 
activation of Jakl and Jak3 kinases in response to IL-4, although designated as being 
associated with the IL-4Ra chain and yc, respectively, appears to be reliant upon the 
physical association of the two individual receptor components. It has been suggested 
that ligand-induced receptor dimerization brings Jakl and Jak3 into close spatial 
proximity, thus, allowing mutual cross-phosphorylation and subsequent activation of the 
two tyrosine kinases [Miyazaki et al., 1994]. In addition, despite some reports 
suggesting that IL-4-induced activation of Jakl and IRS-2 occur independently of one 
another [Kotiandes et al, 1995], it appears that removal of the critical growth signal
%
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transduction region of the IL-4Ra chain cytoplasmic domain [Harada e ta l ,  1990] 
abolishes both of these pathways [Pernis et al, 1995c]. This 41 amino acid critical 
signal transduction domain has previously been demonstrated to be essential for both Jf 
IRS-2 activation and physical association of the two receptor components [Keegan et al,
1994]. The discovery that it is also crucial for Jakl and Jak3 activation links the majority 
of known IL-4-induced signalling pathways to this region and suggests that IL-4 
mediated receptor dimerization is a crucial event for successful signal transduction via the 
IL-4/IL-4 receptor complex.
Interestingly the only stimuli, other than IL-4, capable of up-regulating CD25 appear to 
be activation of the B cell through the B cell receptor itself or through CD40. These three
stimuli are all in some way involved in activation of mature human B cells. High f
.concentrations of anti-IgM antibodies are able to induce DNA synthesis and cell division 
of resting human B cells and, although unable to promote proliferation themselves, both 
IL-4 and anti-CD40 antibodies act as co-stimulants with low, physiological
Iconcentrations of anti-IgM to promote cell division and activation. IL-2 acts to promote 7i7
proliferation and differentiation of previously activated B cells and requires the presence
of high affinity IL-2 receptors in order to mount such a response. Therefore, it seems 
logical that these three stimuli which are involved to some degree in B cell activation,
11should all have the capacity to induce CD25 expression in resting human B cells. !
Chronic phorbol ester treatment of B cells, in an attempt to down-regulate PKC, results 
in the inhibition of CD25 expression in response to IL-4, anti-IgM and anti-CD40, 
suggesting that the activation of PKC is necessary for regulation of induction CD25 
expression in response to all three stimuli. Although there are no data reporting PKC 
activation by anti-CD40 stimulation it is well known that stimulation via the B cell 
receptor involves PKC activation.
3.1 IL-4 Induces Upregulation of CD23 and CD25 in a Dose Dependent 
Manner
High density tonsillar B cells were cultured with the indicated concentrations of 
IL-4 for 24 hours at 37 in a 5% CO2 , humid atmosphere. Following 
incubation with IL-4 cells were simultaneously stained with FITC-anti-CD25, 
PE-anti-CD19 and biotinyl-anti-CD23 monoclonal antibodies (biotin conjugated 
antibodies were visualised using Streptavadin-Quantum Red) and analysed by 
flow cytometry. Results are expressed as % Marker positive B cells: CD23-open 
squares; CD25- open circles. IL-4 induces dose-dependent up-regulation of both 
CD23 and CD25 on the surface of human B cells.
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3.2 IL-4 Induces Up-regulation of CD23 and CD25 on the Same BCell 
Population via Two Different Affinity Receptors
High density tonsillar B cells were cultured with the indicated concentrations of 
IL-4 for 24 hours at 37 °C. Following incubation with IL-4 cells were 
simultaneously stained with FITC-anti-CD25, PE-anti-CD19 and biotinyl-anti- 
CD23 monoclonal antibodies and analysed by flow cytometry. Analysis using 
the Taint a Gate’ software allowed visualisation of single, double and triple 
positive subpopulations of cells: CD19+/CD23“/CD25"- striped bars;
CD19+/CD23+/CD25-- white bars; CD19+/CD23-/CD25+ - grey bars; 
CD 19+/CD23+/CD25+ - black bars.
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3.3 IL-2, IL-7 and IL-13 Do Not Up-regulate CD25 in Resting Human B
Cells
High density tonsillar B cells were cultured with the indicated concentrations of 
(A) IL-2, (B) IL-7 and (C) IL-13 for 24 hours at 37oC. Following incubation 
with cytokines, cells were simultaneously stained with FITC-anti-CD25 and PE- 
anti-CD19 monoclonal antibodies and analysed by flow cytometry. Results are 
expressed as % CD25 positive B cells.
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3.4 CD25 is Up-regulated in High Density Tonsillar B Cells in 
Response to Anti-IgM and Anti-CD40
High density tonsillar B cells were cultured for 24 hours at 3 7 in the presence 
of the indicated concentrations of (A) anti-IgM and (B) anti-CD40 monoclonal 
antibodies. Following incubation with cytokines, cells were simultaneously 
stained with FITC-anti-CD25 and PE-anti-CD19 monoclonal antibodies and 
analysed by flow cytometiy. Results are expressed as % CD25 positive B cells. 
Both anti-IgM and anti-CD40 induce dose dependent up-regulation of CD25 on 
tlie surface of human B cells.
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3.5 Stimulation of Resting Tonsillar B Cells with Phorbol Ester and 
Forskolin Induces CD23 and CD25 Expression
High density tonsillar B cells were stimulated with lOOgM forskolin and lOnM 
PMA for 30 second and 2 minute time periods. In addition, PMA treated cells 
were further stimulated with lOOgM forskolin for a sustained 20 minute period. 
Treated and control cells were cultured for 24 hours at 37°C. Following 
stimulation, cells were simultaneously stained with FITC-anti-CD25, PE-anti- 
CD 19 and biotinyl-anti-CD23 monoclonal antibodies and analysed by flow 
cytometry. Results are expressed as mean channel fluorescence of (A) CD23 
and (B) CD25 expression: 30 second pulse - black bars; 2 minute pulse - white 
bars.
CD23
PMA + Forskolin
Forskolin
PMA
Control
Mean Channel Fluorescence
B CD25
PMA -t- Forskolin
G
BG(U
H
Forskolin
PMA
Control
Mean Channel Fluorescence
100
3.6 Stimulation of Resting Tonsillar B Cells with Phorbol Dibutyrate, 
lonomycin and Forskolin Induces CD23 and CD25 Expression
High density tonsillar B cells were stimulated with 2nM PBu2, l|iM  ionomycin 
singly or in combination and lOOfiM forskolin for 30 second and 2 minute 
periods followed by 24 hour culture at 37°C. In addition, B cells pulsed for 30 
seconds and 2 minutes with PBu2 and ionomycin, both as single and as a 
combined stimulus, were further treated with 100p,M forskolin for a 20 minute 
period. Cells were washed and cultured for 24 hours at 3?oc. Following 
stimulation, cells were simultaneously stained with FITC-anti-CD25, PE-anti- 
CD 19 and biotinyl-anti-CD23 monoclonal antibodies and analysed by flow 
cytometry. Results are expressed as mean channel fluorescence of (A) CD23 
and (B) CD25 expression; 30 second pulse - black bars; 2 minute pulse - white 
bars.
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3.5 Stimulation of Resting Tonsillar B Cells with Phorbol Ester and 
Forskolin Induces CD23 and CD25 Expression
High density tonsillar B cells were stimulated with lOOpM forskolin and lOnM 
PMA for 30 second and 2 minute time periods. In addition, PMA treated cells 
were further stimulated with lOOfiM forskolin for a sustained 20 minute period. 
Treated and control cells were cultured for 24 hours at 37^C. Following 
stimulation, cells were simultaneously stained with FITC-anti-CD25, PE-anti- 
CD 19 and biotinyl-anti-CD23 monoclonal antibodies and analysed by flow 
cytometry. Results are expressed as mean channel fluorescence of (A) CD23 
and (B) CD25 expression; 30 second pulse - black bars; 2 minute pulse - white 
bars.
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3.8 Anti-IgM and Anti-CD40 Antibody Induced Up-regulation of CD25 is 
Abolished by Chronic PMA Treatment
High density tonsillar B cells were treated with lOnM PMA for 48 hours, 
following which both treated and untreated cells were cultured with 25|ig/ml 
anti-IgM and 5|ig/ml anti-CD40 monoclonal antibodies for 24 hours at 37°C. 
Following incubation, cells were simultaneously stained with FITC-anti-CD25, 
PE-anti-CD19 and biotinyFanti-CD23 monoclonal antibodies and analysed by 
flow cytometry. Results are expressed as % CD25 positive B cells: untreated 
cells - black bars; chronically PMA treated cells - white bars.
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3.9 Chelation of Intraceliuiar Calcium Abrogates the Ability of IL-4 to 
Up-regulate CD25
High density tonsillar B cells were loaded with InM BAPTA- 
acetoxymethylester (in the presence of 0.15% (w/v) Pluronic F127) to chelate 
intracellular Ca^+. B cells were then treated with the indicated concentrations of 
IL-4 for 24 hours at 37®C. Following incubation with IL-4, cells were 
simultaneously stained with FITC-anti-CD25, PE-anti-CD19 and analysed by 
flow cytometry. Results are expressed as % CD25 positive B cells: untreated 
cells - open squares; BAPTA loaded cells - open circles.
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A Negative Regulatory Element in the CD25 
Promoter is Regulated by a cAMP Generating
Pathway
i
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4.1  Introduction
I
It has been demonstrated previously that IL-4 is able to induce generation of intracellular 
cAMP in human B cells. However, the answers to a number of pertinent questions |
'S.remain to be determined: the full nature of the kinetics of this second messenger ||
generation; the dose dependency (if any) of IL-4 induced cAMP production; and most fr
importantly, the consequences of activation of this pathway with respect to downstream ■ ;
IIIsignalling events and gene expression. Another issue which has not been addressed is 
which form of the IL-4 receptor is involved in cAMP production and whether other 
cytokines, in particular those with yc as part of their receptor complexes and also IL-13, 
shai'e this capacity to elevate intracellular cAMP.
The promoter region of the CD25 gene contains a number of nucleotide sequences
Acorresponding to motifs which bind common transcription factors including NFkB, Spl f
and the serum response factor (SRF) [Algarte et ai,  1995; Pierce et a i,  1995]. In f
addition to these, the promoter sequence also contains a number of motifs which are 
more lineage specific. These include two negative regulatory elements and a positive 
regulatory element: a retinoic acid response element (RARE) [Bhatti and Sidell, 1994] 
and the negative regulatory element (NRE) [Cross et ai, 1987; Smith and Greene, 1989] 
both of which potentially repress transcription when occupied; a putative IL-4 response 
element (IL-4RE), which could potentially promote transcription when bound. In 7;
3:5
addition, and more recently, a ST AT 6 binding element, occurring downstream of the
IIL-4RE, has been identified. In T cells an 11 base pair, core element in the NRE has 
been shown to bind a 50kDa ‘silencer protein’ [Smith and Greene, 1989] and deletion 
studies show that removal of NRE from the promoter region results in elevation of both 
basal and PMA-inducible promoter activity [Lowenthal et ai, 1988; Smith and Greene,
1989]. However, the questions of whether the NRE in the CD25 promoter in B cells 
displayed similar transcription factor binding activity and, if so, how binding of this 
transcription factor is regulated, have not been addressed until now. The ability of IL-4 I; }
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to regulate transcription factor binding to one or more of these regulatory elements is of 
particular interest due to its unique abihty as the sole cytokine capable of up-regulating 
CD25 expression. In addition to regulation of transcription factor binding to individual 
elements in the CD25 promoter, it is necessary to examine the regulation of 
transcriptional activation in order to define the pattern of transcriptional regulatory 
protein binding which results in activation of the gene.
4 .2  Generation of cAMP in Resting B Lymphocytes
4.2.1 IL-4 Induces cAMP Generation in Resting B Lymphocytes
IL-4 stimulation of resting tonsillar B lymphocytes consistently elevated intracellular 
levels of cAMP (Fig 4.1) a finding consistent with previous reports [Finney et al.,
1990]. However, contrary to previous findings the data presented here demonstrate 
that IL-4 induced cAMP generation over a period of 20 minutes is biphasic, with a 
short, transient peak occurring between 2-5 minutes which returns to baseline prior to 
the onset of a larger, more sustained peak aiising approximately 10 minutes after ligand 
binding. The magnitude of this secondary peak was found to vary from one tonsil 
preparation to another within a range of approximately 65-120 pmol /lO^ cells. The 
reason for this variation in response is unclear; however, as the cells were used only 
one hour following preparation, it could possibly be attributed to the degree of prior, 
in vivo activation which varies from one tonsil preparation to another. If one examines 
cAMP accumulation in response to IL-4 over a longer time course, i.e., 1 hour 
following ligand binding, it can be obseiwed that the secondary peak is sustained, until 
between 20 and 30 minutes, before it begins to decline back to basal levels (Fig 4.2)
:'4
A dose response titration for IL-4-stimulated cAMP accumulation at both 5 and 20 
minutes (Fig 4.3.A & B) demonstrates an EC5 0  of 1-10 units/ml (5 - 50pM) for both. 
Interestingly these values are consistent with cAMP being generated via a high affinity 
IL-4 receptor, i.e., the IL-4R a chain and yc chain. In addition, the data presented in
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Figures 3.1 and 3.2 suggest that IL-4 induced up-regulation of CD23, but not CD25, is 
mediated via a high affinity IL-4 receptor, with the EC5 0  values for CD23 expression 
corresponding to the EC5 0  value for IL-4 induced cAMP generation. In contrast, IL-4- 
induced CD25 up-regulation has a higher EC5 0 , corresponding to IL-4 mediating its 
effects via a low affinity form of the receptor, i.e. the IL-4R a chain alone. These 
results are interesting if one considers the apparent ability of forskolin both as a single 
stimuli and also in combination with phorbol esters and calcium ionophores, to increase 
levels of cell surface CD25. These latter data would suggest that the generation of 
cAMP does have an important role in inducing expression of CD25 in human B cells.
However, the ability of a low affinity IL-4 receptor being able to successfully mediate 
DL-4-mduced signal transduction now seems to be questionable.
4.2.2 IL-2 and IL-7 Induce cAMP Generation in Resting B Lymphocytes
Considering the possibility that IL-4 promotes cAMP production in resting B cells via the 
high affinity form of its receptor (i.e. the yc containing form), it was of interest to 
determine whether or not other cytokines which share yc as a component of their 
receptors, were capable of inducing cAMP production. Upon stimulation of tonsillar B 
cells with IL-2 and IL-7, an increase in intracellular cAMP levels in resting B cells was 
observed. Again the magnitude of this response varied from one cell preparation to 
another, although the general pattern appears to suggest a greater cAMP response to IL-2 
as compared with IL-4 (Fig 4.4), whereas the response to IL-7 appeared to equal that of 
IL-4 (Fig 4.5). Thus, it appears that cAMP generation is a feature of the lymphoid, yc- 
containing subfamily of cytokine receptors and these data reinforce the idea that IL-4 
promotes cAMP production via a high affinity form of the receptor. In addition, it also 
seems likely that it is the yc subunit itself which is responsible. IL-2 and IL-7, as 
described previously (Chapter 3), were found to be incapable of inducing CD25 
expression in resting, human B cells. Therefore, if the premise is that cAMP generation 
is linked to yc then, while it is necessary for induction of CD25, the generation of cAMP 
alone is insufficient for up-regulating the expression of CD25.
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4.2.4 IL-4 Induces PKA Activation in Resting B Lymphocytes
The data reported above give a strong indication that IL-4 regulates transcription factor
4.2.3 IL-13 Does Not Induce cAMP Production in Resting B Cells
It has been reported that IL-4 and IL-13 share certain common cellular functions 
[Keegan et al., 1995; Nilsson and Nilsson, 1995; Smerz-Bertling and Duschl, 1995] 
and a common receptor subunit [Zurawski et al, 1993], initially proposed to be yc, but 
which increasing evidence suggests is the IL-4Ra chain. Unlike IL-4, IL-13 is unable 
to generate cAMP production in resting tonsillar B cells (Fig 4.6). This appears to g
promote the idea that yc is not a component of the IL-13R complex and provides further
evidence that the ability of IL-4 to induce an increase in cAMP levels in B cells is ai %
■fileast partly a function of the yc subunit of the receptor. It is known that certain signal 
transduction pathways induced by IL-4 and which are a feature of the IL-4Ra chain, are
Ialso common to IL-13-induced signal transduction [Keegan et al, 1995]. If the
:,ïhypothesis is that yc is responsible for generating cAMP and IL-4 induces CD25 ri
expression via the low affinity receptor, the question then arises, how is artificially f
generating cAMP by stimulating B cells with forskolin involved in increasing 
expression of the CD25 gene (Figures 3.5 and 3.6)? As IL-13 is unable to induce an siIincrease in surface CD25, it would appear that signalling pathways shared by IL-4 and
éIL-13 are insufficient to promote increased expression of particular genes and it is
possible that a combination of signalling pathways generated by both yc and the IL~4Ra |
sischain are required for induction of CD25. If this latter suggestion is the case then it #
v!would account for the ability of elevated cAMP levels to up-regulate CD25 at the cell
surface. I
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binding to NRE in the CD25 promoter in human B cells via a cAMP generating pathway
is:and the activation of PKA. To determine directly that IL-4 activates PKA, a target ■;3
peptide phosphorylation assay was carried out and preliminary results revealed that PKA
activity is indeed activated by IL-4 stimulation. The data presented here demonstrate t
i#
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PKA activity in extracts made from B cells stimulated for 5 and 25 minutes, with and 
without IL-4, where stimulation with IL-4 shows a marked increase in PKA activity 
compared with unstimulated controls (Fig 4.7). These data are in good accordance with 
the biphasic cAMP production observed in response to IL-4 stimulation, with PKA 
activation being evident at time points where cAMP generation is clear. However, this 
preliminary data, while interesting, will need to be backed up by an extensive 60 mmute 
time course.
4 .3  Transcription Factor Binding to the Negative Regulatory 
Element of the CD25 Promoter
4.3.1 IL-4 Induces a Decrease in NRE Transcription Factor Binding 
Activity
An 11 base pair core region of the CD25 promoter is known to profoundly negatively ; •
regulate CD25 expression in human T cells [Ballard et al, 1989; Lowenthal et ai, 1988;
Smith and Greene, 1989]. Transfection of Jurkat cells with CD25 promoter-CAT 
constructs demonstrated that a deletion mutant lacking NRE (pANRE) induced a 6-fold 
increase in basal reporter activity, compared with the full length CD25 promoter, and a 
12-fold increase following stimulation with PMA [Burlinson et al, 1996]. The presence 
of protein transcription factors capable of binding NRE in resting human B cells and their 
sensitivity to modulation by IL-4 was assessed. As shown in figure 4.8., resting 
tonsillar B lymphocytes possess binding activity for the NRE oligonucleotide and the 
capacity of this protein (or proteins) to bind the oligonucleotide is attenuated by IL-4 
stimulation, over a four hour period. There are two mobility shift bands appearing on 
the EMSA autoradiograph which, as the nature of NRE binding protein(s) remains 
uncharacterized, could possibly be attributed to the formation of homo- or heterodimeric 
complexes. However, the data presented suggest that it is the slowest of the two 
mobility shift bands which is the most sensitive to the effects of IL-4, with almost total 
attenuation of the DNA binding activity after 4 hours of cytokine stimulation. The
:no
!
specificity of binding is demonstrated in figure 4.9 where unlabelled NRE
oligonucleotide acted as a specific competitor for NRE binding, with particularly 
pronounced affects on the slowest mobility shift band. In contrast, an excess amount of 
unlabelled Oct 1 oligonucleotide was unable to compete with NRE for protein binding.
The ability of IL-4 to attenuate the activity of protein(s) binding to the NRE site might 
partially explain the ability of IL-4 to up-regulate CD25 expression in human B 
lymphocytes; thus, this effect in combination with increased binding at positive 
regulatory elements, such as the IL-4 -Response Element, could facilitate expression of 
CD25.
4.3.2 Forskolin and Cholera Toxin Induce a Decrease in NRE Binding 
Activity
Stimulation of B cells with agents which activate intracellular signalling pathways can 
induce expression of the CD23 and CD25 proteins, in a manner analogous to IL-4 itself.
In particular forskolin, which acts directly on the catalytic subunit of adenylyl cyclase 
thereby activating the enzyme and inducing an increase of intracellular cAMP [Seamon 
and Daly, 1981; Whetton et al., 1983], is able to induce modest levels of CD25 
expression at the B cell surface [McKay and Cushley, 1995]. However, this apparent 
relationship between cAMP generation and CD25 up-regulation appears at odds with the
fdata suggesting that cAMP production is linked to yc and that increased CD25 expression 
is mediated via a low affinity (yc lacking) form of the IL-4 receptor. It was therefore of 
considerable interest to try and establish what relationship, if any, might exist between 
increasing intracellular cAMP levels and expression of the CD25 gene, particularly with 
respect to regulation of transcription factor binding. The effects of forskolin and cholera I
toxin upon NRE binding activity in B cells was tested. Protein extracts prepared from 
cells after four hours incubation in medium alone showed no significant decrease in NRE 
binding activity (Fig 4.10.A), while those exposed to IL-4 over the same period of time 
showed the expected loss of activity (4.10 B). Treatment of resting human B cells with 
forskolin resulted in a similar decrease in protein binding activity for the NRE
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oligonucleotide over a four hour time course (Fig 4.10 C). This proposal is supported 
by the observation that cholera toxin (CT), the A subunit of which ADP ribosylates the 
Gsa protein (thereby activating adenylyl cyclase leading to an increase in intracellular 
cAMP) caused a similar decrease in NRE binding activity in B cells over a period of four 
hours (Fig 4.10 D). These data suggest that an elevation of intracellular cAMP levels 
results in decreased binding of a tianscription factor at the negative regulatory element of 
the CD25 promoter, an idea which supports the observations that artificially inducing 
cAMP production by stimulation with forskolin results in elevation of CD25 upon the 
surface of the cell.
4 . 3 . 3  Inhibition of PKA and Tyrosine kinases but not PKC Prevents IL- 
4-Induced Attenuation of NRE Binding Activity
The accepted paradigm for the mechanism of action of cAMP in any cell type is its ability 
to activate a cAMP-dependent protein kinase (PKA). The observations that IL-4 
promotes both cAMP generation and PKA activation and that artificially inducing cAMP 
production mimics the ability of IL-4 to reduce transcription factor binding to the NRE in 
the CD25 promoter, suggest that IL-4 is acting upon this element via a cAMP generating 
pathway. Therefore, to try and establish direct links between IL-4 binding to its receptor 
and the evident decrease in transcription factor binding to NRE, protein extracts were 
made from IL-4-treated resting B cells which had been pre-treated with a range of of 
protein kinase inhibitors (Fig 4.11). As shown previously, untreated controls (Fig 4.11 
A) show no decrease in NRE binding activity over a four hour period compared with IL- 
4 treated extracts, which demonstrate a striking loss in binding activity (Fig 4.11 B). 
However, pre-treatment of B cells with H89, a potent and selective inhibitor of PKA 
with a Ki of 0.048|aM [Chijiwa et ai, 1990; Geilen et al, 1992], blocks the ability of 
IL-4 to cause attenuation of NRE binding activity over a 4 hour period (Fig 4.5.C). This 
observation provides further evidence in favour of the hypothesis that IL-4, by inducing 
cAMP production (probably by activating adenylate cyclase) and in turn activating PKA, 
exerts its effects upon NRE via a cAMP-dependent pathway. The activated catalytic
I
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subunit of PKA may then either function by acting directly upon the transcription factor 
which binds NRE, or by phosphorylating some intermediate protein component in the 
pathway which ulthnately influences NRE binding activity.
It has been observed that PKC has an involvement in the up-regulation of CD25 in 
human B cells, with respect both to the ability of phorbol ester treatment to elevate cell 
surface levels of CD25 and the attenuation of IL-4's ability to up-regulate CD25 
following down-regulation of PKC (Chapter 3). In addition, it has been shown that IL- 
4, upon binding to its receptor, activates the protein tyrosine kinases Jakl [Russell et ai, 
1993; Witthuhn et al., 1994] and Jak3 [Yin et al, 1994]. There is the question, 
therefore, of the role that these second messengers play in IL-4 induced expression of 
CD25. Are they involved in regulating the cAMP/PKA pathway or do they act purely as 
independent signalling pathways which affect the CD25 promoter? IL-4 is known to 
activate ST AT 6  via the IL-4Ra chain and phosphorylation of Jakl [Hou et al, 1994; 
Yin et al, 1994] and the importance of this with respect to the CD25 promoter will be 
addressed in chapter 5. However, in an attempt to establish the involvement of PKC and 
potential protein tyrosine kinase activity in the regulation of transcription factor binding 
to NRE, resting B cells were pre-treated with PKC and protein tyrosine kinase inhibitors 
prior to treatment with IL-4. DNA mobility shift assay with extracts from these cells 
demonstrated that B cells pre-tieated with the PKC inhibitor &w-indolylmaleimide (BIM) 
retained the capacity to attenuate NRE binding activity in response to IL-4 (Fig 4.11 D). 
In contrast, B cells pre-treated with the tyrosine kinase inhibitor genistein lost the 
capacity to decrease NRE binding activity in response to IL-4 (Fig 4.11 E). These data 
indicate that while PKC is not involved in IL-4 regulation of NRE binding activity, 
tyrosine kinase activity plays some role in this pathway, but what this latter activity is 
remains to be elucidated. However, it may be assumed that while the activity of PKC 
obviously has a role in IL-4 signal transduction and CD25 expression (Figures 3.5, 3.6,
3.7 & 3.8), it is independent from IL-4 regulation of NRE protein binding activity.
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4.3.4 The NRE Element in the CD25 Promoter is not a Classical cAMP 
Responsive Element
A number of genes are sensitive to regulation by changing cAMP levels through a cis- 
acting DNA sequence known as the cAMP response element (CRE) [Macchi et al., 1995; 
Montminy and Bilezikjan, 1987; Montminy et aL, 1990]. There are a number of 
different regulatory proteins which bind to CRE; however, the CREB family in particular 
appears to be regulated by phosphorylation by PKA [Habener, 1990]. The pattern of
-■regulation of CRE by this family of proteins is usually one of transcriptional activation, 3
i.e., they are positive regulatory elements whose binding to CRE is up-regulated by PKA 
induced phosphorylation. On the other hand, the situation with respect to NRE is one of 
cAMP/PKA inducing transcriptional activation by removing a negatively regulating factor 
from the promoter region. A competition assay, using an excess amount of unlabelled 
CRE oligonucleotide, demonstrated that this particular sequence was unable to compete 
for protem binding to NRE in human B cell extracts (Fig 4.12). This indicates that NRE ■
is not regulated by a member of the CREB family of transcription factors. Indeed, if one
homology to the classical CRE sequence motif (CRE core element is underlined).
CREB 5' AGA GAT TGC CTG ACG TCA GAG AGC TAG 3'
I
examines the sequence of NRE (shown below) in the CD25 Promoter it bears little
:
NRE 5' TT CAT CCC GGG 3'
This occurrence of a cAMP/PKA-regulated transcription factor which is not a member of 
the CREB family is not extraordinary, as a new motif (a 9 base pair imperfect direct
irepeat, 5 -CCG CTG CCC-3', and an inverted CCAAT box, 5'-ATTGG-3 ) distinct
from CRE, which is transcriptionally regulated by cAMP, has recently been reported in 1.71
the promoter of the human tryptophan hydroxylase gene [Boularand et al., 1995].
5
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4.3.5 IL-2, IL-7 and IL-13 Do Not Induce a Decrease in Transcription 
Factor Binding to NRE
The apparent regulation of transcription factor binding to NRE in the CD25 promoter in 
human B cells by elevation of intracellular c AMP levels and PKA activation, raises the 
question of whether other lymphoid sub-family cytokines may have similai* effects in 
human B cells. Neither IL-2, IL-7 nor IL-13 elevate CD25 expression in B cells; 
however, IL-2 and IL-7 do induce cAMP generation and their receptors do share the yc 
subunit with the IL-4 receptor. Therefore, it was a possibility that these two cytokines 
were able to regulate protein binding to NRE, but that this signal alone was insufficient 
to drive CD25 expression and that a decreased binding of NRE, together with other 
intracellular signals generated uniquely by IL-4, were required to drive transcription. 
Also, it was necessary to ask whether the inability of IL-13 to induce cAMP production, 
and the lack of yc in its receptor, was an impediment to its regulation of transcription 
factor binding to NRE. The results show that none of these cytokines are able to induce 
a decrease in DNA-protein interaction at NRE over a four hour period (Fig 4.13 B, C & 
D): this is in contrast with IL-4 which diminishes transcription factor binding to NRE 
almost entirely (Fig 4,13 A). These data are interesting in that they suggest that IL-4 
alone is able to regulate DNA-protein binding activity at NRE, despite the capacity of IL- 
2 and IL-7 to generate cAMP in human B cells.
'i
4.3.6 IL-4-Induced cAMP Generation is Regulated by Adenylyl Cyclase 
Activation rather than by PDE Inhibition
It is recognized that elevation of intracellular cAMP levels can be induced either by 
activation of adenylyl cyclase activity or by inhibition of phosphodiesterase (PDE) 
activity; cAMP is degraded to 5' AMP by phosphodiesterase enzymes. There are eight 
recognized PDE isoforms which have distinct sequences and are subject to different 
mechanisms of regulation. PDE inhibitor studies were used in order to determine 
whether the IL-4-induced cAMP generation which attenuates transcription factor binding 
to NRE is regulated by activation of adenylyl cyclase activity or by inhibition of PDE
:ÿ'
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activity. IB MX is an general inhibitor of most PDE isoenzymes; thus resting tonsillar B 
cells were treated with either IB MX or IL-4 for four hour periods and nuclear extracts, 
made at two hourly intervals, were examined for NRE binding activity. As observed 
previously, IL-4 mduces a decrease in NRE binding activity over a period of four hours 
(Fig 4.14 A), whereas IB MX was unable to mduce a similar decrease tianscription factor 
binding to NRE oligonucleotide (Fig. 4.14 B). These data indicate that inhibition of 
PDE activity in human B cells is unable to promote sufficient cAMP generation to induce 
a decrease in NRE binding activity, therefore, it seems likely that IL-4-induced cAMP 
generation is regulated by activation of one or more isoforms of adenylyl cyclase.
4 .4  Regulation of NRE Protein Binding Activity in EDR B 
Cells
4.4.1 Induction of CD25 Expression in EDR B Cells
Despite the ability of IL-4 to induce CD25 expression in primary, resting human B cells, 
the contrary has been true for most of the human B cell lines tested. In particular, the 
mature EBV transformed B cell line EDR was found to be incapable of responding to IL- 
4 by up-regulating CD25 at the cell surface. It was considered a possibility that certain
response to IL-4 becomes dose dependent (Fig 4.15 B).
elements of the intiacellular signalling machinery were inactive, perhaps as a result of the 
transformation process; whether such lesions are at the level of receptor coupling or 
transcriptional regulation remains equivocal. However, co-stimulation of EDR B cells 
with IL-4 and forskolin revealed that when these cells are stimulated with a single :
concentration of IL-4 in conjunction with increasing levels of forskolin they respond by 
increasing cell surface expression of CD25 in a dose dependent manner (Fig 4.15 A). 
Similarly when these cells are stimulated with a high concentration of forskolin the Hr
■I’
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4.4.2 IL-4 Induced cAMP Production in EDR B Cells
Taking the above results into account, it seemed possible that the inability of IL-4 to 
induce CD25 might be coupled to a defect in cAMP production in EDR B cells. In fact 
IL-4 does induce cAMP generation in the EDR B cell line, but this response is extremely 
low, approximately 10-fold less (Fig 4.16), in comparison to the response observed in 
primary human B cells (Fig. 4.1). The lack of an IL-4-induced cAMP response of the 
magnitude seen in primary cells could account for the inability of IL-4 to up-regulate 
CD25 at the cell surface of EDR B cells; this inteipretation is in agreement with the 
capacity of forskolin to restore induction of CD25 expression when used as a co­
stimulant with IL-4.
:
4.4.3 Regulation of Transcription Factor Binding to NRE in EDR B Cells
In primary B cells, IL-4 is able to induce CD25 expression and a reduction in 
transcription factor binding to the Negative Regulatory Element (NRE) in the CD25 
promoter. It seems likely that a decrease in DNA-protein interactions at NRE is regulated 
via a cAMP/PKA pathway and that this phenomenon is at least partially responsible for 
the ability of IL-4 to induce CD25 expression. In contrast, CD25 up-regulation is not 
observed in the EDR B cell line upon stimulation with IL-4 and IL-4-induced cAMP 
generation is severely diminished in this cell line, as compared with primary B cell 
responses. It is possible, therefore, that these two factors are linked by a lack of IL-4- 
induced reduction of NRE tianscription factor binding in EDR B cells. Indeed, the DNA 
mobility shift data indicate that IL-4 is unable to inhibit DNA-protein interactions at NRE 
over a four hour period in EDR B cells (Fig 4.17.A), whereas in primary B cells such 
stimulation leads to an almost total abrogation of transcription factor binding to NRE (Fig 
4.8). The converse is true for forskolin treatment of these cells; as with the primary B 
cells, forskolin treatment leads to almost total loss of protein binding to this element after 
four hours. Therefore, it would appear that the reduced capacity of IL-4 to induce cAMP 
production in EDR B cells is responsible for the loss of ability to down-regulate protein 
binding to the NRE in the CD25 promoter - an effect which prevents IL-4 up-regulation
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of CD25 - and that this discrepancy can be overcome by artificially elevating intracellular 
cAMP using forskolin (Fig 4.17 B).
4.4.4 Transcriptional Activation of the CD25 Promoter
The data presented so far support the hypothesis that transcription factor binding to a 
negative regulatory element in the CD25 promoter prevents expression of the gene. In 
human B ceUs IL-4 is responsible for control of this binding activity by down-regulating 
it via a cAMP-generating pathway. However, the question of the significance of this 
event with respect to transcriptional activation has remains unaddressed. Is the removal 
of this negative influence sufficient to drive transcriptional activation or is it one of a
■ :number of factors required for successful expression of the CD25 gene? In an attempt to 
address these questions it was necessary to look directly at activation of transcription, ' .1
using a CD25 promoter-CAT reporter gene construct. Due to the difficulties of 
transfecting primary, resting human B ceils, the EDR B cell line was chosen as a model 
system. Additionally, as this cell line only gives a cellular response to IL-4 (i.e., cell 
surface CD25 expression) when co-stimulated with forskolin, it provides an ideal system 
for studying the importance of elevating intracellular cAMP with respect to tianscriptional 
activation. Transfected cells which had been stimulated with IL-4 for 48 hours showed 
no up-regulation of CD25 at the plasma membrane, as judged by flow cytometry; in 
contrast, forskolin stimulation of transfected cells showed increased CD25 expression 
and this response was enhanced when transfected cells were co-stimulated with IL-4 and 
forskolin (Fig 4.18 A). Measurement of CAT reporter gene activity demonstrated that, 
although there was no real difference between cells treated with and without IL-4, the 
forskolin stimulated cells showed considerably increased reporter activity, compared 
with unstimulated transfected cells. Cells which had been co-stimulated with IL-4 and 
forskolin showed enhanced reporter activity, a response which appears to be synergistic 
(Fig 4.18 B & C). These latter data are in very good agreement wiüi the cell surface data 
of Figure 4.18 A and suggest that while cAMP-induced down-regulation of protein 
binding at NRE is able to drive some expression of the CD25 gene, this response, in
:
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combination with other unknown signalling pathways also activated by IL-4, is 
necessary for maximal transcriptional activation. In other words, IL-4-induced cAMP 
generation is a necessary but insufficient signal required to drive CD25 gene expression.
4 .5  D iscussion
The results presented in this chapter demonstrate that IL-4 is able to induce a decrease in 
DNA-protein binding activity at the negative regulatory element in the CD25 promoter,
and that this effect occurs over a four hour time period, a result which is consistent with I
:the initial appearance of CD25 at the plasma membrane [Butcher et ai,  1990]. In 
addition, it is possible to mimic this decrease in transcription factor binding by |
stimulating the cells with forskolin or cholera toxin, indicating that an increase in 
intracellular cAMP is able to regulate binding to NRE. This finding was of particular 
interest, as IL-4 has been shown to induce cAMP production in human B cells, an 
observation which suggests a link between IL-4-induced cAMP generation and inhibition |j
of protein binding to NRE. Using a PKA inhibitor, H89, it was possible to demonstrate 
this link more directly, as PKA inhibition results in total abrogation of the ability of IL-4 
to reduce DNA-protein interactions at NRE. Conversely, inhibition of PKC had no such 
inhibitory effects, suggesting that if PKC is involved in IL-4 signal transduction then it 
exerts its effects through an entirely independent pathway. These results are in very 
good accordance with the ability of IL-4 to elevate PKA activity in resting human B cells; |
however, the question of how PKA acts upon NRE binding proteins remains to be 
elucidated. CREB is known to be one of the major cellular targets for PKA and its 
activation by phosphorylation of the amino acid Seri 33 renders it transcriptionally active 
[Habener, 1990; Montminy and Bilezikjan, 1987]. The inability of CRE DNA sequences 
to compete for NRE binding activity in human B cells, would appear to eliminate CREB 
as a candidate for an NRE binding transcription factor. However, other putative means 
of PKA regulating transcription have been put forward, including the action of the WI
1 1 9  I
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regulatory (RII) subunit of the enzyme acting directly as a regulator of transcription
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[Constantinou e ta l,  1985; Nagamine and Reich, 1985] and also the identification of a 
new cAMP responsive element in the tryptophan hydroxylase gene promoter [Boularand /:
et al, 1995]. Mutational analyses of two short sequences within this element, a 9 base 
pair imperfect direct repeat (5-CCG CTG CCC-3') and an inverted CCAAT box (5'- 
ATTGG-3'), revealed that point mutations within both abrogated gene transcription in 
response to cAMP. Both of these sequences are distinct from recognized CRE elements 
(5'- TG ACG TCA -3'), identifying the promoter region of this gene as a novel cAMP 
responsive element. The newly identified cAMP responsive element in the tryptophan 
hydroxylase gene promoter has a sequence which is distinct from the sequence of NRE 
(5'-TT CAT CCC AGG -3') thus, it would seem unlikely that the two were related; 
however, this does not discount the possibility of the existence of other unidentified 
cAMP/PKA-responsive transcription factors, which are structurally distinct from 
members of the CREB family. There is little information about the regulation ol 
transcription factor binding to NRE in T cells. However, there exists an apparent 
dichotomy in the importance of this promoter element, with respect to CD25 expression, 
which seems to be dependent upon the developmental stage of T cells. Thus, in a cell 
line with an immature T cell phenotype (YT-1 cells) the removal of this element 
profoundly enhances both basal and PMA-inducible expression of CD25, whereas in a 
phenotypically more mature T cell line (Jurkat cells) a similar deletion has relatively little 
effect upon transcriptional activation [Lowenthal etal,  1988]. The implications of these 
observations may be due to differences in developmental activation of T cells; e.g., the 
availability of a fully functional signalhng pathway at a particular* developmental stage or 
the differential expression of transcription factor proteins at each phase of development.
Either way a more comprehensive knowledge of the underlying mechanisms which 
account for this diversity and its relevance to NRE binding, may assist in the 
understanding of regulation of an NRE-binding transcription factor. The importance of 
cAMP regulation of CD25 expression has been reported elsewhere, in as much that IL-1- 
induced cAMP generation in natural killer cells is responsible for transcriptional
regulation of the CD25 gene [Shirakawa and Mizel, 1989b], However, there are two 
veiy important differences in this system compared with the data presented here. Firstly, 
IL-1-induced elevation of cAMP in these cells results in increased binding of a positive 
regulatory factor to the CD25 promoter [Shirakawa and Mizel, 1989b], whereas cAMP 
regulation of transcription factor binding to NRE seems to involve the removal of a 
negative regulatory factor. Secondly, the nature of the DNA binding factors themselves 
is profoundly different; IL-1 induced generation of cAMP results increased binding 
activity to an NF-kB site in the CD25 promoter [Shirakawa and Mizel, 1989b], an 
element which is both stmcturally distinct and spatially removed from NRE. However, it 
is a possibility that a common signalling pathway such as cAMP generation/PKA 
activation, may utilize different effector molecules, i.e., two entirely different 
transcription factors, in order to achieve a common function. The need for this diversity 
may arise from cell lineage-specific expression of, and therefore the availability of, 
specific transcription factors.
It is unlikely that IL-4-induced CD25 expression is determined solely by a cAMP 
generating pathway inducing a decrease in transcription factor binding to NRE. Rather, 
it is probable that this second messenger response is a necessary but insufficient signal 
for gene expression. The EDR B cell line, unlike primary B cells, does not up-regulate 
CD25 in response to IL-4. However, when these cells are co-stimulated with IL-4 and 
forskolin a substantial increase in cell surface expression of CD25 is observed. In 
addition, IL-4-induced cAMP generation in this cell line is greatly reduced in comparison 
to normal human B cells, an approximately 10-fold lower response, and DNA-protein 
binding interactions at NRE remain unaffected by stimulation of the cells by IL-4, but are 
abrogated by treatment with forskolin. The implication of these findings was that the 
cAMP response to IL-4 in EDR B cells was insufficient to induce a decrease in binding 
of transcription factors to NRE, but by artificially elevating cAMP levels it is possible to 
override this block in the signal transduction pathway and up-regulate CD25. Transient 
transfection of EDR B cells with a CD25 promoter-CAT reporter gene construct lends
1 2 1
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further support to this hypothesis, in that IL-4 is unable to drive transcription whereas a 
substantial increase in reporter activity is observed upon stimulation with forskolin and 
co-stimulation with IL-4 and forskolin results in an enhancement of this response. The 
apparently synergistic elevation in reporter activity in réponse to co-stimulation with IL-4 
and forskolin, suggests the involvement of a second, or even third, IL-4-induced
signalling pathway in increasing CD25 gene expression. There are a number of
■candidates for this secondary activation pathway, based on the presence of other known
a
DNA binding elements in the CD25 promoter. In T cells, CD25 promoter deletion 
studies have highlighted a region required for transcriptional activation of the gene, 
which seems to be PMA-inducible. Recognized elements within this PMA-responsive 
region include an NF-kB site, an SRE and an Sp-1 binding site. In human B cells it has 
been demonstrated that there is no particular alteration in DNA binding activity to these 
elements in response to IL-4 as detected by DNA mobility shift assay [Burlinson, 
personal communication] cells involves the exchange of a negative regulatory complex 
(an NFkB p50 homodimer) for a positive regulatory complex (an NFkB p50-p6() 
heterodimer), at the NFkB binding site in the 5' promoter region of the gene [Algarte et 
al,  1995; Pierce et al, 1995]. In such a case a change in transcription factor binding 
may remain undetected by DNA mobility shift assay. Therefore, the possibility of the 
NFkB binding site of the CD25 promoter having a role in IL-4-induced gene 
transcription in human B cells remains equivocal. Finally, there are two putative lL-4 
response elements in the CD25 promoter, one of them a Stat6 binding site, and these 
seem likely sites for IL-4-induced regulation of CD25 gene expression.
IL-2 and IL-7, but not IL-13, are able to induce cAMP generation in resting human B 
cells. Such a result, if one agrees with the hypothesis that IL-13 does not share yc as
■ ;part of its receptor complex, suggests that cAMP generation is linked to the -yc subunit of 
these lymphokine receptors. IL-2 and IL-7, unlike IL-4, are unable to induce a decrease 
in transcription factor binding to NRE, an event which appears to be regulated by a 
cAMP-dependent pathway. However, the inability of IL-2 and IL-7 to decrease NRE
1 2 2
binding, despite their ability to induce cAMP generation, is consistent with the inability 
of both these cytokines to up-regulate cell surface CD25 in human B cells. This result 
also highlights the ability of a particular cell stimulus to initially generate a ubiquitous 
second messenger pathway, which somehow translates into a highly specific response at 
a point much further downstream. This phenomenon is found throughout most known 
signalling events and remains relatively unexplained.
I
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4.1 IL-4 Induces cAMP production in Resting tonsillar B Cells
High density tonsillar B cells (5 x lO^/ml) were incubated in complete medium 
for 1 hour prior to stimulation with IL-4 (100 units/ml) for the indicated time 
points, at 37 °C in a 5% CÛ2  ^humid atmosphere. Reactions were stopped by the 
addition of 2% (v/v) PGA and 50p.l aliquots were removed for analysis. Results 
are expressed as picomoles cAMP produced per 10  ^ cells: control cells - open 
squares; stimulated cells - open circles. Three independent repeats are shown.
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4.2 IL-4 Induces a Sustained Production of cAMP over a 60 Minute 
Period
High density tonsillar B cells (5 x lO^/ml) were incubated in complete medium 
for 1 hour prior to stimulation with IL-4 (100 units/ml) for the indicated time 
points, at 3 7 0 c . Reactions were stopped by the addition of 2% (v/v) PC A and 
50pl aliquots were removed for analysis. Results are expressed as picomoles 
cAMP produced per 10^ cells: control cells - open squares; stimulated cells - 
open circles.
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4.3 BL-4 Induced cAMP Production in Resting B Cells is Dose Dependent
High density tonsillar B cells (5 x lO^/ral) were incubated in complete medium 
for 1 hour prior to stimulation with the indicated concentrations of IL-4, for (A) 
5 minutes and (B) 20 minutes, at 37*^ 0. Reactions were stopped by the addition 
of 2% (v/v) PCA and 50pl aliquots were removed for analysis. Results are 
expressed as picomoles cAMP produced per 10^ cells.
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4.4 JDL-2 Induces cAMP Production in Resting Tonsillar B Cells
High density tonsillar B cells (5 x 10^/mI) were incubated in complete medium 
for 1 hour prior to stimulation with IL-2 (lOng/ml) for the indicated time points, 
at 37°C. Reactions were stopped by the addition of 2% (v/v) PCA and 50pl 
aliquots were removed for analysis. Results are expressed as picomoles cAMP 
produced per 10^ cells: control cells - open squares; stimulated cells - open 
circles. Two independent repeats aie shown.
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4.5 IL-7 Induces cAMP Production in Resting Tonsillar B Cells
High density tonsillar B cells (5 x 10^/ml) were incubated in complete medium 
for 1 hour prior to stimulation with IL-7 (0.5ng/ml) for the indicated time points, 
at 37°C. Reactions were stopped by the addition of 2% (v/v) PCA and 50|il 
aliquots were removed for analysis. Results are expressed as picomoles cAMP 
produced per 10^ cells; control cells - open squares; stimulated cells - open 
circles. Two independent repeats are shown.
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4.6 IL-13 Does Not Induce cAMP Production in Resting Tonsillar B Cells
High density tonsillar B cells (5 x 10^/ml) were incubated in complete medium 
for 1 hour prior to stimulation with IL-13 (6ng/ml) for the indicated time points, 
at 37^C. Reactions were stopped by the addition of 2% PCA (v/v) and 50|al 
aliquots were removed for analysis. Results are expressed as picomoles cAMP 
produced per 10^ cells: control cells - open squares; stimulated cells - open 
circles. Two independent repeats are shown.
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4.7 EL-4 Induces Activation of PKA in Resting Tonsillar B Cells
High density tonsillar B cells (5 x lO^/ml) were stimulated for 5 and 20 minute 
periods with IL-4 (lOOunits/ml), at 37°C. Lysates were made at the appropriate 
time points from both treated and untreated cells and zero minutes, unstimulated 
cells. 25|h11 aliquots were incubated with 25p.M cAMP, lOOcpm/pmol ^[32p]_ 
ATP/ATP mix, 0.5mM biotinylated PKA Peptide substrate and PKA assay 
buffer for 15 minutes. Reactions were terminated and aliquots transferred to 
streptavidin-coated discs, washed and counted by liquid scintillation 
spectrometry. Results are expressed as pmol ^^P transferred/minute/mg protein: 
IL-4 treated B cells - black bars; unstimulated B cells - open bai's.
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4.8 IL-4 Induces a Decrease in Transcription Factor Binding to NRE
High density tonsillar B cells (5 x lOh/ml) were incubated in complete medium 
at 37 for 16 hours prior to stimulation with IL-4 (100 units/ml) for 4 hours. 
Nuclear extracts were made at hourly intervals and examined by DNA mobility 
shift, with 0.175pmol, 32p_iabelled NRE oligonucleotide probe. The lane 
numbers at the top of the figure conespond to time of culture in the presence IL- 
4 in hours. Two distinct mobility shift bands are observed.
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4.9 Specificity of NRE Binding Activities in Human B Cells
Nuclear extracts from resting tonsillar B cells were incubated with 32p_iabelled 
NRE and excess, unlabelled NRE oligonucleotide (lane 1) or excess, unlabelled 
Oct 1 oligonucleotide (lane 2). Extracts were also incubated in the absence of 
any competing oligonucleotide (lane 3). Protein binding to NRE appears to be 
specific for both distinct mobility shift bands in human B cells.
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4.10 Forskolin and Cholera Toxin Mimic the Ability of IL-4 to Induce a 
Decrease in NRE Binding
High density tonsillar B cells (5 x lO^/ml) were incubated in complete medium 
at 37 °C for 16 hours prior to incubation with (A) medium alone, (B) lOOunits/ml 
IL-4 (C) lOOqM Forskolin or (D)l|ig/ml Cholera Toxin for 4 hours. Nuclear 
extracts were made at hourly intervals and examined by DNA mobility shift, 
with 0.175pmol, end labelled NRE oligonucleotide probe. The lane numbers 
at the bottom of the figure correspond to time (hours) in culture with or without 
stimulus.
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4.11 Inhibition of PKA and Protein Tyrosine Kinase activity, but not PKC 
Inhibits the Ability of IL-4 to Induce a Decrease in NRE Binding
Activitl
High density tonsillar B cells (5 x 10^/ml) were incubated in complete medium 
at 37^C prior to treatment. Cells were incubated with either (A) medium alone 
or (B) IL-4 (100 units/ml) for 4 hours, or pretreated (C) 50nM H89, (D) lOOnM 
Bisindolylmaleimide or (E) lOpM Genistein for 30 minutes prior to stimulation 
with IL-4 (100 units/ml) for 4 hours. Nuclear extracts were made at hourly 
intervals and examined by DNA mobility shift, with 0.175pmol, labelled 
NRE oligonucleotide probe. The lane numbers at the bottom of the figure 
coirespond to time of culture with or without IL-4 in hours.
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4.12 cAMP Response Element Does Not Compete for Binding With NRE
Nuclear extracts from high density tonsillar B cells were incubated with 32p_ 
labelled NRE oligonucleotide and a 10-fold (+) or 100-fold (++) excess of either 
unlabelled NRE oligonucleotide (lanes 3 & 4) or unlabelled CREB 
oligonucleotide (lanes 5 & 6). Extracts were also incubated in the absence of 
any competing oligonucleotide (lane 2) and 32p_iabelled NRE oligonucleotide 
was incubated in the absence of protein extracts (lane 1). Unlabelled NRE but 
not unlabelled CREB competes for protein binding with labelled NRE 
oligonucleotide.
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4.13 IL-2, EL-7 and IL-13 Do Not Affect Transcription Factor Binding to
NRE
High density tonsillar B cells (5 x lO^/ml) were incubated in complete medium 
at 37 °C for 16 hours prior to stimulation with (A) IL-4 (lOOunits/ml), (B) IL-2 
(lOng/ml), (C) IL-7 (0.5ng/ml) or (D) IL-13 (6ng/ml) for 4 hours. Nuclear 
extracts were made at hourly intervals and examined by DNA mobility shift, 
with 0.175pmol, 32p labelled NRE oligonucleotide probe. The lane numbers at 
the bottom of the figure correspond to time of culture with each cytokine, in 
hours.
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4.14 Inhibition of PDE Activity Does Not Attenuate NRE Binding Activity
High density tonsillar B cells (5 x lO^/ml) were incubated in complete medium 
at 37°C for 16 hours prior to stimulation with (A) IL-4 (lOOunits/ml), (B) IpM 
IBMX for 4 hours. Nuclear extracts were made at two hourly intervals and 
examined by DNA mobility shift, with 0.175pmol, ^2p labelled NRE 
oligonucleotide probe. The lane numbers at the bottom of the figure correspond 
to time of culture with IL-4 in hours.
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4.15 Costimulation of EDR B Cells with IL-4 and Forskolin Induces CD25 
Expression
EDR B cells (1 x 10  ^cells/ml) were resuspended in fresh, complete medium for 
24 hours prior to stimulation with either (A) the indicated concentrations of IL-4 
alone (white bars), or in the presence of lOjiM (black bars) or lOOpM (grey bars) 
forskolin or (B) the indicated concentrations of forskolin in the absence (white 
bars) or presence (black bars) of 400units/ml IL-4 , at 37®C, 5% CO2 for 48 
hours. Following incubation with IL-4 cells were simultaneously stained with 
FITC-anti-CD25 and PE-anti-CD19 monoclonal antibodies and analysed by flow 
cytometry. Results are expressed as % CD25 positive cells
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4.16 cAMP Production in EDR B Cells is Significantly Lower than in 
Primary B Cells
EDR B cells (5 x 10  ^cells/ml) were resuspended in fresh, complete medium for 
24 hours prior to stimulation with IL-4 (100 units/ml) for the indicated time 
points. Reactions were stopped by the addition of 2% (v/v) PGA and 50^1 
aliquots were removed for analysis. Results are expressed as picomoles cAMP 
produced per 10^ cells: control cells - open squares, stimulated cells - open 
circles.
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4.17 Forskolin but not IL-4, Induces a Decrease in Transcription Factor 
Binding to NRE in EDR B Cells
EDR B cells (5 x 10  ^cells/ml) were resuspended in fresh, complete medium for 
24 hours prior to stimulation with (A) IL-4 (100 units/ml) or (B) lOOfiM 
forskolin for 4 hours. Nucleai' extracts were made at hourly intervals and 
examined by DNA mobility shift, with 0.175pmol, ^^P-labelled NRE 
oligonucleotide probe. The lane numbers at the bottom of the figure correspond 
to time of culture with IL-4 or forskoHn in hours.
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4.18 IL-4 and Forskolin Induce Synergistic Transcriptional Activation of 
the CD25 gene
Maiiire EDR B cells (6.25 x 10^ cells/ml) were resuspended in fresh, complete 
medium for 24 hours prior to transfection with 40|ag of the pGEM-7Zf(+) 
cloning vector containing a promoter fragment from pIL-2a-CAT. Cells were 
stimulated, 2 hours following transfection, with either 400 units/ml IL-4, 100|iM 
forskolin or both these stimuli in combination and cultured at 37° C, for 48 hours. 
After 48 hours an aliqout of transfected cells were taken and simultaneously 
stained with FITC-anti-CD25 and PE-anti-CD19 monoclonal antibodies and 
analysed by flow cytometry (A). Cell lysates were made from remaining cells 
and transcriptional activation was analysed by CAT assay. Results are presented 
as Relative Reporter Activity from phosphorimager data (B) and as an 
autoradiograph of the TLC plate (C). The upper black arrow indicates mono- 
acetylated chloramphenicol (C).
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Chapter 5
Activity to the IL-4 Response Element of the 
CD25 Promoter
sIL-4-Induced Regulation of Transcription Factor Binding
:: : :
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5.1 Introduction
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A number of elements which have been defined as binding motifs for a range of 
intracellular transciiption factors, have been identified within the promoter region of the 
CD25 gene. Thus, there exists a group of positive regulatory elements - a kB  binding 
site, a serum response element (SRE) and an Spl binding site - whose sequences are
j
adjoining and in the case of SRE and Spl, overlapping [Algaite et al, 1995; Pierce et ai, 
1995]. In T cells, activation of transcription of the CD25 gene appears to be 
predominantly regulated by the exchange of a negatively acting NF-kB p50-p50 
homodimer for a transcriptionally active p50-p60 heterodimer at the kB site [Algarte et 
al., 1995]. In addition, this exchange of a negative factor for a positively acting one 
appeal's to facilitate binding of SRF and Spl to their respective binding elements [Pierce 
et al, 1995]. A sequence 5’ of this region (NRE) which binds a 50kDa 'silencer' protein 
does not appear to play a large functional role in the induction of the CD25 gene in 
human T cells, despite the observed increase in both basal and PM A-inducible reporter 
activity of a deletion mutant-CAT construct lacking this particular element [Lowenthal et 
al,  1988]. In contrast, the binding of a transcription factor to NRE seems to be one of 
the major regulatory components of CD25 transcription in human B cells. IL-4, which
has been demonstrated to be one of the most potent inducers of CD25 in human B cells 
(Chapter 3, Fig 3.4), is able to induce a decrease in DNA-protein binding activity to NRE 
via a cAMP generating pathway (Chapter 4). This latter effect appears to be at least 
partially responsible for IL-4 induction of CD25 up-regulation in human B cells, 
assigning a more important role to NRE with respect to CD25 expression than is 
observed in T cells. In addition, yet another contrast between T and B lymphocytes, 
with respect to CD25 transcriptional activation, is the apparent inability of IL-4 to induce 
any alteration in transcription factor binding to NF-kB, SRE or Spl in human B cells 
[Burlinson, personal communication]- This data is, however, inconclusive and the 
question, which other signalling mechanisms might IL-4 employ in human B cells in
Î
order to elevate expression of CD25, arises. Two putative positive regulatory response
145
elements are present in the CD25 promoter in human B cells. The first of these is an IL-4 
response element (IL-4RE), a sequence located upstream of the NF-kB binding site, 
which has sequence homology to IL-4 response elements located in the promoter regions 
of a number of IL-4 inducible genes [Boothby et ai, 1988; Kohler and Rieber, 1993; 
Kretsovali and Papamatlieakis, 1995]; e.g., a sequence which binds a nuclear factor-IL-4 
(NFIL-4) has been located in the C region of the Class II MHC Ea gene promoter 
[Kretsovali and Papamatheakis, 1995]. In addition, the IL-4RE of the CD25 promoter 
bears a degree of sequence homology with both the IFNy-activated sequence (GAS) 
located in the FcyRI gene promoter and with the Stat6 sequence described in the human 
FcyRI gene [Hou et a l,  1994; Witthuhn et ai, 1994]. The second and more recently 
identified element is a Stat6 binding site. IL-4 is the predominant activator of Stat6 in 
the majority of lymphoid cells and is reported to mediate this activation via tyrosine 
phosphorylation by Jakl following IL-4 receptor oligomerization, the association of Jakl 
with the IL-4Ra chain and its subsequent phosphorylation [Quelle et al., 1995]. It was, 
therefore, of interest to determine the regulatory effects of IL-4 upon transcription factor 
binding to the IL-4RE and also whether any relationship existed between this element and 
Stat6. Indeed, one or both of these positive regulatory elements may provide the key to 
IL-4 induced expression of CD25 in human B cells. In addition, the effects of cytokines 
which contain IL-4 receptor subunits in their own receptor complexes i.e., IL-13 
(putatively the IL-4Ra chain) and IL-7 (yc), were of interest; neither is able to regulate 
NRE binding activity or induce CD25 expression, so the possibility of these cytokines 
sharing any signalling pathways with IL-4, with respect to CD25 expression, comes into 
question.
5 .2  IL-4 Up-regulates Transcription Factor Binding to an IL- 
4 Response Element in the CD25 Promoter
Positive regulatory IL-4 responsive elements have been identified in a number of IL-4 
inducible genes [Boothby et al, 1988; Kretsovali and Papamatheakis, 1995; Schindler et
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al., 1994]. Statô, identified by its ability to bind to GAS (interferon-y activated 
sequences) elements, binds specific DNA sequences in its homodimeric (STF-IL-4) torm 
[Schindler et al., 1994]. An alternative IL-4 response element has also been identified in 
the promoter regions of the CD23 (low affinity IgE receptor- FcyRII) gene [Kohler and 
Rieber, 1993]. A similar element has been located in the CD25 promoter in human B 
cells based on these sequences. Considering the ability of IL-4 to up-regulate cell surface 
expression of CD25 in human B cells, it was of interest to determine whether IL-4 could 
regulate transcription factor binding to this element in these cells. The response to IL-4 
in resting tonsillar B cells is variable; however, the consensus seems to be that IL-4 up- 
regulates the activity of a protein which binds this element over a four hour period of 
stimulation (Figure 5.1). The five independent repeats of the same experiment shown in 
Figure 5.1 demonstrate the variation in transcription factor binding to IL-4RE, in 
response to IL-4, which occurs from one tonsil preparation to another. The extent of IL- 
4’s ability to induce this DNA -protein binding activity appears to be dependent upon the 
level of binding occurring at time zero, i.e., in extracts from unstimulated cells cultured 
in medium alone. The degree of DNA binding activity in unstimulated cells is variable 
between tonsil preparations and is more than likely a feature of differential states of in 
vivo activation of B cells in the tonsils. When binding of IL-4RE oligonucleotide is non­
existent at time zero the ability of IL-4 to induce an increase is in some instances 
extensive, with maximal binding occurring one hour after stimulation (Fig. 5.1 A), while 
in others the response is less dramatic even after four hours (Fig. 5.1 B). In contrast, in 
preparations where transcription factor binding is apparent at time zero, i.e., prior to any 
exogenous stimulation, any observed increases in response to IL-4 are small (Fig. 5.1C) 
and in some instances there is no discernible increase in DNA binding over the four-hour
stimulatory period (Fig. 5. ID). It could be predicted that if the degree of in vivo 
activation is high, the exposure of B cells to IL-4 will have induced activation of an IL- 
4RE binding factor to such an extent that exposure to exogenous IL-4 is unable to induce 
any further response, i.e., the binding protein has been maximally activated. 
Alternatively, exposure to endogenous IL-4 in vivo could result in desensitzation of the
IL-4 receptor.
Another factor which is variable between different preparations is the nature of the 
mobility shift band which is affected by IL-4. There are in all cases, two distinct 
mobility shift bands observed on the gel. In the majority of experiments earned out with 
IL-4RE oligonucleotide it is the upper band, i.e., the slowest mobility shift band, which
shift bands which is up-regulated in response to IL-4; an increase is observed over a four
■is sensitive to IL-4 stimulation. However, in one or two instances it is the faster of the
hour period of stimulation (Fig. 5. IE), whereas in one experiment an increase in DNA 
binding in the second mobility shift band is observed after one hour stimulation, 
subsequently dropping back to basal levels at the three hour time point (Fig. 5.1 A). The 
presence of two mobility shift bands is probably due to the presence of monomeric and 
dimeric forms of the transcription factor which binds IL-4RE. The question of the 
variability in sensitivity of these bands to IL-4 activity is curious. Despite this, the 
obvious underlying mechanism is one of IL-4 inducing an increase in binding of a 
transcription factor to this IL-4 response element, i.e., IL-4 increases DNA-protein 
binding activity at a positive regulatory element in the CD25 promoter in human B cells. 
This effect is no doubt partially responsible for IL-4-induced transcriptional activation 
and expression of the CD25 gene in human B cells, possibly acting in parallel with the 
decreased binding to NRE.
5 .3  A Stat6 Binding Site Competes with the IL-4 Response 
Element for DNA Binding Protein
One of the major signal transduction pathways activated by IL-4, which has been 
identified in recent years, is the activation of two members of the Janus tyrosine kinase 
family, Jakl and Jak3, and the tyrosine phosphorylation and concomitant activation of 
Stat6 [Hou et al, 1994; Quelle et al, 1995; Witthuhn et al, 1994]. The promoter region 
of the CD25 gene in human B ceUs, in addition to containing the IL-4RE, also contains a
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putative binding site for Stat6, or rather its activated DNA binding homodimeric form 
(STFIL-4). Stat6 binding sites are present in an array of IL-4-inducible genes and the 
binding of Stat6 homodimers acts in a positive regulatory manner to activate gene 
expression [Hou et ai, 1994; Quelle et al, 1995; Schindler et ai, 1994]. It is interesting 
that the CD25 promoter should contain two positive regulatory elements which are 
putative IL-4 response elements. IL-4RE bears a distinct sequence from that of the Stat6 
site although there is a degree of homology. However, the consensus sequence for a 
Stat binding site is TT-N(4 _6 )-AA, a sequence which is not found in the IL-4 response 
element (the underlined regions shown below demonstrate the absence of a consensus 
Stat binding site in the IL-4RE).
Stat6 5’ GTA TFT CCA GAA AGG GAA 3’
IL-4RE 5’ CAC TGC CAA GAA GTG CTT 3’
A competition assay was earned out in an attempt to determine the potential of the IL-4 
response element to act as a Stat6 binding site and at the same time determine the 
specificity of IL-4RE binding in human B cells. DNA-protein binding to 32p_iabelled IL- 
4RE oligonucleotide in human B cell extracts is sensitive to competition by an excess of 
both unlabelled IL-4RE and Stat6 oligonucleotide (Fig. 5.2). It seems likely, therefore, 
that the IL-4 response element is a Stat6 binding site. What is particularly interesting is 
that unlabelled Stat6 oligonucleotide competes for transcription factor binding far more 
strongly than cold IL-4RE; i.e., at a 100-fold excess of unlabelled Stat6 there is no 
binding of radio-labelled oligonucleotide whereas there is still obvious radio-labelled 
oligonucleotide binding, although substantially diminished, in the presence of cold IL- 
4RE oligonucleotide. Thus, it would seem that the IL-4 response element is a weak Stat6 
binding site and that its reduced capacity to bind Stat6 is probably due to the observed 
differences in DNA sequence, in particular, the absence of a consensus Stat binding site. 
A second feature of note is that unlabelled oligonucleotide bearing the sequence of an 
AP2 binding site cannot compete with radio-labelled IL-4RE oligonucleotide for DNA- 
protein binding activity in human B cells. Therefore transcription factor binding to IL-
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4RE is specific in as much as only IL-4RE or Stat6-binding oligonucleotides are able to 
compete with radiolabelled probe for protein binding. The Stat6 competition studies |
demonstrate that Stat6 may be at least a component of the IL-4RE binding complex. f
5 .4  Forskolin and Cholera Toxin do not Affect Protein 
Binding Activity of the IL-4 Response Element
The data presented in the previous chapter indicate that an IL-4-induced cAMP 
generating/PKA activating pathway is a major factor in induction of CD25 expression in 
that it initiates a decrease in transcription factor binding to a negative regulatory element l|
in the CD25 promoter. Removal of this negative influence is at least partially responsible 
for up-regulation of CD25 in human B cells. It was, therefore, of considerable interest to 
examine the effects of forskolin and cholera toxin, both of which elevate intracellular f
cAMP, on DNA-protein interactions at the IL-4 response element. Neither forskolin nor 
cholera toxin mimic the ability of IL-4 to elevate binding to IL-4RE in resting human B 
cells. Again the presence of DNA binding activity present in unstimulated, time zero |
extracts is problematic, indicating that prior activation of some B cells has occuiTed even 
in a high density, quiescent B cell fraction (Figure 5.3 A & B). There is a modest
increase in ÏL-4RE binding at the 2 hour time point in response to stimulation with
,forskolin (Fig 5.3 A), whereas treatment with cholera toxin appears not to produce such 
a response (Fig 5.3 B). However, in B cell extracts where binding of IL-4RE
oligonucleotide at time zero is low, no elevation of transcription factor binding to this i
■1
element in response to forskolin or cholera toxin is observed over four hours (Figure 5.3
C & D). Thus, the general consensus from a number of independent repeats is that IL- 
4RE binding remains relatively unaffected by cAMP generating reagents. One feature
which is of considerable interest is, that neither forskolin nor cholera toxin is able to 
diminish DNA-protein binding to IL-4RE to any significant degree. This particular result 
serves as a very good internal control for the NRE-binding response observed to both 
these stimuli (Chapter 4), indicating that abrogation of transcription factor binding to Ii1 4 9 I
,
_     _ _ _      __________________
NRE is a result of genuine, specific sensitivity of the NRE-binding protein to cAMP and 
not a general decrease in DNA protein interactions in response to gross stimulation of the 
B cell.
5 .5  Tyrosine Kinase and PKC Inhibition Do Not Affect IL-4 
Induced Transcription Factor Binding to the IL-4
Response Element
;;r
The data presented so far have demonstrated that IL-4 up-regulates a protein which binds 
to a putative positive regulatory element in the CD25 promoter in human B cells. In 
addition, evidence suggests that this protein may be Stat6  and that IL-4RE is a weak 
Stat6  binding site. Pre-treatment of resting tonsillar B cells with the tyrosine kinase 
inhibitor genistein prior to stimulation with IL-4 does not affect the ability of IL-4 to up- 
regulate transcription factor binding to IL-4RE. In the two independent repeats of this 
experiment which are shown, IL-4 strongly up-regulates IL-4RE binding activity over a 
four hour period when there are no apparent levels of binding at time zero (Fig. 5.4 A), 
and in the instance where levels of DNA-protein binding activity at time zero are high, 
genistein does not exert any negative influence over IL-4RE binding (Fig. 5.4 C). This 
is interesting as IL-4RE has been shown to act as a Stat6  binding site and the accepted 
mechanism of IL-4-induced activation of Stat6  is mediated via its tyrosine 
phosphorylation by Jakl. However, no available information exists on the ability of 
genistein to inhibit members of the Janus kinase family. It is a possibility, therefore, that 
this particular inhibitor is unable to affect the kinase activity of this family. Treatment of 
human B cells with a protein kinase C inhibitor prior to IL-4 treatment does not diminish 
transcription factor binding to IL-4RE (Fig. 5.4 B & D). Therefore, PKC activity, 
which was demonstrated to have a role in IL-4 induced CD25 expression (Chapter 3,
Figs. 3.3 & 3.7), has no effect upon IL-4 induced regulation of Statô binding to the IL-4 
response element in the CD25 promoter.
I
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5 .6  The Effects of IL-13 and IL-7 on Transcription Factor 
Binding to the IL-4 Response Element
The suggestion that IL-13 and IL-4 share a common receptor component and activate 
similar’ signal transduction pathways is commonly accepted [Kishomoto et al, 1994], 
however, the identity of the receptor subunit and the nature of common signalling 
pathways remain equivocal. Evidence against yc being a component of the IL-13 
receptor is strong and the suggestion that the IL-4Ra chain is the component which both 
the IL-4 and IL-13 receptors share seems more plausible [He et al., 1995a; He and 
Malek, 1995b; Keegan et aL, 1995; Matthews e ta l,  1995; Smerz-Bertling and Duschl, 
1995; Zurawski et aL, 1993]. Considering the ability of IL-4 to activate Statô, via the 
IL-4Ra chain and Jakl, and also that the IL-4 response element of the CD25 promoter is 
a potential Statô binding site, it was of interest to determine whether or not IL-13 was 
capable of regulating protein binding to IL-4RE. The data presented from two 
independent repeats of a 4 hour time course of IL-13 stimulated resting B cells are not 
particularly compelling. However, in one instance there does appear to be a slight 
increase in DNA-protein binding activity to IL-4RE over the 4 hour period (Fig. 5.5A). 
Again the problem of prior activation in tlie high density B cell fraction, resulting in high 
levels of IL-4RE binding at time zero, makes observation of any changes in IL-4RE 
binding difficult (Fig. 5.5 A & B). It has also been possible to observe the effects, or 
lack thereof, of IL-7 on elevation of transcription factor binding to IL-4RE. Thus, in two 
independent repeats it seems clear that IL-7 (Fig 5.Ô A & C), unlike IL-4 (Fig 5.6 B & 
D), is unable to induce any increase in DNA-protein binding activity to IL-4RE. These 
data are consistent with the theory that Statô forms part of the IL-4RE binding complex, 
as many cytokines demonstrate a high degree of selectivity with respect to activation of 
Stat family members.
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5 .7  IL-4 Induces Tyrosine Phosphorylation of Stath in EDR 
B Cells
The data presented in this chapter indicate that IL-4 is capable of inducing an increase in 
transcription factor binding to an IL-4 response element in the CD25 promoter in resting, 
human B cells. In addition, competition data from section 5.5 strongly suggest that IL- 
4RE is a weak Statô binding site. It has been shown previously that IL-4 activates Statô 
by tyrosine phosphorylation in a variety of cell types [Hou et aL, 1994; Quelle et aL, 
1995; Schindler et aL, 1994]. One of the major problems of determining the ability of 
IL-4 to up-regulate DNA-protein binding activity at a positive regulatory element such as 
IL-4RE in resting, tonsillar B cells, is the varying degree of prior activation of the B cells 
between one cell preparation and another. Thus, even in high density B cell fractions 
there will exist some proportion of previously activated cells. This is obseiwed when one 
examines tyrosine phosphorylation of Statô in response to IL-4 in tonsillar B cells. 
Immunoprecipitates made, using a rabbit anti-Statô monoclonal antibody (S-20), from a 
control population of high density B cells demonstrate a degree of tyrosine 
phosphorylation of Statô which is essentially no different from IL-4 stimulated cells (Fig. 
5.8). Western blot analysis of the Statô content of control and stimulated resting B cells 
and the EDR B cell line demonstrates that total Statô content of these cells is not altered 
by stimulation (Fig. 5.7). The monocyte cell line U937, which has been included as a 
control for IL-4 induced Statô activation, showed considerably less Statô content than 
either EDR or tonsillar B cells. The difference observed between control and stimulated 
U937 cells is probably due to a problem in gel loading, as opposed to a genuine 
difference in Statô levels in response to IL-4. In contrast to resting tonsillar B cells, a 
dramatic increase in tyrosine phosphorylation of Statô, i.e., the level of Statô activation 
in response to IL-4 is observed in EDR B cells. The observation that IL-4 induces 
activation of Statô in EDR B cells does not necessarily mean that a Statô homodimer will 
regulate CD25 expression in these cells. However, CAT-reporter gene studies pCD25- 
CAT Uansfected EDR cells suggest that IL-4 activates a second signalling pathway which,x"
'
is required, in combination with a cAMP-dependent pathway, for maximal transcriptional 
activation of the gene. The ability of IL-4 to activate Statô in these cells and the presence 
of a Statô binding site in the CD25 promoter, suggest STF-IL-4 formation as a possible 
candidate for this second IL-4-induced pathway.
5 .8  D iscussion
The major conclusions which can be drawn here are, firstly, that the putative IL-4 
response element in the CD25 promoter has DNA-protein binding activity which is up- 
regulated in response to IL-4 and, secondly, competitive DNA binding studies revealed 
this site to be a weak Statô binding site. This latter observation is rather unusual if one 
considers the absence of a consensus Stat binding site in the IL-4RE. What is also 
unusual is that two potential Statô binding sites are present in the same promoter. One 
possible explanation for this is that the availability of two positive regulatory binding 
sites in the CD25 promoter may facilitate a greater response, with respect to expression 
of the gene. What has not been determined is whether the increased DNA binding 
activity which is observed in response to IL-4 (Figure 5.1) is actually the binding of 
STF-IL-4, a Statô homodimer. Reports of a second IL-4-responsive transcription factor, 
NFIL-4, define a 75kDa protein which is distinct from Statô [Kretsovali and 
Papamatheakis, 1995]. The IL-4RE in the CD25 promoter has a core sequence of 9 base 
pail’s which shai’es a high degree of sequence homology with both the 9 base pair IL-4RE 
in the CD23b gene [Kohler and Rieber, 1993] and a region of the 42 base pair sequence 
believed to confer IL-4-inducibility on the MHC class II Ea promoter [Kretsovali and 
Papamatheakis, 1995] (the sense sequences for these three elements are shown below, 
the underlined bases signifying the regions of homology).
IL-4RE CD25 5’- CAC TGC CAA GAA GTG -3'
IL-4RE CD23b 5’- GAT TTC TA A GAA AGG -3'
MHC class n  Ea 5'- GGT TCG AAG GAA CCC -3'
Does the similarity between CD25 IL-4RE and these NFIL-4 binding sequences, and
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Another important obseiTation concerns the effects of the cytokines IL-7 and IL-13 on 
DNA-protein binding activity to IL-4RE. IL-7, unlike IL-4, is unable to up-regulate 
transcription factor binding to IL-4RE over a 4 hour period. The receptor complexes for 
IL-4 and IL-7 share a common subunit, 7c, identified as the third component of the IL-2 
receptor complex. The inabihty of IL-7 to induce IL-4RE DNA binding activity strongly 
suggests that IL-4 mediates its effects on ti anscriptional regulation of this element via the
also the ability of a Stat6  site to compete for transcription factor binding with the CD25 
IL-4RE, then suggest the presence of a multi-functional IL-4 response element capable of 
binding two distinct transcription factors? If this were so, might it be a function of 
differential expression of DNA binding proteins at different stages of B cell 
development? However, expression of Stat6  appears to be ubiquitous throughout IL-4- 
responsive cell types and also throughout most stages of B cell development, a fact that 
would negate the requirement for a second IL-4 responsive transcription factor. One
:observation which may provide a clue to the nature of the DNA-protein binding activity 
of IL-4RE in the CD25 promoter is the apparent insensitivity of this activity to treatment 
with the protein tyrosine kinase inhibitor genistein. IL-4-induced Ea binding activity by 
NFIL-4 is also unaffected by genistein, indicating that tyrosine kinase activity is not a 
requirement for activation of this binding protein [Kretsovali and Papamatheakis, 1995]. 
Treatment of extracts of human B cells with anti-phosphotyrosine antisera inhibits 
activation of NFIL-4 and it has been determined that anti-phosphotyrosine antibodies also 
abrogate the binding activity of the IL-4RE in the CD25 promoter [Buriinson, personal 
communication]. The accepted mechanism for Stat6  activation is tyrosine 
phosphorylation by Jakl [Quelle et al, 1995], however, as no information exists on the 
ability of genistein to inhibit phosphorylation of Stat6  the nature of the protein which 
binds the IL-4RE in the CD25 promoter remains very much equivocal.
i"
IL-4Ra chain. There is a suggestion in Figure 5.5 that IL-13 up-regulates DNA-protein 
binding activity to IL-4RE, however, these data are not particularly compelling. IL-13 
shares certain cellular functions with IL-4 and extensive studies have revealed that the
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receptors for these two cytokines share a common component, the majority of evidence 
suggesting that this is the IL-4Ra chain. Thus, IL-13 inducing an increase in binding 
activity to IL-4RE further promotes the notion that IL-4 mediates this response via the IL- 
4Ra chain.
Analysis of the ability of IL-4 to activate Stat6  in EDR B cells revealed that Stat6  is 
tyrosine phosphorylated in response to a 15 minute stimulation with IL-4. In the 
previous chapter, transient transfection studies demonstrated that although IL-4 alone 
could not initiate transcription from the CD25 promoter, it did synergize with forskolin to 
induce transcriptional activation. The suggestion is that activation of a cAMP pathway, 
while necessary for facilitating transcription from the CD25 promoter, is insufficient for a 
complete response and that a second signalling pathway, activated by IL-4, is required to 
initiate maximal activation of transcription. The ability of IL-4 to induce tyrosine 
phosphorylation of Stat6  in EDR B cells and the presence of a Stat6  binding site in the 
CD25 promoter seems to provide a suitable candidate for this second pathway. 
However, the presence of the IL-4 response element in the CD25 promoter provides 
another possible tar get for IL-4 activation of CD25 transcription. Although there is some 
evidence to suggest that this IL-4RE is bound by an NFIL-4-like transcription factor, the 
nature of the IL-4RE binding protein remains equivocal. However, a suggested 
mechanism for IL-4-induced up-regulation of CD25 in human B cells is that the 
combination of a decrease in binding to a negative regulatory element, mediated via a 
cAMP-dependent pathway and an increase in binding to one or both of these positive
. :regulatory elements, is sufficient to drive transcription of the CD25 gene. A final 
observation relating to the inability of IL-13 to up-regulate CD25 in human B cells is, that 
if both of these signalling pathways are required for transcriptional activation of the 
CD25 gene then the inability of IL-13 to generate cAMP or affect NRE binding activity, 
despite its possible potential to activate Stat6  or NFIL-4 and increase binding to IL-4RE,
I
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5.1 IL-4 Induces an Increase in Transcription Factor Binding to IL-4RE
High density tonsillar B cells were incubated in complete medium at 37°C, 5% 
CO2  for 16 hours prior to stimulation with IL-4 (100 units/ml) for 4 hours. 
Nuclear extracts were made at hourly inteiwals and examined by DNA mobility 
shift assay, with 0.175pmol, ^2 p labelled IL-4RE oligonucleotide probe. The 
lane numbers at the bottom of the figure correspond to time of culture with IL-4 
in hours. One full length DNA mobility shift demonstrates two distinct mobility 
shift bands are observed (A). In addition four independent repeats are shown 
(the upper, i.e., the slowest, mobility shift band B, C, D and both mobility shift 
bands E).
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5.2 A Stat6 Binding Element but not an AP2 Binding Element Competes 
with the IL-4 Response Element for Transcription Factor Binding
Nuclear extracts from high density tonsillar B cells were incubated with 52p_ 
labelled IL-4RE oligonucleotide and either a 10-fold (+) or 100-fold (++) excess 
of unlabelled IL-4RE oligonucleotide (lanes 3 & 4) or unlabelled Stat6  
oligonucleotide (lanes 5 & 6 ), or a 100-fold excess of unlabelled AP2 (lane 7). 
Extracts were also incubated in the absence of any competing oligonucleotide 
(lane 2) and 32p-iabelled IL-4RE oligonucleotide was incubated in the absence 
of protein extracts (lane 1). Unlabelled IL-4RE and unlabelled Stat6 , but not 
unlabelled AP2, compete with radio-labelled IL-4RE oligonucleotide for protein 
binding.
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5.3 Forskolin and Cholera Toxin Do Not Affect Transcription Factor 
Binding Activity at IL-4RE
High density tonsillar B cells were incubated in complete medium at 3 7 5 %  
CO2  for 16 hours prior to stimulation with lOOjuM Forskolin or Iqg/ml Cholera 
Toxin for 4 hours. Nuclear extracts were made at hourly intervals and examined 
by DNA mobility shift assay, with 0.175pmol, labelled IL-4RE 
oligonucleotide probe. The lane numbers at the bottom of the figure correspond 
to time of culture with IL-4 in hours. Two independent repeats of extracts from 
forskolin (A & C) and cholera toxin (B & D) treated B cells are shown.
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5.4 Inhibition of Protein Tyrosine Kinase Activity or PKC Activity, Does 
Not Inhibit the Ability of IL-4 to Induce an Increase in IL-4RE 
Binding Activity
High density tonsillar B cells were incubated in complete medium at 37°C, 5% 
CO2  for 16 hours prior to treatment. Cells were pre-treated with lOpM 
Genistein or lOOnM Bisindolylmaleimide for 30 minutes prior to stimulation 
with IL-4 (100 units/ml) for 4 hours. Nuclear extracts were made at hourly 
intervals and examined by DNA mobility shift assay, with 0.175pmol, 32p 
labelled IL-4RE oligonucleotide probe. The lane numbers at the bottom of the 
figure correspond to time of culture with IL-4 in hours. Two independent 
repeats of extracts from genistein (A & C) and bisindolylmaleimide (B & D) pre­
treated B cells are shown.
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5.5 IL-13 Induces a Slight Increase in Transcription Factor Binding to
NRE
High density tonsillar B cells were incubated in complete medium at 37°C, 5% 
CO2 for 16 hours prior to stimulation with IL-13 (6 ng/ml) for 4 hours. Nuclear 
extracts were made at hourly intervals and examined by DNA mobility shift 
assay, with 0.175pmol, labelled IL-4RE oligonucleotide probe. The lane 
numbers at the bottom of the figure correspond to time of culture with IL-4 in 
hours. Two independent repeats of extracts from IL-13 treated B cells are 
shown.
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5.6 IL-7 Does Not Increase DNA-Protein Binding Activity to the IL-4 
Response Element
High density tonsillar B cells were incubated in complete medium at 37°C, 5% 
CO2  for 16 hours prior to stimulation with either IL-4 (lOOUnits/ml) or IL-7 
{().5ng/ml) for 4 hours. Nuclear extracts were made at hourly intervals and 
examined by DNA mobility shift assay, with 0.175pmol, 32p labelled IL-4RE 
oligonucleotide probe. The lane numbers at the bottom of the figure correspond 
to time of culture with each cytokine, in hours. Two independent repeats of 
extracts from IL-4 (A & C) and IL-7 (B&D) treated B cells are shown.
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5.7 Stat6 is Expressed in Equal amounts in both Resting and IL-4 
Treated Resting, Human B Cells and EDR B Cells
High density tonsillar B cells (1 x 1 0  ^ cells/ml) were incubated in complete 
medium at 37°C, 5% CO2 for 16 hours and EDR B cells and U937 monocytes 
were isolated from culture 24 hours after addition of fresh medium, prior to 
stimulation with IL-4 (lOOUnits/ml) for 20 minutes. 15pg of cell lysate protein 
for each sample were denatured by boiling in the presence of p-mercaptoethanol 
for two minutes and separated by SDS-PAGE. Western blots were probed with 
O.lpg/ml S-20 monoclonal antibody and visualized by ECL. Equal quantities of 
Stat6  protein were detected in both untreated (-) and IL-4 stimulated (+) tonsillar 
B cells, U937 monocytes and EDR B cells.
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5.8 Stat6 is Tyrosine Phosphorylated in EDR B cells in Response to IL-4
High density tonsillar B cells (1 x 10^ cells/ml) were incubated in complete 
medium at 37°C, 5% CO2  for 16 hours and EDR B cells and U937 monocytes 
were isolated from culture 24 hours after addition of fresh medium, prior to 
stimulation with IL-4 (lOOUnits/ml) for 20 minutes. Unstimulated (-) and IL-4 
(100 units/ml) treated B cells were lysed and immunoprecipitated with S-20 
monoclonal antibody. 2 0 jil aliquots of immunoprecipitates were denatured by 
boiling in the presence of p-mercaptoethanol for two minutes and separated by 
SDS-PAGE. Western blots were probed with O.lpg/ml PY-20 monoclonal 
antibody and visualized by ECL. IL-4 induces tyrosine phosphorylation of 
Slat6  in EDR B cells.
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D i s c u s s i o n
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6.1  Major Conclusions
It has been reported previously that IL-4 promotes PIP2  hydrolysis, IP3 production and 
consequent Ca^+ mobihzation, PKC activation and cAMP generation in resting human B 
cells [Arruda and Ho, 1992; Finney et a l,  1990]. The results presented here, further 
demonstrate the ability of IL-4 to induce cAMP generation in human B cells and also 
provide direct links between this second messenger production and the transcriptional 
activation of an IL-4-inducible gene, CD25. Thus, we have shown that IL-4-induced 
cAMP production is biphasic; with a small transient peak occurring 1-2 minutes after
ligand stimulation followed by a larger, more sustained generation starting - 1 0  minutes
.after ligand binding and returning to basal levels within 35-40 minutes after initiation of 
stimulation. In addition, preliminary data demonstrate the ability of IL-4 to induce 
activation of the cAMP-dependent protein kinase, PKA. Thus, PKA is activated at time 
points which correspond to the generation of cAMP.
IL-4 promotes simultaneous expression of both CD23 and CD25 antigens in resting 
human B cells in a dose dependent manner. Simultaneous three-colour flow cytometry 
revealed that CD19+/CD23+/CD25+ triple positive cells were derived from a 
CD19+/CD237CD25" pool, and that induction of CD23 required lower doses of IL-4 
than did induction of CD25 (EC5 0  values for IL-4 induced expression of CD23 and 
CD25 are 35pM and ISOpM respectively). It was found that both CD23 and CD25 
expression could be induced by stimulation ol the B cells with the same combination of 
pharmacological reagents. Thus, maximal expression of CD23 and CD25 was obtained 
with a 30 or 120 second pulse with phorbol ester and/or ionomycin followed by a 
sustained treatment with forskolin. Use of BAPTA to chelate intracellular calcium 
suggested that IL-4-driven CD25 expression required mobilization of intracellular 
calcium. Additionally, the use of chronic phorbol ester treatment to down-regulate PKC 
in resting human B cells abolished the ability of IL-4 to elevate both CD23 and CD25 
expression. Similarly, phorbol ester treatment abrogated the ability of anti-
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Immunoglobulin and anti-CD40 monoclonal antibodies to induce CD25 expression in 
resting human B cells. These two stimuli are the only factors, other that IL-4, known to 
induce expression of CD25 in human B cells.
The importance of cAMP generation, with respect to IL-4 up-regulation of CD25 
expression, is demonstrated in the ability of reagents which elevate intracellular cAMP, 
such as forskolin, to mimic the ability of IL-4 to decrease transcription factor binding to 
a negative regulatory element (NRE) in the CD25 promoter. The involvement of a 
cAMP-dependent protein kinase in this pathway is further demonstrated by the 
abrogation of IL-4-induced down-regulation of this DNA-protein binding activity 
following pre-treatment of resting human B cells with a selective PKA inhibitor, H89. 
Inhibition of protein tyrosine kinase activity also abrogates IL-4-induced attenuation of 
NRE binding whereas, in contrast, inhibition of PKC has no effect. The importance of 
the cAMP/PKA pathway is highlighted in the EDR B cell line, where IL-4 fails to up- 
regulate CD25. This phenomenon is possibly a result of the reduced capacity of IL-4 to 
induce cAMP generation in this cell line compared with the response obseiwed in primaiy 
restmg B cells, which is -10-fold greater in magnitude. Indeed, IL-4 fails to promote a 
decrease in DNA binding activity to NRE in EDR B cells, whereas forskolin elicits 
similar responses to those observed in primary B cells. Studies of transcriptional 
activation, in EDR ceUs transfected with a full length CD25 promoter-CAT reporter gene 
construct, demonstrate that IL-4 fails to promote any increase in reporter activity, 
whereas forskolin induces CAT activity approximately twice that of basal levels. 
Stimulation of tliese cells with both IL-4 and forskolin promotes greater enhancement of 
reporter gene activity (three times basal levels). This latter obseiTation suggests, that 
while IL-4-induced generation of cAMP and activation of PKA are necessary for 
induction of CD25 expression, this signal alone is insufficient to promote maximal 
transcriptional activation of the gene and a second or even third IL-4-induced signalling 
pathway is required. A potential candidate for such a pathway is the activation of Stat6  
by IL-4; the CD25 promoter in human B cells contains a Stat6  binding site and also an
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IL-4 response element which has been demonstrated as a weak Stat6  binding site. In 
addition, in EDR B cells, IL-4 has been shown to activate Stat6  by induction of tyrosine 
phosphoiylation of this signal Uansducmg molecule.
6 .2  The IL-4 Receptor and Signal Transduction
It is generally accepted that receptors of the haematopoietin receptor superfamily are 
multi-component structures and that subfamilies within this superfamily can be grouped 
according to the common receptor subunits which feature in their structure [Cosman et 
ai, 1990; Foxwell et al, 1992]. Thus, the lymphoid receptor family, including IL-2,
IL-4, IL-7, IL-9 and IL-15, all share the common gamma chain (7c) as a component of 
their receptor complexes [Grabstein et a l, 1994; Kondo et al,  1993; Russell et al,
1993]. This sharing of receptor subunits between cytokine receptors is believed to 
confer a degree of functional redundancy upon cytokines, with respect to early signal 
transduction pathways and occasionally to certain biological activities, e.g. IL-4 and IL- 
13 have a number of biological effects in common [Aversa et al, 1993; McKenzie et al,
1993; Punnonen et al, 1993]. However, there remains a large degree of distinction 
between many of the cellulai" functions of cytokines; thus, they are able to activate or 
repress a specific set of genes, activate different types of target cells and promote distinct 
responses within a single cell type. The question of how one commonly utilized early 
signal transduction pathway is translated into a specific response, dependent upon the :
cytokine which initiates it, is an intriguing one and one which has arisen often with 
respect to a number of second messenger systems in a multitude of cell types. The 
answers to such questions remain to be determined; however, evidence from the study of 
cytokine signal transduction pathways suggests that the availability of multi-receptor 
components which are able to activate an array of second messengers, results in a 
specific pattern of activation which is unique to a single stimulus.
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6 . 2 . 1  High and Low Affinity IL-4 Receptors
Evidence suggests that IL-4 is able to bind two receptors of different affinity; a high 
affinity receptor consisting of the 140kDa IL-4Rcx chain and the 65kDa yc chain, and a 
low affinity receptor consisting of the 140kDa IL-4Ra chain [Russell et al, 1993]. The 
differences in binding affinity of these two receptors are small and are 79pM and 266pM, 
respectively [Russell et al., 1993]. However, the presence of two different affinity 
receptors, as described by ligand binding analyses, does not necessarily imply that both 
are functionally active. The accepted mechanism of cytokine activation is that ligand 
binding induces the association of individual receptor components and increasing 
evidence suggests that receptor oligomerization is a requirement for successful activation 
of intracellular signalling pathways [Miyazaki et ai, 1994; Ternis et ai, 1995a]. If this 
is the case, then binding of IL-4 to a low affinity form of the receptor may not result in 
the formation of an active ligand/receptor complex. Thus, the availability of the yc 
component may limit the number of fully functional IL-4 receptors which are formed and 
although the cytokine is able to bind to a single IL-4Ra chain, an inability to associate 
with yc may render it functionally inactive. Data reporting the potential for two 
biologically active IL-4 receptors of different affinities, describe the differential capacity 
of IL-4 to up-regulate CD23 and membrane Ig (mig) in human B cells [Rigley et al, 
1991]. IL-4-induced CD23 and mIg expression displayed EC50 values of approxhnately 
40pM and 4pM respectively [Rigley et al, 1991]. Interestingly, these values are lower 
than both those described in ligand binding analyses [Russell et al, 1993]and those 
reported here, for IL-4-induced CD23 and CD25 expression. It has been accepted for 
some time that the receptors for both IL-4 and IL-13 share IL-4Ra as a common subunit. 
Recent studies have highlighted the presence of a third IL-4 receptor component whcih 
may constitute part of the low affinity IL-4 receptor. Use of biotinylated IL-4 in recetor 
binding studies revealed the presence of an IL-4 binding protein of 65-75 kDa on the 
membrane of a pre-B cell line [Fanslow et al, 1993]. Subsequent purification and 
characterisation of this subunit determined it to be novel and distinct from both the IL-
4R a and yc chains [Fanslow et al, 1993]. Additionally, recent studies have
1 6 8
demonstrated the presence of an IL-4 binding protein of 65-75 kDa on the membrane of 
endothelial cells and colorectal epithelial cancer cells [Murata et al, 1995; Schnyder et al, 
1966a]. This as yet unidentified protein has a high binding affinity for IL-13 and a low 
affinity for IL-4, suggesting the formation of a low affinity IL-4 receptor between this 
protein and the IL-4Ra. These is also the possibility that this low affinity IL-4 receptor
Schnyder et al, 1966].
Ï
forms a tripartate complex with the IL-13 receptor [Hilton et al, 1996; Murata et al, 1995;
I
In resting human B cells IL-4 induces expression of both CD23 and CD25 at the plasma 
membrane. Dose response data for the induction of these two surface markers 
demonstrates a difference in the EC5 0  values which is in accordance with the responses 
to IL-4 being mediated via two different, high and low, affinity IL-4 receptors. 
Additionally, simultaneous 'three colour’ analyses of CD23 and CD25 expression on 
CD 19 positive B cells, demonstrate that these two surface markers are up-regulated on 
the same sub-population of cells and again it appears that IL-4 mediates these two 
responses via receptors of two different affinities. Interestingly, these 'three colour' 
analyses highlight the presence of a small CD19+/CD237CD25+ population which 
remains at equilibrium, i.e., CD25 levels remain constant over the IL-4 titration range. 
The underlying reasons for the apparent lack of responsiveness of this sub-population are 
unknown, either there is a constant turnover of CD25 at the B cell surface or the ceUs are 
unable to respond to IL-4. If the latter scenario is the case, a possible explanation may lie 
with the presence, or rather, absence of functional IL-4 receptors. Since the dose 
response data suggested that the effects of IL-4 upon CD23 and CD25 expression might 
be mediated by distinct receptors, we attempted to establish whether different intracellular 
signals were responsible for inducing CD23 and CD25 expression. Quiescent tonsillar B 
cells were stimulated with combinations of phorbol ester, calcium ionophore and the 
adenylate cyclase activator forskolin and, while the combinations of stimuli required for 
maximal up-regulation of the two markers were essentially identical, some interesting 
differences were evident. Thus, maximal expression of both CD23 and CD25 occurred 1'
l « 9
170
'd
when cells were stimulated with PMA, PBu2 or ionomycin alone, or PBu2  and 
ionomycin combined, followed by a more sustained period of stimulation with forskolin; 
suggesting that PKC, Ca^+ mobilization and elevation of intracellular cAMP levels are 
important for up-regulation of these two cell surface proteins. However, it was 
consistently noted that brief pulses with forskolin alone could promote a significant two­
fold increase in CD25 expression, whereas CD23 levels were only increased by 
approximately one third over baseline. This fact, coupled with the observation that 
forskolin further enhanced CD25 expression when used in combination with other 
sthnuli, suggests that cAMP generation may be necessary in the up-regulation of CD25.
i'
6 . 2 . 2  The Receptor Paradox
The data presented here highlight an apparent paradox which is not easily explained. The 
dose response data for IL-4-induced cAMP generation give an EC5 0  value which is in 
agreement with its generation being induced by a high affinity form of the IL-4 receptor. 
Artificially generating cAMP by stimulation with forskolin seems to more efficiently 
elevate CD25 levels than those of CD23. However, the dose response data for IL-4- 
induced CD25 expression ai'e in line with a low affinity form of the receptor, whereas IL- 
4-induced CD23 expression and cAMP generation are in agreement with both each other 
and these responses being delivered via a high affinity receptor. The importance of IL-4- 
induced cAMP generation with respect to CD25 expression is apparent when one 
examines the data for regulation and activation of transcription of the CD25 gene and will 
be discussed in more detail in a future section. If the high and low affinity receptors for 
IL-4 are both functionally active and if, as the dose response data presented here 
suggests, IL-4-induced CD23 and CD25 expression are mediated by high and low 
affinity receptors respectively, it seems rather incongraous that by artificially activating 
similar second messenger systems one can induce both of these cell surface marker 
proteins. In addition, the apparent importance of cAMP regulating transcription factor 
binding to elements within the CD25 promoter conflicts with the suggestion that IL-4- 
induced cAMP elevation and CD25 expression are under control of the high and low
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affinity IL-4 receptors, respectively. This apparent paradox is not one which is easily 
understood or explained. There is now much evidence in favour of the idea that cytokine 
oligomerization is a requirement for full activation of intracellular signalling pathways. 
Recent studies utilizing chimeric receptors containing wild type and mutant IL-2Rp and 
IL-2Ry cytoplasmic domains have demonstrated the importance of the association of 
individual receptor components [Miyazaki et ciL, 1994], Transfection of a T cell line with 
c-kit-IL-2 receptor chimeras demonstrated that a successful proliferative response to stem 
cell factor (the natural ligand for c-kit receptors) only occurred when c-kit-IL-2Rp and c- 
kit-IL-2Ry were co-expressed [Miyazaki et a l, 1994]. In addition, mutation of the 
cytoplasmic domain of one or other of the two IL-2 receptor components resulted in the 
abrogation of this proliferative response. Co-transfection of chimeric receptor molecules 
with wild-type IL-2Rp and IL-2Ry cytoplasmic domains bearing different extracellular 
domains also resulted in abrogation of this proliferative response, suggesting that 
association of the extracellular-ligand binding domains is a requirement for successful 
signal transduction and is likely to be responsible for the association of the cytoplasmic 
domains. Additionally, expression of mutant forms of the IL-4 receptor demonstrates 
that receptor association is also important for successful IL-4 signal transduction. 
Mutations within the critical growth signal transduction domain of the IL-4Ra chain 
result, not only in loss of proliferation and Jakl, IRS-2 and Stat6 activation in response 
to IL-4 (events all associated with the IL-4Ra) [Keegan et aL, 1994; Pernis et a i, 
1995a], but also in the failure to activate Jak3. Activation of Jak3 is an event associated 
with the yc component of all cytokine receptors which share this particular subunit 
[Johnston et al., 1994; Witthuhn et al., 1994; Yin et a l, 1994; Zeng et al., 1994]. In 
addition, it is not only a disruption in the signalling capacity of IL-2Rp, IL-4a and IL-7a 
receptor chains which diminishes yc signal transduction, as disruption of yc associated 
signalling also inhibits cytokine responses. Over-expression of a yc truncation mutant 
into BA/F3 pro-B cells, co-transfected with either IL-2Rp, IL-4Ra or IL-7Ra chains, 
results in inhibition of proliferation in response to all three of these cytokines [Kawahara 
et al, 1994]. The dominant negative effect of this yc truncation mutant is also observed
with inhibition of IL-2-induced o-myc expression [Kawahara et a l,  1994]. The 
revelation that the mechanism of activation of Jak tyrosine kinases most likely involves 
cross-phosphorylation by two kinase molecules (previously associated with their 
respective inactive individual receptor components), an event which only occurs when 
they are brought into close spatial proximity by receptor subunit association, reinforces 
the appai'ent need for receptor ohgomerization for successful functional receptor activity. 
In light of such findings, and if one accepts the idea that a single functional receptor type 
is capable of inducing all of the signals required for up-regulation of CD23 and CD25, it 
seems logical that the activation of similar signalhng pathways mimics IL-4-induction of 
both these surface proteins. However, the difference in dose-response data remains 
unexplained. In order to try and define more clearly the relationship between the IL-4 
receptor, cAMP generation and CD25 expression, the effects of three other cytokines on 
these cellular responses were examined. Neither IL-2, IL-7, both of which have yc in 
their receptor complexes, nor IL-13 which is known to have certain biological activities 
in common with IL-4, were capable of inducing CD25 expression in human B cells. In 
contrast, IL-2 and EL-7, but not IL-13, were able to increase levels of intracellulai* cAMP 
in these cells. This latter observation, together with the fact that IL-4 also induces cAMP 
generation, indicates the possibility that increases in this second messenger may be 
associated with yc. Such a proposition is supported by the inability of IL-13 to mediate 
such a response. IL-4 and IL-13 are thought to share a receptor component and, 
although yc was originally proposed as a candidate for this role [Kishomoto et a l,
1994], there is much evidence to suggest that this is not the case. The IL-4Ra chain is 
now favoured as the receptor component common to these two cytokines [Keegan et al, 
1995; Matthews et a l, 1995; Smerz-Bertling and Duschl, 1995; Zurawski e ta l, 1993]. 
Reports which suggest the possibility of a low affinity IL-4 receptor which may be 
indistinguishable in strutcure from the IL-13 receptor, promote the idea of a functionally 
dimeric low affinity IL-4 receptor. It has also been hypothesized that the functional 
capacity of IL-13 depends upon the availability of IL-4Ra, which is often sequestered by 
yc in human B cells. Such an hypothesis might explain IL-13's inability to induce cAMP
J
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generation if this particular response were linked to IL-4 stimulation via IL-4Ra. The 
data presented here are further in favour of cAMP generation being a function of the high 
affinity IL-4 receptor but do not resolve the conflict of this idea with the dose-response 
data for IL-4-induced CD25 expression. Indeed, the ability of IL-2 and IL-7 to induce 
cAMP production, but not up-regulation of CD25, seems to confuse the issue further. 
However, the relationship between cAMP generation and the high affinity IL-4 receptor 
seems clear, as does the relationship between cAMP production and transcriptional 
regulation of the CD25 gene (see section 6.3.2 ). The inability of IL-2, IL-7 and IL-13, 
all of which share one or other of the receptor components of the IL-4 receptor, to induce 
CD25 suggests that this response is unique to IL-4 and as such may require the presence 
of both IL-4 receptor subunits (i.e., the high affinity form) for successful completion. 
Furthermore, if the hypothesis that receptor oligomerization is necessary for complete 
activation of cytokine signal h ansduction is correct, then the importance of IL-4-induced 
cAMP generation in CD25 expression seems somewhat more logical. The apparent 
differences in EC5 0  values for CD23 and CD25 expression ai*e small and the higher EC50  
value for IL-4-indiiced CD25 expression may merely be a function of a requirement for 
total receptor occupation in order to initiate this response.
6 ,3  IL-4“Induced Transcriptional Regulation of CD25
The CD25 promoter has been well characterised and described, particularly in human T 
cells, to the extent that sequences which bind to well known transcription factor 
complexes have been identified along with more lineage restricted binding elements. 
Information regarding the regulation of transcription factor binding to these elements is 
varied, some being well characterised while others are less so. Thus, it is known that in 
Jurkat and YT-1 T cell lines, an NF-kB binding site is regulated by differential binding of 
dimeric complexes of the c-rel oncogene family and, in addition, is closely associated 
with and, to an extent, regulates the binding of a serum response element and an Sp-1 
binding site [Algarte et a l, 1995; Pierce et aL, 1995]. Use of CD25 promoter-CAT
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reporter gene constmcts demonstrated that stimulation of transfected T cells with PMA 
increases reporter gene activity and deletion mutants lacking this NF-kB binding element 
lose the ability to respond to phorbol ester, indicating that this site is under the control of 
a protein kinase C regulated pathway [Cross et al., 1987; Lo wen thaï et al., 1988]. In
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contrast, analyses of deletion mutants of the CD25 promoter, lacking a region 5' of this
NF-kB site, led to the discovery of an element which negatively regulates transcription 
[Cross et aL, 1987; Lowenthal et a l, 1988; Smith and Greene, 1989]. Although it is 
known that this element binds a 50kDa 'silencer' protein, which represses transcription 
when bound to the promoter [Smith and Greene, 1989], the nature of this protein and the 
signal transduction mechanisms which regulate its binding remain relatively unknown.
Until recently, mechanisms of regulation of the DNA binding proteins involved in 
transcriptional activation of the CD25 gene in human B cells were less well understood.
The discovery that IL-4 is the only cytokine capable of inducing CD25 expression in 
human B cells, led us to try and understand the mechanisms by which IL-4-induced 
signal transduction regulates transcription factor binding to the CD25 promoter. The 
identification of two putative IL-4 response elements in tire promoter pointed towards an 
obvious pathway for IL-4-induced regulation of CD25 expression, i.e., the activation of 
the transcriptional regulator Stat6. However, the work presented in this thesis describes 
an IL-4 regulatory pathway which targets transcription factor binding to the NRE and 
demonstrates the importance of removal of a DNA binding protein(s), which binds this 
element, from the promoter.
■A.
6 . 3 . 1  Regulation of Negative Regulatory Element Binding Activity
The Negative Regulatory Element (NRE) consists of an 11 base pair core element lying 
within a region -400 to -368 base pairs upstream from the transcriptional initiation site. 
Transfection of 5' deletion mutants into YT-1 T cells and HTLV-1 transformed MT-2 T 
cehs demonstrated that deletion of this region of the CD25 promoter resulted in a 4-5-fold 
increase in basal and PMA-inducible transcription of a CAT reporter gene [Cross et al,
1987; Lowenthal et a l, 1988]. In the human EDR B cell line, deletion of NRE resulted
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in a 5-fold increase in basal promoter activity and a 13-fold increase in PMA-inducible 
activity [Buiiinson et al., 1996]. The data presented here demonstrate that treatment of 
primary human B cell with IL-4 results in almost total attenuation of DNA-binding 
activity to this element over a period of four hours. Considering the ability of IL-4 to up- 
regulate CD25 in these cells, this result indicates that a potential mechanism of achieving 
such a response lies with the IL-4-induced removal of DNA binding factor which
,represses transcription. Interestingly, in human T cell lines, IL-2, but not IL-4, induces 
cell surface expression of CD25 [Jankovic et al, 1989] and, in contrast to the situation in 
B ceils, IL-4 promotes an increase in binding activity to NRE [Buriinson e ta l,  1996].
The ability of forskolin, a direct activator of adenylyl cyclase, to induce a modest 
elevation of cell surface CD25 in human B cehs and to act with phorbol ester and calcium 
ionophore to enhance this expression, points to the second messenger cAMP as a 
candidate for regulation of CD25 transcription. Indeed, treatment of primary human B 
cells with either forskolin or cholera toxin, which activates adenylyl cyclase by inducing 
ADP-ribosylation of Gsa, mimics the ability of IL-4 to reduce transcription factor- 
binding to NRE. IL-4 has been shown, both here and by others, to elevate intracellular 
levels of cAMP and we have demonstrated here for the first time that IL-4 stimulation of 
primary human B cells leads to activation of the cAMP-dependent protein kinase, PKA.
These data, along with the knowledge that IL-4 and adenylyl cyclase-activating agents 
abrogate DNA-binding activity to NRE, suggest that IL-4 mediates this latter response 
via a cAMP generating pathway. Indeed, the ability of a specific PKA inhibitor to 
abolish IL-4's capacity to reduce transcription factor binding to NRE provides a direct 
link between IL-4-induced cAMP generation/PKA activation and regulatory control by 
this cytokine of a DNA binding protein which binds to the CD25 promoter. These data, 
despite providing evidence that IL-4 is able to regulate DNA-protein binding activity to 
the CD25 promoter, do not demonstrate any direct regulation of transcription of the 
CD25 gene, nor do they provide evidence that a cAMP-dependent pathway contributes to 
transcriptional activation of the gene.
■'i.
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Using a full length CD25 promoter -CAT reporter gene construct (pCD25-CAT), it has 
been possible to demonstrate the importance of a cAMP-dependent signalling pathway on 
transcriptional activation of the CD25 gene. The EDR B cell line, a mature EBV 
transfonned B cell line, was chosen for ease of transfection and also because the inability 
of IL-4 to drive CD25 expression in these cells provided a model system where some 
part of the endogenous signalling pathways were blocked. Initial studies of CD25 
expression at the surface of these cells demonstrated that IL-4 was unable to promote 
CD25 expression over a wide concentration range. However, there was an increase in 
CD25 expression when EDR cehs were co-stimulated with IL-4 and a high concentration 
of forskolin. Such observations hinted that adenylyl cyclase and downstream signalling 
machinery were intact and that by directly activating adenylyl cyclase it was possible to 
promote the ability of IL-4 to induce CD25 expression. Examination of cAMP 
production in EDR cells in response to IL-4 revealed that, while it was possible to 
promote cAMP generation in these cells the response was approximately 10-fold lower
I
than that which is observed in primary human B cells. In addition, stimulation of EDR 
cells with IL-4 failed to promote a decrease in NRE binding over a period of four hours,
whereas forskolin mimicked the response obseiwed in primary B cells by inducing almost 
total attenuation of DNA binding activity to this element over the same time period.
These data suggested that the inability of IL-4 to promote sufficient cAMP generation in 
these cells, or a resultant decrease in binding of a repressive transcription factor to NRE, 
was responsible for the inability of IL-4 to induce up-regulation of CD25 at the surface of 
these cells. Transfection of EDR cells with pCD25-CAT demonstrated that while IL-4 
was unable to induce reporter gene activity, stimulation with forskolin doubled reporter 
activity compared with basal activity in unstimulated pCD25-CAT transfectants. 
Additionally, co-stimulation with IL-4 and forskolin enhanced this response (CAT
:activity was three times that in unstimulated cells), indicating that while the removal of 
transcription factor binding from NRE via a cAMP dependent pathway is necessary for 
transcriptional activation of the CD25 gene, it is insufficient for inducing a maximal 
response. It appears, therefore, that a second or even third IL-4-induced signalling
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pathway may be involved in regulation of CD25 transcriptional activation and 
expression.
6 . 3 . 2  Regulation of IL-4 Response Element Binding Activity
There is now much evidence documenting the involvement of Jak kinases and a member 
of the Stat family of proteins (Stat6) in IL-4 signal transduction pathways [Hou et al,
1994; Quelle et a l, 1995; Schindler et a l, 1994]. Thus, upon binding to the high 
affinity form of its receptor, IL-4 promotes tyrosine phosphorylation and activation of 
Jakl and JakS kinases via the IL-4Ra chain and yc, respectively [Witthuhn et al, 1994].
In addition, there is now evidence supporting the ability of IL-4 to activate Jak2 in 
epithelial cancer cells [Murata e ta l, 1995] suggesting that in the absence of a particular 
kinase (i.e., JakS) cytokines will adapt to their environment by using other, closely 
related, signalling molecules. IL-4 activates the transcription factor Stat6 by promoting 
its tyrosine phosphorylation by Jakl and inducing consequent homodimerization, to form 
a transcriptionally active protein which translocates to the nucleus of the cell. The 
homodimeric form of Stat6 (STF-IL-4) binds specific GAS-related binding sequences in 
the promoter regions of IL-4-inducible genes [Schindler eta l, 1994].
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The presence of a Stat6 binding site in the CD25 promoter along with a putative IL-4 
response element (IL-4RE), identified due to its sequence similarity to the IL-4 response 
elements in die CD23 gene promoter [Kohler and Rieber, 1993], suggested two potential 
sites for IL-4 regulation of transcription of the CD25 gene. DNA mobility shift analysis 
revealed that IL-4 promotes an increase in binding activity to the IL-4-response element 
over a four hour period, demonstrating the ability of IL-4 to induce transcription factor 
binding to a putative positive regulatory element in the CD25 promoter. Interestingly, 
competition analyses determined that protein binding to this IL-4-response element could 
be competed for by a recognised Stat6 sequence and that this competition was stronger 
than that of unlabelled IL-4RE probe itself. These data suggest that either the IL-4- 
response element is a weak Stat6 binding site, or that the protein complex which binds to
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IL-4RE contains Stat6. The presence of two Stat6 binding sites, with different 
transcription factor binding affinities, within the same promoter seems unusual. One 
possible explanation is that the availability of multiple binding sites for a single 
transcription factor allows for greater transcriptional activation of a gene. An alternative 
explanation centres around the identification of a second IL-4 responsive transcription 
factor of 75kDa, designated NFIL-4 (Nuclear Factor IL-4), which binds an IL-4- 
response element in the MHC class II Ea gene promoter [Kretsovali and Papamatheakis,
1995]. This particular promoter element is able to bind to IL-4 response elements of 
similar sequence in a number of other genes and also bears a high degree of sequence 
homology to the IL-4 response element in the CD25 promoter. The Ea IL-4 response 
element is similar in sequence to certain GAS elements and NFIL-4 is able to bind some 
Stat recognition sequences. However, super-shift data using anti-Stat antibodies suggest 
that NFIL-4 is distinct from Stat proteins [Kretsovali and Papamatheakis, 1995]. Thus, 
the IL-4 response element in the CD25 promoter could potentially bind two distinct 
transcription factors, i.e., the Stat6 homodimer STF-IL-4 or the 75kDa NFIL-4 
described previously. The presence of an IL-4 response element with dual binding 
ability in the CD25 promoter could be a function of differential expression of specific 
transcription factor proteins in different lymphoid cell types and indeed in different 
developmental phases of lymphoid cells. However, such an hypothesis seems rather 
unlikely as reports suggest that Stat6 is expressed in the majority of cell lineages 
examined, therefore, making the presence of a second IL-4-inducible ti'anscription factor 
somewhat superfluous. One piece of evidence which is in favour of the CD25 promoter 
IL-4RE binding a factor similar' to NFIL-4, is the inability of the tyrosine kinase inhibitor 
genistein to inhibit IL-4-induced binding to this element or binding of NFIL-4 to Ea. As 
Stat6 activation relies on the Jakl tyrosine kinase, it may be predicted that such activity 
would be inhibited by genistein. DNA mobility super-shift assays carried out in this 
laboratory, using anti-Stat6 antibodies, have demonstrated no super-shift of the IL-4RE 
oligonucleotide binding complex from human B cell extracts. However, anti- 
phospho tyro sine antibodies do prevent the formation of a CD25 promoter IL-4RE
:
complex with B cell extracts, an obseiwation which also conelates with the activation of 
NFIL-4. Thus, there appears to be the potential for IL-4 to regulate the binding of two 
positive transcriptional activators to the CD25 promoter, but whether it is NFIL-4 or 
Stat6 which mediates IL-4-induced CD25 expression remains equivocal. In light of this, 
future studies which directly examine the nature of the transcription factor which binds to 
the CD25 promoter IL-4RE, in response to IL-4 in human B cells, wiU be important.
6 . 3 . 3  Other Transcriptional Binding Sites in the CD25 Promoter
The CD25 promoter has a number of other elements with sequences which are able to 
bind known transcription factors; including NF-kB, SRE and Spl binding sites, which 
bind members of the c-rel proto-oncogene family, serum response factor and Spl, 
respectively [Leung and Nabel, 1988; Pomerantz et a l, 1989]. There is also a retinoic 
acid response element which is very closely associated with the NRE [Bhatti and Sidell, 
1994]. It is now known that in unstimulated T cells the NF-kB site is constitutively 
bound by an NF-kB p50 homodimer which represses transcription and that, upon 
stimulation, this repressive binding complex is exchanged for an NF-kB p50-p60 
heterodimer capable of activating transcription [Algarte et a l, 1995]. In addition, the 
region encompassing the NF-kB, SRE and Spl binding sites has been proposed as a 
PMA-inducible region of the CD25 promoter in T cells. Examination of transcription 
factor binding to the NF-kB and Spl binding sites in human B cells, by DNA mobility 
shift assay, demonstrated no changes in binding activity in response to IL-4 over a four 
hour period of stimulation [Buriinson, personal communication]- These observations led 
to the suggestion that IL-4 did not affect expression of the CD25 gene via hanscriptional 
activation through these particular binding sites. In light of the evidence which suggests 
that it is the nature of the DNA-binding complex associated with the NF-kB site which 
changes upon stimulation and that this element is bound in both an inactive and active 
state, a lack of alteration in DNA binding activity, as observed by DNA mobility shift 
assay, does not necessarily indicate that IL-4 is unable to regulate transcription via these 
promoter elements. Chronic phorbol ester treatment of resting B cells attenuates CD25
I
179
__i£.
6 .4  What is the NRE Binding Protein?
Little is known about the nature of the transcriptional repressor protein which binds to the 
negative regulatory element in the CD25 promoter. Information regarding this factor in 
human T cells tells us only that NRE is bound by a 50kDa ’silencer’ protein [Smith and 
Greene, 1989], i.e., a protein which represses transcription of the CD25 gene when it is 
bound to the promoter. The lack of published data concerning regulation of binding of 
this ’silencer' protein to NRE in T cells has meant that, to date, speculation about the
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up-regulation in response to IL-4 and both anti-IgM and anti-CD40 antibodies. These 
data, together with the observation that both PMA and PBuz in combination with other 
stimuli are able to induce CD25 in human B cells, suggest the potential involvement of 
PKC activation in IL-4-induced CD25 expression in human B cells and also the 
importance of PKC in the signalling pathways of other stimuli known to promote CD25 
expression. Bearing such observations in mind, and with the knowledge that PMA 
regulates NF-kB binding activity in T cells, it may be that a PKC-activating pathway is 
utilized by IL-4 in order to regulate transcription factor binding to this element in human 
B cells. As the DNA mobility shift data concerning DNA binding activity to NF-kB in 
human B cells does not give a definitive answer about the capacity of IL-4 to regulate 
such activity, such a hypothesis cannot be ruled ou t. It will, therefore, be an important 
future step to define whether IL-4 is able to induce an exchange of a repressive 
transcriptional complex for an active one at the NF-kB site in human B cells and if so, to 
detennine which signalling pathway(s) are responsible for regulating such an exchange. 
Interestingly, IL-1 has been shown to induce the up-regulation of CD25 by a cAMP- 
dependent pathway in a natural killer cell line, a signalling pathway which is believed to 
be linked to transcriptional activation through an NF-kB binding site. With the certain 
knowledge that IL-4 is able to promote cAMP generation and up-regulation of CD25 in 
human B cells, it will be of interest to determine whether IL-4 can mediate similar cAMP- 
dependent effects on NF-kB binding activity in these cells.
nature of this factor has been minimal. The observations presented in this thesis 
regarding the regulation of protein binding to NRE via a cAMP-dependent pathway, have 
allowed the proposition of certain hypotheses as to what this DNA-binding protein may 
be. However, a more definitive statement may be made about what this protein is not, 
rather than what it is.
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Our data have indicated that IL-4 regulates binding of a transcriptional repressor to the 
CD25 promoter via a cAMP-dependent pathway. The most commonly recognized means 
of cAMP and active PKA regulating transcription is by the serine/threonine 
phosphorylation and subsequent activation of CREB (cAMP-responsive element binding 
protein), which is followed by its binding of CRE sequences in cAMP-responsive genes 
[Reviewed by Montminy et al, 1990]. In this instance, however, the evidence suggests 
that NRE binding protein is not a member of the CREB family; thus, the 11 base pair 
core sequence of NRE is distinct from a classic CRE sequence and, more definitively, 
data presented here demonstrate that a CRE sequence is unable to compete with NRE for 
DNA-protein binding activity. However, CRE sequences and CREB proteins are not the 
only reported cAMP-responsive transcriptional activators. There is a somewhat 
controversial hypothesis that while the catalytic subunit of PKA activates CREB family 
members by phosphorylation, the simultaneously released regulatory subunits are also i
capable of translocating to the nucleus and acting directly as transcriptional activators by 
binding to specific sequences in the promoters of certain cAMP-responsive genes 
[Nagamine and Reich, 1985]. Additionally, a recent study has identified novel motif 
within the promoter of the cAMP-responsive tryptophan hydroxylase gene [Boularand et 
a l, 1995]. This element contains two motifs which have been determined essential for 
cAMP-responsiveness, an inverted CCAAT box and a 9 base pair sequence 5 -CCG
CTG CCC-3', which are entirely distinct from a classic CRE sequence. While neither of 
the sequences of this element bear any resemblance to the NRE sequence (Table 6.1), it 
highlights the potential for the existence of a variety of novel cAMP-responsive elements.
____
Table 6.1 cAMP-Responsive Transcription Factor Binding-Promoter 
Elements
■
c AMP-responsive element Sequence (5'-3')
CRE AGA GAT TGC CTG ACG TCA GAG AGC TAG
NRE TT CAT CCC GGG
RE Binding motif GAA AGG GTG AGA AAG AGC TGA TTG AGG
Tryptophan hydroxylase:
- mverted CCAAT motif ATTGG
- 9 base pair motif CCG CTG CCC
Thus, it seems that the sequence of NRE defines a novel cAMP-response element and the 
question of the nature of the 50kDa binding protein remains unknown. It is, however, 
probably safe to surmise that CREB is not involved in this IL-4-induced cAMP/PKA 
dependent signalling pathway.
Efforts to identify DNA binding sites for other lymphoid expressed transcription factors 
which have a recognition sequence similai* to that of NRE have revealed the existence of a 
zinc finger DNA binding protein, YYl, which binds a consensus sequence with a high 
degree of homology to NRE. Analyses of the binding sites for YYl from a number of 
gene promoters revealed a consensus sequence consisting of a conserved 5 -CAT-3' core 
flanked by two variable regions with the consensus 5'- (C/g/a) (G/t) (G/l/a) CATN (T/a) 
(T/g/c)-3' [Hyde-DeRuyscher et al., 1995]. If one examines the sense strand sequence 
for NRE (5'- TT CAT CCC AGG -3') it is possible to observe the sequence similarity 
between NRE and YYl sites. Judging by the sequence similarity between the YYl and 
NRE binding sites it seems possible that NRE may bind a YYl complex. In addition to 
structural similarities between the two sequences, they have certain functional
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characteristics in common. Thus, NRE binding protein very obviously acts as a 
repressor of transcription of the CD25 gene and it has been shown that YY1 has the 
capacity to act either as a repressor or activator of transcription, depending upon the gene 
which it regulates. An element within the GM-CSF promoter (sequence CATT(A/T)) 
which is required for promoter activity was found to bind YYl [Ye et al, 1994]. These 
studies were the first to link YYl activity to regulation of cytokine gene expression. 
Sequences close to the initiator region of HIV-1 are also homologous to YYl binding 
sequences and HIV long terminal repeat expression (i.e., an LTR-CAT gene construct) 
can be repressed by co-transfection with a YYl expression vector [Margolis et al., 
1994]. Thus, YYl is highly versatile and can act as both an activator or repressor of 
transcription. Considering the sequence similarity between YY 1 binding sites and NRE, 
the possibility that the NRE binding protein contains YYl as at least part of its structure 
is something which should be examined.
6 .5  How does the IL-4 Receptor Couple to Adenylyl Cyclase?
There are now eight fully characterised isoforms of adenylyl cyclase all of which are 
under multiple differential mechanisms of regulation [Reviewed by Pieroni etal., 1993; 
Taussig and Gilman, 1995]. Thus, all can be activated by the alpha subunit of the 
stimulatory G protein, Gs. However, other G protein subunits produce different, less 
ubiquitous, patterns of regulation such that some are activated by the py subunits of Gs 
while others are inhibited by Gi alpha [Tang and Gilman, 1991b]. In addition to 
regulation by G proteins, some adenylyl isoforms are activated by Ca2+/Calmodulin 
[Krupinski et a l, 1989; Tang et a l, 1991a] and others are inhibited by increases in 
intracellular calcium [Debernardi e ta l, 1993; Yoshimura and Cooper, 1992], while the 
activity of one or two isofoims are enhanced by protein kinase C activity [Yoshimura and 
Cooper, 1993]. It is now apparent tliat the activity of each individual isoform of adenylyl 
cyclase may be subject to regulation by more than one signalling pathway and that the 
mechanism of regulation is ultimately dependent upon the initial stimulus received at the
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Icell surface. Additionally, it is probable that certain isoforms are subject to more than one mechanism of regulation at any one time in response to specific stimuli and so the 
magnitude of the cAMP response which is subsequently generated is under very tight 
control. The duration and magnitude of a cAMP response, as well as being dependent on 
activation of adenylyl cyclase, is also regulated by the activity of phosphodiesterases, 
enzymes which degrade cAMP to inactive 5-AMP. In addition to the attenuation of an 
adenylyl cyclase response by degrading cAMP, elevation of basal levels of cAMP by the 
inhibition of phosphodiesterase activity is now known to have a role in intracellular 
signalling in certain circumstances. Thus, a cAMP response can be generated either by 
activation of adenylyl cyclase or by inhibition of phosphodiesterase activity.
Data presented here, and previously, have demonstrated the ability of IL-4 to promote 
cAMP generation in primary human B cells. The question of how IL-4 induces this 
response, i.e., how the IL-4 receptor complex couples to either an adenylyl cyclase or a 
phosphodiesterase remains to be determined, as does the question of whether it is 
activation of an adenylyl cyclase or inhibition of a phosphodiesterase which is 
responsible for mediating IL-4-induced cAMP generation. We have shown that by 
stimulation of human B cells with certain pharmacological agents it is possible to induce 
modest increases in CD25 expression at the plasma membrane of these cells. Thus, 
stimulation with forskolin alone promotes some up-regulation of CD25 and co­
stimulation of human B cells with either PMA and forskolin or with PBu^ and/or 
ionomycin in combination with forskolin enhances this response. It is a possibility that 
activation of protein kinase C or elevating levels of inhacellular calcium may enhance the 
effects of forskolin by directly activating specific adenylyl cyclase isofonns. PKC is able 
to activate types II and VII adenylyl cyclase and Ca^+ZCalmodulin activates types I, IH 
and VIII. It cannot be ruled out however, that activation of PKC and mobilization of 
Ca^ "** in this way have a role in up-regulating CD25 via signalling pathways which are 
distinct from the cAMP-dependent pathway. The ability of IL-4 to decrease transcription 
factor binding to NRE in the CD25 promoter and the knowledge that this is most likely
mediated via a cAMP-dependent pathway, provides a model for examining other second 
messengers which may be responsible for IL-4 regulation of cAMP generation. The 
inability of the PKC inhibitor bisindolylmaleimide to abrogate IL-4-induced down- 
regulation of NRE binding activity, in the manner which the PKA inhibitor H89 does, 
strongly suggests that IL-4 does not regulate adenylyl cyclase activity via a PKC 
dependent pathway. The effects of tyrosine kinase inhibitor genistein on this binding 
activity are somewhat more ambiguous; in some instances the inhibitor abrogates ÏL-4- 
induced attenuation of NRE binding and in others it does not. The concept of tyrosine 
kinases being able to regulate adenylyl cyclase activity is a controversial one, although 
there is some evidence in favour of growth factor receptors with intiinsic tyrosine kinase 
activity being able to regulate adenylyl cyclase. It has been demonstrated that EOF, 
which is known to activate adenylyl cyclase via Gsa, can also activate this enzyme via 
the tyrosine kinase domain of the EGF receptor [Nair and Patel, 1993]. Thus, inhibition 
with tyrphostins and treatment with protein tyrosine phosphatases inhibited both EGF 
receptor phosphoiylation and EGF-induced adenylyl cyclase activation without alteration 
of specific binding of the ligand [Nair and Patel, 1993]. Whether EGF directly activates 
adenylyl cyclase, by tyrosine phosphorylation of the latter, or whether it achieves 
activation via a mediator molecule, such as a switch kinase, is unknown. The possibility 
that chelation of intracellular calcium affecting this NRE binding activity is one which 
remains to be investigated and may give some more insight into how IL-4 regulates 
adenylate cyclase activity, as will examination of the effects of PKC, tyrosine kinase 
inhibitors etc. on the ability of IL-4 to generate cAMP directly. The question of whether 
it is IL-4-induced activation of adenylyl cyclase or inhibition of phosphodiesterase 
activity which is responsible for the cAMP-dependent pathway which regulates NRE 
binding activity, is more readily answered. Treatment of primaiy human B cells with the 
general phosphodiesterase inhibitor IBMX does not result in a decrease in DNA binding 
activity to NRE over a four hour period, a result which is in direct contrast with the 
effects of IL-4 on B cells isolated from the same source. It seems likely, therefore, that 
IL-4 generates cAMP in human B cells by activating adenylyl cyclase rather than by
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Iinhibiting phosphodiesterase activity. The question of which isoform of adenylyl cyclase 
IL-4 activates remains unanswered, however, from the evidence presented here it does 
appear that it is unlikely to be activated by PKC. This does not rule out the possibihty of 
the involvement of one of the isoforms which can be regulated by PKC because, as 
mentioned earlier, all eight isoforms are subject to more than one regulatoiy mechanism. 
Examination of the pattern of expression of adenylyl cyclase isoforms in human B cells, 
either by use of adenylyl cyclase isoform-specific antibodies or by PCR, may give at 
least some clues to which isoforms are available for signal transduction. Additionally, 
one plausible method of determining whether or not Jak3 was involved in generation of 
cAMP,would be the over expression of a Jak3 mutant with a kinase inactive domain in an 
IL-4-responsive B cell line. Similar studies have shown that such mutants can exert a 
dominant negative effect on Jak2 related signalling pathways [Guschin et al, 1995].
Another factor in IL-4 regulation of adenylyl cyclase activity is which component of the 
receptor is involved in coupling the receptor to cAMP generation. Most evidence 
suggests that receptor subunit oligomerization is a requirement for functional activation of 
cytokine-induced signal transduction pathways. The high affinity form of the IL-4 
receptor consists of the IL-4Ra chain and yc, however, there is now evidence of a 
second multi-component receptor that is able to bind IL-4 and possibly IL-13 as well. 
This contains the IL-4Ra chain and a novel protein of 65-70kDa molecular weight, 
which has also been proposed as the IL-13Ra chain, and is generally considered to be 
the sti'ucture of the IL-13 receptor complex. One defining characteristic of this IL-4/IL- 
13 receptor is the absence of the IL-2 receptor yc chain. We examined the ability of 
cytokines such as IL-2 and IL-7, both of which have yc in their structure, and IL-13, 
which is known to share a number of biological functions with IL-4, to generate cAMP 
in human B cells. Our data demonstrate that while both IL-2 and IL-7 promote the 
generation of cAMP, IL-13 does not. This would seem to suggest the possibility of yc 
being involved in the activation of cAMP. In contrast, neither IL-2, IL-7 or IL-13 were 
capable of promoting a decrease in transcription factor binding to NRE in the CD25
$
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promoter. Although this lack of response is in agreement with the inability of all three of 
these cytokines to up-regulate CD25 in human B cells, it does seem at odds with the 
cAMP data and may be the function of a requirement for more than one signalling 
pathway to regulate NRE binding activity. As previously suggested the up-regulation of 
CD25 by cytokines may require a pattern of signal transduction pathways unique to IL-4 
signalling through its unique high affinity receptor.
6 .6  Hypothetical Model for IL-4 Signal Transduction 
Pathways Which Regulate CD25 Expression
A partial hypothetical model of how IL-4 regulates both the binding of transcription 
factors to the CD25 promoter element and transcriptional activation of the gene can be 
considered (Figure 6.1). IL-4-induced elevation of intracellular levels of cAMP results in 
the activation of a cAMP-dependent protein kinase, PKA. This cAMP-generating/PKA- 
activating pathway is responsible for modulation of the DNA binding activity of a protein 
which constitutively binds to the negative regulatory element of the CD25 promoter in 
unstimulated cells. How PKA mediates this response is unknown, however, our 
evidence suggests that it does not involve the activation of CREB, an observation which 
is in accordance with the lack of sequence similarity between NRE and a consensus 
CREB binding element, CRE. There are two possible mechanisms for PKA regulating 
NRE binding protein(s); either PKA directly phosphorylates the binding protein(s) on 
serine/threonine residues or it activates an inteimediaiy signalling molecule(s) which in 
turn regulates NRE binding activity. Until the identification of the NRE binding protein, 
there is no easy way of determining which of these mechanisms is employed. The data 
demonstrating the inability of phosphodiesterase inhibitor IBMX to mimic the ability of 
IL-4 to attenuate DNA binding activity to NRE suggests that IL-4-induced cAMP 
generation is a product of activation of adenylyl cyclase rather than inhibition of a 
phosphodiesterase. Additionally, the data presented here which demonstrate the ability
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With respect to other regulatory elements in the CD25 promoter; IL-4 promotes the 
attenuation of DNA binding activity to a retinoic acid response element (RARE) which,
5
of IL-2 and IL-7, but not IL-13, to induce cAMP generation, point towards activation of
-adenylyl cyclase being regulated by the 7c component of the IL-4 receptor. If this is the 
case it is possible that such a response is mediated by Jak3, the major signalhng molecule 
associated with 7c. There is no evidence demonstrating the tyrosine phosphorylation of 
adenylyl cyclase isoforms, however, it has been shown that inhibition of tyrosine 
phosphorylation does interfere with the ability of the EGF receptor to activate adenylyl 
cyclase. It is possible that if the intrinsic tyrosine kinase domain of the EGF receptor 
does not induce this activation directly, it may do so via an intermediate factor such as a 
'switch' kinase.
CD25 promoter-CAT reporter transfection studies in the EDR B cell line demonstrate the 
importance of cAMP generation with respect to transcriptional activation of the CD25 
gene. The ability of forskolin and IL-4 to synergistically increase reporter gene activity 
in these cells highlights the need for a second IL-4-induced signal transduction pathway 
to promote a maximal transcriptional response. One plausible candidate for a second IL- 
4-induced signalling pathway is the activation of Stat6  and the formation of a 
transcriptionally active homodimeric complex, STF-IL-4. IL-4 is able to induce the 
tyrosine phosphorylation and therefore activation of Stat6  in EDR B cells. In addition, 
there are two putative IL-4-response elements in the CD25 promoter; a Stat6  binding site 
and an IL-4-response element. The latter has sequence homology to other IL-4 response 
elements which have been identified binding to a second 75kDa IL-4 induced 
transcription factor, NFIL-4. Our data demonstrate the IL-4 response element in the 
CD25 promoter is a weak Stat6  binding site, although super-shift data suggest that the 
IL-4RE-binding complex in human B cells is not Stat6 . The tyrosine kinase inhibition
■jdata also seem to favour NFIL-4 as the IL-4RE binding protein, however, the role of 
such a factor and Stat6  in regulation of CD25 expression remains equivocal.
7
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when bound by its transcription factor(s), negatively regulates transcription of the gene. 
However, little is known about the signal transduction pathways which regulate RARE 
binding. Despite reports that IL-4 does not promote any alteration in DNA-protein 
complex binding to the NF-kB site in the CD25 promoter in human B cells, such 
observations remained undefined. The PMA-induced exchange of a repressive 
transcriptional complex for a positive one at the NF-kB site in T cells suggests a process 
of activation that may not necessarily be detectable by DNA mobility shift. This fact, 
together with the data demonstrating that a phorbol ester-sensitive PKC dependent 
pathway may be involved in IL-4 signal transduction, particularly in IL-4-induced up- 
regulation of CD25, suggests that IL-4 regulation of transcription factor binding to NF- 
kB should be re-investigated.
The work presented in this thesis has demonstrated a down-stream target for the 
previously identified IL-4-induced cAMP generation, namely, the as yet unidentified 
NRE-binidng protein(s). Additionally, there is strong evidence that this cAMP response 
occurs as a result of activation of adenylyl cyclase and that the effects of this second 
messenger upon NRE binding activity are mediated by PKA. IL-4-induced down- 
regulation of transcription factor binding to NRE via this cAMP dependent pathway, 
while being necessary for transcriptional activation, is an insufficient signal for 
producing maximal expression of the CD25 gene. The CD25 promoter is complex and 
there are a number of potential regulatory elements through which IL-4 may control 
transcription. Thus, determining the importance of IL-4-induced regulation of 
transcription factor binding to the IL-4 response element, the Stat6 site and the NF-kB 
site may be the key to fully understanding the ability of IL-4 to up-regulate CD25 
expression in human B cells.
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